









Characterisation of HIV-1 Subtype C Envelope 
Functional Determinants of Dual Infected 
Individuals  
By 
Shatha Sultan Ahmed Omar 
Thesis Presented for the Degree of 
DOCTOR OF PHILOSOPHY 
Department of Integrative Biomedical Sciences 
UNIVERSITY OF CAPE TOWN 



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 




I, Shatha Sultan Ahmed Omar, hereby declare that the work on which this dissertation/thesis 
is based is my original work (except where acknowledgements indicate otherwise) and that 
neither the whole work nor any part of it has been, is being, or is to be submitted for another 
degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever. 
Signature: 
Date:   19/02/2018 





After an intensive period of seven years, I would like to dedicate this work to the soul of my 
father Sultan Ahmed Omer and my mother Zahra Hibatulla Ali “the minaret of education” 
that enlighten my path of study from childhood up to higher degree. And to the soul of my 
kind husband who has been supporting me all over the time and particularly, during my stay 


















First and foremost, I have to thank and express my gratefulness to “Allah” the almighty God 
who provided me with strength throughout my social and scientific life. 
I would like to express the deepest gratefulness to my committee chair Dr. Zenda Woodman, 
who continually conveyed a spirit of exploration in regard to research and scholarship. 
Without her aspiring guidance, invaluably constructive criticism, friendly advice and 
persistent help this dissertation would not have been possible. 
My special thanks go to Dr. David Micklem, Director of Biomarkers and Assay Development 
at BerGenBio ASA, for his permanent and tremendous help that introduced me to charity 
work in this world.  
I would also like to thank Dr. Philippe Selhorst and Dr. Melissa Abraham for their kind 
training and assistance in the replication assay.  
I am thankful to the Organisation for Women in Science for the Developing World (OWSD), 
Schlumberger foundation, Faculty for the Future (FFTF) and Poliomyelitis Research 
Foundation (PRF) for their financial support that I received from them without which my 
studies would not have been possible. 
I would like to show gratitude to my bright daughter who has been sharing with me the ups 
and downs and the happy and sad moments of this achievement.  
Getting through my dissertation required more than academic support, and I have many, 
many people to thank for listening to and, at times, having to tolerate me over the past seven 
years. For you, relatives and friends, I cannot begin to express my gratitude and appreciation 




   
iv 
 
TABLE OF CONTENTS 
 
DECLARATION ................................................................................................................. I 
DEDICATION .................................................................................................................... II 
ACKNOWLEDGEMENTS .............................................................................................. III 
TABLE OF CONTENTS .................................................................................................. IV 
LIST OF TABLES .......................................................................................................... VIII 
LIST OF FIGURES .......................................................................................................... IX 
ABBREVIATIONS ......................................................................................................... XII 
ABSTRACT ........................................................................................................................ 1 
 ................................................................... 4 
1.1 Introduction .................................................................................................... 4 
1.2 Overall HIV structure ..................................................................................... 4 
1.3 HIV Diversity ................................................................................................. 6 
1.4 Mechanisms and impact of Diversification .................................................... 8 
 Point mutation ................................................................................... 9 
 HIV-1 Recombination..................................................................... 10 
1.5 HIV-1 transmission ...................................................................................... 12 
1.6 HIV-1 disease progression ........................................................................... 15 
1.7 Dual infection ............................................................................................... 18 
 Incidence of dual infection ............................................................. 19 
 Method of Identification ................................................................. 22 
 Association between dual infection and increased disease 
progression...................................................................................... 23 
 Dual infection and Drug Resistance ............................................... 25 
1.8 HIV-1 Envelope ........................................................................................... 26 
 Structure and function ..................................................................... 26 
1.9 Viral fitness .................................................................................................. 36 
 Env as an HIV fitness determinant ................................................. 36 
 Env fitness and disease progression ................................................ 37 
1.10 Research Aim and objectives ....................................................................... 38 
 Rational ........................................................................................... 38 
 Objectives ....................................................................................... 38 
   
v 
 
 .................................................................................. 40 
2.1 Introduction .................................................................................................. 40 
2.2 Research Aim and Objectives ...................................................................... 42 
2.3 Materials and Methods ................................................................................. 43 
 Study cohort and samples used in this analysis .............................. 43 
 Analysis of SGA-derived envelope sequences ............................... 44 
 Cloning functional Env SGA .......................................................... 45 
 Pseudovirus Entry Efficiency ......................................................... 47 
 Env determinants for viral fitness ................................................... 49 
 Site direct mutagenesis ................................................................... 50 
2.4 Statistical analysis ........................................................................................ 53 
2.5 Results .......................................................................................................... 54 
 Diversity of variants infecting dual infected individuals ................ 54 
 Frequency of viral populations infecting dual-infected 
individuals ...................................................................................... 56 
 Identification of phylogenetically distinct master sequences ......... 56 
 Changes in Env Entry efficiency of viruses infecting dual 
infected individuals over time ........................................................ 69 
 Env Fitness determinants ................................................................ 80 
2.6 Discussion .................................................................................................... 87 
LONGITUDINAL, PHENOTYPIC CHARACTERISATION OF 
HIV-1 SUBTYPE C ENVELOPE ISOLATED FROM DUAL INFECTED 
INDIVIDUALS  ...................................................................................................... 93 
3.1 Introduction .................................................................................................. 93 
3.2 Research Aim and Objectives ...................................................................... 95 
3.3 Materials and Methods ................................................................................. 96 
 Samples used in this study .............................................................. 96 
 Coreceptor phenotype ..................................................................... 96 
 Cellular tropism .............................................................................. 96 
 Env sensitivity to entry inhibitor T-20 ............................................ 99 
 Expression and incorporation of Envelope into pseudovirus.......... 99 
 Data analysis ................................................................................. 100 
 Statistical analysis ......................................................................... 101 
3.4 Results ........................................................................................................ 103 
   
vi 
 
 Coreceptor phenotype ................................................................... 103 
 Differences in cellular tropism ..................................................... 103 
 Validity of TZM-bl cells to compare Pseudovirion entry 
efficiency ...................................................................................... 107 
 Pseudovirus Fusion Capacity ........................................................ 112 
 Association between PSV entry efficiency and fusion capacity ... 116 
 Envelope Expression and cleavage ............................................... 117 
 Env incorporation ......................................................................... 121 
 Characterisation of Env fitness determinants ............................... 126 
 Summary of results ....................................................................... 135 
3.5 Discussion .................................................................................................. 136 
THE EFFECT OF ENVELOPE ON VIRAL 
REPLICATION  .................................................................................................... 142 
4.1 Introduction ................................................................................................ 142 
4.2 Research Aim and Objectives .................................................................... 144 
4.3 Material and Methods ................................................................................ 145 
 Samples ......................................................................................... 145 
 Plasmids used in the assay ............................................................ 145 
 Yeast recombination assay............................................................ 147 
 Generation of Infectious Molecular Clones .................................. 149 
 Virus Titre ..................................................................................... 149 
 IMC Replication ........................................................................... 149 
 Statistical analysis ......................................................................... 151 
4.4 Results ........................................................................................................ 152 
 Generation of Infectious Molecular Clones .................................. 152 
 Identification and isolation of responsive donor PBMCs ............. 152 
 Replication of IMCs in PBMCs .................................................... 154 
 Association between viral replication in PBMCs and in vivo 
frequency of variants .................................................................... 157 
 Association between viral replication in PBMCs and PSV Entry 
Efficiency...................................................................................... 158 
 Association between viral replication in PBMCs and Env fusion 
capacity ......................................................................................... 162 
 Association between viral replication in PBMCs and disease 
progression.................................................................................... 164 
 The impact of Env fitness determinants on IMC replication ........ 167 
   
vii 
 
 Summary of results ....................................................................... 170 
4.5 Discussion .................................................................................................. 171 
 ............................................... 174 
5.1 Discussion .................................................................................................. 174 
5.2 Conclusion ................................................................................................. 182 
5.3 Summary of results .................................................................................... 183 
BIBILOGRAPHY ........................................................................................................... 185 
APPENDIX A.      PRIMERS SEQUENCES AND PCR CONDITIONS ..................... 216 
APPENDIX B.      ALIGNMENTS AND PHYLOGENETIC TREES .......................... 219 
APPENDIX C.      MEDIA AND SOLUTIONS ............................................................ 226 
   
viii 
 
LIST OF TABLES 
 
Table 1.1 Incidence of dual infections ............................................................................... 21 
Table 2.1. Characterisation of viral populations over time in dual infected 
individuals ....................................................................................................... 64 
Table 3.1. Density of CD4 and CCR5 induced by Minocycline and Ponesterone A ........ 98 
Table 3.2. Antibodies used in Western blot ..................................................................... 101 
Table 3.3. Ranking of PSV entry efficiency according to cell type ................................ 107 
Table 3.4. Overall relationship between PSV entry efficiency, in vivo viral 
outgrowth and Envelope function and processing ........................................ 135 
Table 3.5.  Phenotypic characterisation of Envelope fitness determinants ..................... 135 
Table 4.1.  Ranking of replication capacity of IMCs in PBMCs ..................................... 170 
Table 4.2.  Summary of associations between infectious molecular clone 
replication capacity and in vivo outgrowth and other Env phenotypes ........ 170 
Table 4.3 Impact of Env fitness determinants on chimeric infectious molecular 
clone replication capacity ............................................................................. 170 
Table 5.1.  Summary of Env phenotype associated with in vivo outgrowth overtime .... 183 
Table 5.2.  Association between fitness determinants and Env phenotype ..................... 184 
 
 
   
ix 
 
LIST OF FIGURES 
 
Figure 1.1. HIV-1 genes and proteins. ................................................................................. 5 
Figure 1.2. HIV Classification. ............................................................................................ 7 
Figure 1.3. Distribution of HIV-1 subtypes worldwide. ...................................................... 8 
Figure 1.4. Template switching during HIV-1 reverse transcription. ................................ 11 
Figure 1.5. Recombination between 2 HIV viruses can select for fitter viruses. .............. 12 
Figure 1.6. HIV-1 transmission bottleneck. ....................................................................... 14 
Figure 1.7. Time course of HIV-1 infection and disease progression. .............................. 18 
Figure 1.8. Schematic of Envelope Structure. ................................................................... 28 
Figure 1.9. HIV entry process. ........................................................................................... 29 
Figure 1.10. HIV-1 Env trimer. ......................................................................................... 32 
Figure 1.11. Location of broadly neutralizing antibody (bNAbs) epitopes on the 
Envelope trimer. .............................................................................................. 33 
Figure 1.12. Env incorporation models explains. .............................................................. 35 
Figure 2.1. CAP84 chimeric Env clones and mutants. ...................................................... 51 
Figure 2.2.  Construction of CAP267 chimeras and CAP137 mutant. .............................. 52 
Figure 2.3. Diversity and Diversification of envelope sequence over time. ...................... 55 
Figure 2.4. Phylogenetic analysis of SGA-derived env at early time points. .................... 58 
Figure 2.5. Highlighter Plot of sequences generated at early time points. ........................ 59 
Figure 2.6. Sequence diversity over the course of infection. ............................................. 62 
Figure 2.7. RIP analysis to determine whether AB variants are recombinants. ................ 63 
Figure 2.8. In vivo frequency of viral populations over time. ........................................... 68 
Figure 2.9. Pseudovirion Entry Efficiency over 12 months of infection. .......................... 75 
Figure 2.10. Overall relationship between “in vivo” frequency and Env entry 
efficiency over time. ....................................................................................... 77 
Figure 2.11. Env entry efficiency and disease markers (viral load and CD4 count) 
over time. ........................................................................................................ 79 
Figure 2.12. Association between pseudovirion entry efficiency and CD4+ T cell 
count. ............................................................................................................... 80 
   
x 
 
Figure 2.13. Entry efficiency of CAP84 Envelope chimeras and mutants. ....................... 84 
Figure 2.14. Identification of CAP137 Envelope determinants......................................... 85 
Figure 2.15. Entry efficiency of CAP267 chimeras. .......................................................... 86 
Figure 3.1. Determine coreceptor tropism over time. ...................................................... 104 
Figure 3.2. Cellular tropism using dual inducible 293 Affinofile cells. .......................... 106 
Figure 3.3. PSV entry efficiency in U87 CD4+CCR5+ cell line. .................................... 108 
Figure 3.4. PSV Entry Efficiency in Affinofile cells expressing CD4high/CCR5low. ....... 109 
Figure 3.5. Pseudovirus entry efficiency relative to changes in CCR5 levels. ................ 110 
Figure 3.6. Correlation between PSV entry efficiency of TZM-bl and T-
lymphocyte like Affinofile cells. .................................................................. 111 
Figure 3.7. Pseudovirion sensitivity to the entry inhibitor, T20. ..................................... 115 
Figure 3.8. Correlation between pseudovirus entry efficiency and fusion capacity. ....... 116 
Figure 3.9. CAP137 Env Expression. .............................................................................. 118 
Figure 3.10. CAP267 Env Expression. ............................................................................ 120 
Figure 3.11. Correlation of gp160 cleavage with Env entry efficiency and fusion 
capacity. ........................................................................................................ 121 
Figure 3.12. CAP137 Env incorporation into PSVs. ....................................................... 123 
Figure 3.13. CAP267 Env incorporation into PSVs. ....................................................... 124 
Figure 3.14. Correlation between Env gp120 expression and gp120 incorporation. ....... 125 
Figure 3.15. Correlation between Env entry efficiency and gp120 incorporation. ......... 126 
Figure 3.16. Fusion capacity of CAP84 and CAP267 chimeras. ..................................... 128 
Figure 3.17. Env Expression and cleavage of CAP267 chimeras. .................................. 130 
Figure 3.18. CAP267 Env incorporation of the chimeras. ............................................... 131 
Figure 3.19. CAP137 Env Expression. ............................................................................ 133 
Figure 3.20. CAP137 mutant incorporation. .................................................................... 134 
Figure 3.21.  Structural modelling of potential N-glycans at positions N332 and 
N339. ............................................................................................................. 141 
Figure 4.1. Map of shuttle vector and helper plasmid used in yeast recombination 
assay. ............................................................................................................. 146 
Figure 4.2. Replication in PBMCs from different donors. .............................................. 153 
   
xi 
 
Figure 4.3. Replication of CAP137 IMCs. ...................................................................... 155 
Figure 4.4. Replication of CAP267 chimeric IMCs. ....................................................... 156 
Figure 4.5. Association between Replication Capacity and in vivo frequency of 
viral populations over time. .......................................................................... 158 
Figure 4.6. Association between overall outgrowth of viral populations and Env 
function. ........................................................................................................ 161 
Figure 4.7. Correlation between IMC Replication capacity and PSV entry 
efficiency. ...................................................................................................... 162 
Figure 4.8. Correlation between RC and fusion capacity. ............................................... 164 
Figure 4.9. Association between replication capacity of chimeric infectious 
molecular clones and markers of disease progression. ................................. 166 
Figure 4.10.  Impact of CAP137 PNG at position 332 on infectious molecular 
clone replication capacity. ............................................................................ 168 
Figure 4.11. Replication Capacity of CAP267 chimeras. ................................................ 169 
 
 




AIDS Acquired immune deficiency syndrome 
ART Antiretroviral therapy  
AUC Area under the curve  
BCN Broadly cross neutralising antibodies 
bnAbs Broadly neutralising antibodies 
C1-C5 Conserved regions 
CAPRISA Centre for the AIDS Programme of Research in South Africa 
CCR5   C-C Motif Chemokine Receptor 
CMV Cytomegalovirus 
CO2  Carbon dioxide 
CRFs Circulating recombinant forms 
CSM Complete supplement mixture 
CT C- terminal cytoplasmic tail 
CTL Cytotoxic T-cell 
CTL Cytotoxic T-lymphocytes 
CXCR4 C-X-C chemokine receptor type 4  
DCs Dendritic cells 
DC-SIGN Dendritic cell–specific intercellular adhesion molecular 3-grabbing non-integrin  
DMEM Dulbecco’s minimal essential medium 
E.coli  Escherichia coli 
EC Elite controllers 
ECL2 Extracellular loop-2  
EDTA  Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ENF Enfuvirtide 
Env Envelope 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum  
gag Coding for the viral capsid proteins 
GALT Gut-associated lymphoid tissue 
gp120  120kDa Envelope Glycoprotein 
gp41  41kDa Envelope Glycoprotein 
HAART Highly active antiretroviral therapy  
   
xiii 
 
HEK-293T Human embryonic kidney cells 
HIV-1 Human immunodeficiency virus-type1 
HIV-2 Human immunodeficiency virus-type 2 
HLA Human leukocyte antigen  
HMA Heteroduplex mobility assay 
HR1 and HR2 Heptad repeat regions1 and 2 
HTA Heteroduplex tracking assay  
IL-2  Interleukin 2 
IMC Infectious molecular clone 
Ks Kennedy sequence  
LB Luria broth 
LEU Leucine 
LL Dileucine motif  
LTNPs Long-term non progressors  
M  Molar 
MCS Multiple cloning site  
MDR Multi-drug resistant 
mg milligram 
ml millilitre  
MPER Membrane-proximal external region  
mpi month post infection 
mRNA Messenger ribonucleic acid 
MSM Male sex to male 
MVC Maraviroc  
nAb Neutralizing antibody 
Nef Negative Regulatory Factor 
ng nanogram 
ºC  Degrees Celsius 
PBMCs Peripheral blood mononuclear cells 
PBS Primer binding sequence  
PCR Polymerase Chain Reaction 
PEG polyethylene glycol 
PEI Polyethylenimine  
PHA-P Phytohemagglutinin-P 
PNGs Potential N-linked glycosylation sites 
pol Coding for reverse transcriptase   
PSVs Pseuodvirions  




RC Replication capacity 
RER Rough endoplasmic reticulum 
rev Coding for Trans activating protein  
RIP Recombinant Identification Program  
RLU Relative luciferase units  
RT Reverse transcriptase 
SDM Site direct mutagenesis  
SDS  Sodium Dodecyl Sulphate 
SDS-PAGE Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis 
SGA Single genome amplification 
SIV Simian immunodeficiency virus  
STIs Sexually transmitted infections 
Tat Trans-activator of transcription 
TBS Tris-buffered saline 
TBS-T Tris-buffered saline + Tween 20 
TCID50 Tissue culture infectivity dose 50 % 
TF Transmitted founder 
TMD Transmembrane domain  
UDS Ultra-deep sequencing  
URFs Unique recombinant forms 
USA United State of America 
V1-V5 Variable regions  
Vif Viral infectivity factor 
VL Viral load 
Vpr Viral Protein R 
Vpu Viral Protein U 
µg micrograms 
µl Microliter 
5- FOA 5 – flouro – 1, 2, 3, 6 – tetrahydro – 2, 6 – dioxo – 4 – pyrimidine carboxylic acid 
6HB Six helices bundle 





Identification of HIV-1 Envelope (Env) fitness determinants could provide functionally 
constrained, accessible regions that could be included in subunit vaccines to induce broadly 
neutralising antibodies (bnAb). We hypothesised that Env fitness determinants are common 
to circulating variants but that the plasticity of Env structure limits identification. Rapid 
evolution; however, could select for sequence changes within the determinants coincident 
with alterations in function, making identification easier. Dual infection with two 
phylogenetically distinct HIV-1 variants under the same selective pressures might result in 
rapid functional evolution, facilitating identification of Env fitness determinants. It has been 
shown that the Env plays a significant role in viral adaptation to the host environment, which 
then increases disease progression. Therefore, this study used dual infections as a model 
system to characterise Env function, its role in in vivo viral outgrowth of variants and disease 
progression and to identify fitness determinants for future vaccine design. 
Single-genome amplification (SGA)-derived env sequences of four dual infected individuals 
sampled at enrolment (0 months), 3, 6, and 12 months post infection (mpi) were analysed 
using Highlighter plots, RIP, DNA pairwise distance and Neighbour-joining trees to 
determine the in vivo evolution of infecting viral populations and their relative frequency 
over time within each participant. Representative amplicons were cloned at each time point 
and compared using a pseudovirus (PSV) entry efficiency assay. PSV infection of Affinofile 
cells induced to carry levels of CCR5 and CD4 similar to T-lymphocytes 
(CD4high/CCR5low) correlated significantly with that of TZM-bl entry (p = 0.049, r = 0.50), 
suggesting that PSV entry of TZM-bl cells was an appropriate model to represent infection 
of CD4+ T cells.  
In three participants recombinant viruses were identified early during infection, suggesting 
either rapid recombination within the dual infected individual or recombination within the 
donor prior to transmission. These recombinants had an apparent fitness advantage as they 
outgrew other viruses at 12 mpi. However, the apparent in vivo dominance of recombinants 
was not associated with enhanced Env entry efficiency for 2/3 individuals, suggesting that 
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recombination within Env did not always select for fitter variants. The variants that became 
dominant over time were further characterised by Affinofile system, T-20 IC50 and Western 
blotting to identify whether tropism, Env expression/cleavage, incorporation into viral 
particles and fusogenicity were most likely responsible for the variation in Env entry 
efficiency. All variants were R5- and T-tropic and only Env fusion capacity correlated 
significantly with Env entry efficiency data (p = 0.02, r = 0.59), suggesting that variants 
infecting dual infected participants evolved towards higher fusion capacity. Changes in Env 
fusogenicity indicated that gp41 might be a fitness determinant of PSV entry efficiency and 
analysis of SGA sequences indicated that recombination within gp41 was common to 3/4 
participants. Env chimeras were generated where gp41 was swapped between clones that 
either had the same (CAP84) or different (CAP267) PSV entry efficiency. For both 
participants, and (CAP137) gp41 was identified as a potential determinant of Env fitness. 
Moreover, two potential N-glycan sites (PNG) at position N332 and N339, previously 
reported to be involved in neutralising antibody escape, were also identified. While N332 
enhanced Env entry efficiency in one participant, N339 attenuated Env entry efficiency in 
another, potentially due to the escape mutation carrying a fitness cost.  However, neither 
PNG seemed to affect Env expression/cleavage, incorporation into viral particles and 
fusogenicity. 
As Env phenotypic characterisation focussed on PSV assays, we wanted to determine 
whether viral replication was also similarly affected. Infectious molecular clones (IMCs) 
were generated from two participants using a recombination yeast assay and replication 
capacity (RC) in peripheral blood mononuclear cells (PBMCs) was assessed using parallel 
replication. A significant correlation between RC of viruses in PBMCs and Env entry 
efficiency in TZM-bl and fusion capacity (p = 0.03, r = 0.7; p = 0.04, r = 0.7, respectively) 
was determined. IMC RC was also associated with in vivo outgrowth of viral populations at 
12 mpi although this relationship did not always coincide with the frequency of individual 
variants. Changes in the RC of the Env chimeras and mutants was not associated with 
phenotypic changes, suggesting that Env entry efficiency determinants did not play the same 
role in IMC RC as it did in PSV entry.  
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 Lastly, there was a significant negative association (p = 0.046, r = -0.59) between Env entry 
efficiency and CD4+ T decline, a marker of disease progression, supporting the previous 
finding that Env entry efficiency could be the driving agent of disease progression. This was 
also corroborated by the trend in association between RC of IMCs and faster CD4+ T decline.  
Our findings suggest that despite different host pressures, viral competition in most dual 
infected individuals selected for rapid recombination within gp41 that enhanced fusion 
capacity. Enhanced gp41 fusogenicity of the dominant viral population at 12 mpi increased 
PSV entry efficiency and replicative fitness enabling viral outgrowth. Therefore, vaccines 
that target gp41 might prevent HIV infection or at least attenuate viral fitness and slow 
disease progression. On the other hand, we showed that targeting the PNG at position N339 
of gp120 might influence viral fitness and increase viral load and/or decrease CD4 T cell 
count. This is in keeping with the association between CD4 T cell decline and PSV entry 
efficiency and IMC RC, suggesting that Env fitness plays a role in HIV pathogenicity.   







The greatest challenge to vaccine design is the high diversity of Human immunodeficiency 
virus-1 (HIV-1) as the design of one immunogen based on one population might not elicit a 
protective immune response to another divergent strain. The rapid introduction of point 
mutations and homologous swapping of regions by recombination generates a vast array of 
inter-related variants (Charpentier et al., 2006; Smyth et al., 2012). Therefore, the presence 
of two different viral strains within a single individual provides an opportunity to generate 
highly divergent variants within a short period of time (Smyth et al., 2012; Tebit et al., 2007). 
Whether these variants survive will depend on phenotypic changes that provide a replicative 
advantage and thus increase in viral fitness. Survival advantages can include resistance to 
anti-retroviral therapy (ART) (Smith, Wong, et al., 2005), escape from immune responses 
(van Gils et al., 2010; Song et al., 2012; Troyer et al., 2009) and changes in function of viral 
proteins (Gordon et al., 2016) all of which can ultimately lead to increased viral load and 
faster disease progression. This review will explore the importance of dual-infections within 
the context of viral fitness and potential consequences to HIV-1 pathogenesis. 
1.2 Overall HIV structure 
HIV-1 genome comprises nine viral genes encoding structural and accessory viral proteins 
(Figure 1.1)  (Frankel and Young, 1998). There are six accessory proteins, namely Vif, Vpr, 
Tat, Rev, Vpu and Nef, that function as trans-activators and regulators of gene expression 
and three structural proteins, Gag, Pol and Envelope (Env) (Varmus, 1988) essential to the 
production of infectious particles. HIV-1 Protease, Reverse Transcriptase (RT) and Integrase 
are encoded by polymerase (pol) with Protease required for cleavage of viral polyprotein 
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precursors into mature functional proteins (Johnson and Desrosiers, 2002; Wu, 2004). The 
polyprotein precursor, Gag-p55 (Mervis et al., 1988; Veronese et al., 1988) is encoded by 
gag and is cleaved into: 1) matrix (MA) (p17) that initiates the budding of viral particles 
(Ono et al., 2000), 2) capsid (CA)(p24) that encloses the viral genome and is important in 
assembly of infectious viral particles (Göttlinger et al., 1989), 3) p6, important for the 
incorporation of the accessory protein, Vpr into budding virus (Kondo and Göttlinger, 1996) 
and 4) nucleocapsid (p7) that helps to direct viral RNA transport and packaging, efficient 
reverse transcription and viral infectivity (Levin et al., 2005; Poon et al., 1996). 
 
 
Figure 1.1. HIV-1 genes and proteins.   Relative juxtaposition of the nine HIV-1 genes along 
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1.3 HIV Diversity 
HIV-1 is characterized by extensive genetic diversity driven by many factors: the “in vivo” 
rapid turnover rate of the virus (~ 2.6 days/replication cycle) (Ho et al., 1995), high 
replication rate of the virus (1010 viral particle/day) (Tebit et al., 2007), high mutation rate 
and lack of efficient proof-reading activity of HIV RT (Mansky and Temin, 1995), 
recombination within the quasispecies (Charpentier et al., 2006) or between two 
phylogenetically distinct variants within a single cell in the same individual (Smyth et al., 
2012) and the selection pressure of host immune responses [cytotoxic T-lymphocytes (CTL) 
and neutralizing antibody (nAb)] or ART (Frost et al., 2005; Michael, 1999). The evolution 
rate was estimated to be 0.0024 and 0.0019 substitutions per base pair (bp) per year for 
envelope (env) and gag, respectively (Capel et al., 2012). Remarkably, the virus is able to 
tolerate high mutation rates and maintain its replication fitness (Ndung’u and Weiss, 2012).  
Based on phylogenetic analysis, HIV is divided into two genetically distinct types, type 1 
(HIV-1) and type 2 (HIV-2), both able to cause AIDS although type 1 accounts for most 
global HIV infections (Kerina et al., 2013). Each type is then further subdivided into a 
hierarchy of groups, subtypes (or clades) and sub-subtypes (Figure 1.2). HIV-1 is classified 
into three groups: major (M), outlier (O), and non-M/non-O (N). HIV-1 Group M is the 
pandemic branch of HIV-1 and further classified into nine subtypes; designated with letters, 
A, B, C, D, F, G, H, J and K, distributed globally according to region (Figure 1.3). Subtype 
C is the most prevalent virus across eastern and southern Africa, contributing 52 % to HIV-
1 infections globally (www.unaids.org). The highest genetic diversity between these 
subtypes is about 30 % within env and about 20 % and 15 % within gag and pol, respectively, 
(Kerina et al., 2013; Tebit et al., 2007).  
Additionally, recombination between different subtypes has given rise to circulating 
recombinant forms (CRFs) and unique recombinant forms (URFs), that are responsible for 
20 % of global infections (Hemelaar et al., 2011) (Figure 1.3). Virus strains are designated 
as CRFs if they have identical recombination breakpoints (Robertson et al., 2000; Tebit et 
al., 2007) and are isolated from at least three epidemiologically unlinked individuals, capable 
of establishing an epidemic on its own (Hemelaar et al., 2011; Kerina et al., 2013). Thus far, 
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there are 48 different CFRs described (Hemelaar et al., 2011) such as CRF01-A/E 
responsible for the epidemic in Southeast Asia while CRF02-A/G is predominant in West 
and West Central Africa, as they represent between 50 % to 70 % of the circulating strains 
(Figure 1.3) (Peeters, 2000; Requejo, 2006; Tebit et al., 2007). However, URFs have 
heterogeneous recombinant breakpoints (Tebit et al., 2007) with no evidence of epidemic 




Figure 1.2. HIV Classification.  Human immunodeficiency virus is first grouped into type 1 and  
type 2, with the former driving the global HIV pandemic. HIV-1 is classified into 4 groups: M, 
N, O and P. Group M is further divided into nine distinct subtypes (A, B, C, D, F, G, H, J and 
K) as well as circulating recombinant forms (CRFs) (Kerina et al., 2013). 
  
HIV-1 subtypes might influence the efficacy of vaccines as plasma neutralization potency 
were significantly greater against clade-matched viruses than against mismatched variants 
(Hraber et al., 2014). Thus, polyvalent mosaic immunogens, assembled by recombination of 
natural strains of HIV-1, is one promising vaccine strategy to expand cellular immunologic 
coverage against genetically diverse circulating viruses (Barouch et al., 2010; Santra et al., 
2010).  
 





Figure 1.3. Distribution of HIV-1 subtypes worldwide.  A) The relative global dominance of  
HIV-1 subtypes including both circulating recombinant forms (CRFs) and unique recombinant 
forms (URFs) between 2004-2007. B) The dominant subtype indicated globally where the size of 
the circle indicates the extent of the pandemic in each region with subtype C driving the epidemic 
in South Africa. Modified from (Hemelaar et al., 2011). 
 
1.4 Mechanisms and impact of Diversification 
HIV-1 is a retrovirus that replicates through DNA intermediates generated by the error prone 
RT. During viral replication, misincorporation of nucleotides by RT results in a mutation 
rate of between 1.4 × 10-5 (Abram et al., 2010) to 3.4 × 10-5 mutations per bp per replication 
cycle (Mansky and Temin, 1995).  Given that HIV replicates very rapidly with a life cycle 
of 1 to 2 days (Ho et al., 1995; Wei et al., 1995) and millions of cells become infected in 
blood and different lymphoid compartments, the potential for high genetic variation is 
considerable. Although mutations may occur randomly, mutations that favour effective 
replication capacity and growth advantages will be selected (Desrosiers, 1999). In addition, 
mutations that rescue the virus from host immune responses will also provide a selective 
advantage even if they reduce the replication capacity of the virus (Desrosiers, 1999; Liu et 
al., 2007).  
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 Point mutation  
Point mutations that lead to the shifting, loss or gain of potential N-glycosylation sites 
(PNGs) are well documented in gp120 and gp41 (Kalia et al., 2003; Wang et al., 2013). 
Recently a study showed that a PNG shift from position 332 to 334 in Env during chronic 
infection enabled escape from broadly neutralising antibodies (BCN) (van den Kerkhof et 
al., 2016; Lynch et al., 2015; Moore et al., 2012). However, escape from antibody 
neutralisation is not only due to changes in N-glycosylation as point mutations within highly 
conserved structural motifs such as within the intracytoplasmic tail (CT) of gp41 also 
resulted in escape from neutralisation due to concomitant conformational changes within 
gp120 (Kalia et al., 2005).  
HLA-associated point mutations have been shown to drive viral evolution in acute HIV-1 
infection (Crawford et al., 2009; Goepfert et al., 2008; Goonetilleke et al., 2009; Li et al., 
2007; Wang et al., 2009).  Mutation within CD8+ cytotoxic T-cell (CTL) epitopes that 
conferred escape from CTL responses were detected within Gag before seroconversion 
(Altfeld et al., 2001) and individuals carrying certain HLA alleles such as B*57, B*5801 and 
B*27 in Gag tended to have slowed disease progression (Brockman et al., 2007; Chopera et 
al., 2008; Crawford et al., 2009; Leslie et al., 2004; Martinez-Picado et al., 2006). This was 
because CTL escape mutations within epitopes that fell within conserved regions had a 
detrimental effect on Gag function (Leslie et al., 2004; Martinez-Picado et al., 2006) leading 
to decreased replication fitness (Liu et al., 2007; Sunshine et al., 2015; Troyer et al., 2009). 
Previously, Miura et al., (2008) reported that in elite controllers (EC), selection of rare escape 
variants by HLA-B*57 resulted in severely compromised viral replication (Miura et al., 
2008).  
Additionally, point mutations also confer drug resistance to RT and protease inhibitors that 
have been linked to lowered viral fitness (Nijhuis et al., 2001; Quiñones-Mateu and Arts, 
2006). CCR5 inhibitors such as maraviroc (MVC) and vicriviroc (VVC) bind to CCR5 
preventing viral entry (Kuhmann and Hartley, 2008). However, MVC-resistance can be 
conferred by mutations within the CD4-binding site of Env while VVC-resistant variants are 
able to bind to inhibitor-bound CCR5 due to point mutations within the V3 loop and gp41 
fusion peptide (Anastassopoulou et al., 2009; Pugach et al., 2007; Tsibris et al., 2008) 
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although these latter changes were not linked to viral fitness (Anastassopoulou et al., 2007). 
Amino acid changes in gp41 associated with resistance to enfuvirtide (ENF/T20) has been 
associated with decreased replicative fitness (Lu et al., 2004; Reeves et al., 2005) although 
this was not always the case (Neumann et al., 2005). Therefore, single or multiple point 
mutations not only allow escape from immune responses and resistance to drug therapy, it 
can also lead to concomitant changes in viral fitness which might then influence disease 
progression. 
 HIV-1 Recombination 
HIV-1 is a diploid virus with two RNA genomes packed into one virion. During virus 
replication, RT may jump from one RNA template to another, generating genomic sequences 
comprising two (or more) parent genomes (Figure 1.4). If the two parent viruses have non-
identical genetic information, then the newly packaged RNA molecules will be a mosaic 
virus that might have “novel” properties (Blackard et al., 2002; Charpentier et al., 2006; Jetzt 
et al., 2000). These new “heterogeneous” virions continue to replicate and form a 
quasispecies of recombinant variants. Recombination was mainly found in gag/pol and env 
(Charpentier et al., 2006; Santoro and Perno, 2013; Simon-Loriere et al., 2009) and events 
can occur from 2-20 per genome per replication cycle (Charpentier et al., 2006). Both inter-
subtype (different HIV subtypes) (Magiorkinis, 2003), and intra-subtype (same subtype) 
(Kiwelu et al., 2013; Rousseau et al., 2007) recombination between two or more 
phylogenetically distinct viruses have been reported. 
 






Figure 1.4. Template switching during HIV-1 reverse transcription.  In HIV and other  
retroviruses, the reverse transcriptase (RT) enzyme can shuffle from one virus template to 
another during the formation of the double stranded DNA provirus. This generates new mosaic 
infectious virions carrying a mixture of parent viral genomes. Figure was adapted from Blackard 
et al., (2002). 
 
Similar to point mutations, recombination may also confer variants with advantageous traits, 
such as escape from immune recognition and drug resistance, resulting in enhanced 
pathogenicity (Mostowy et al., 2011). Furthermore, recombination can change viral tropism 
and virus replicative fitness and thus accelerate disease progression (Figure 1.5) (Blackard 
et al., 2002; Mostowy et al., 2011). Recombinants can also be transmitted, resulting in the 
spread of highly fit variants and altering the natural history of the HIV-1 epidemic (van der 
Kuyl and Cornelissen, 2007). 
 






Figure 1.5. Recombination between 2 HIV viruses can select for fitter viruses.   
Recombination between two HIV virions with differing drug resistance profiles can generate a 
new infectious recombinant virus resistant to both drugs. Figure adapted from Blackard et al. 
(2002). 
 
1.5 HIV-1 transmission 
The majority of HIV-1 transmission cases occur heterosexually while only 20 % of infections 
are due to percutaneous or intravenous inoculations (Cohen et al., 2011). The genital tract 
mucosa forms a protective barrier against HIV infection. However, many factors can disrupt 
this barrier such as inflammation, infection of vaginal epithelium as in the case of sexually 
transmitted infections (STIs), and hormonal contraceptives (Sagar et al., 2004), increasing 
the risk of HIV infection. Following transmission, there is a virus bottleneck. Despite the 
high diversity of HIV quasispecies in donors, a homogenous viral population was identified 
in newly infected individuals (Derdeyn et al., 2004). Studies on heterosexual transmission 
estimated that approximately 80 % of infections was as a result of transmission of a single 
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virus termed the transmitted founder (TF) (Abrahams et al., 2013; Keele et al., 2008) while 
only 60 % of men who have sex with men (MSM) and about 40 % of injection-drug users 
(IDU) became infected with a single virus (Cohen et al., 2011). Subtype C and A TF Envs 
have distinct phenotypes such as CCR5 coreceptor tropism, shorter V1-V2 loop lengths that 
are less N glycosylated, and greater sensitivity to antibody neutralization (Chohan et al., 
2005; Derdeyn et al., 2004). Other studies reported the transmission of multiple variants 
(quasispecies) (Grobler et al., 2004; Sagar et al., 2003; Woodman et al., 2011) where more 
than one virus, transmitted from the donor to the recipient, established infection. The 
frequency of multiple variant transmission varied greatly between these studies most likely 
influenced by virus subtype, study population and the route of infection (Haaland et al., 
2009). However, even in the case of multiple variants, there is evidence to suggest that the 
transmission bottleneck selects for virus with higher replication fitness (Joseph et al., 2015) 
although, this is not always the case (Song et al., 2016).  
Two scenarios have been proposed to explain the transmission bottleneck (Figure 1.6) and 
how it results in the transmission of a single virus: the first scenario suggests that after 
transmission of multiple variants only the fittest virus survives and establishes clinical 
infection while viruses with poor fitness are lost. In the second scenario, after exposure to 
HIV-1, only one virus replicates at the site of transmission and establishes systemic infection 
(Cohen et al., 2011; Joseph et al., 2015).  
However, the mechanism of multiple variant transmission is still unclear. Recent studies 
hypothesised that genital tract infections and STIs may destroy the intact mucosa and 
increase the availability of activated CD4+ T cells, thus increasing the rate of multivariant 
transmission (Haaland et al., 2009; Woodman et al., 2011). Alternatively, transmission of 
multiple variants are linked events: the transmission of one virus enhances the transmission 
of a second virus (Abrahams et al., 2013). It has been shown that high risk individuals are 
more likely infected with recombinants or phylogenetically distinct variants, suggesting that 
multiple sexual partners might provide a source of URF and fitter variants that contribute to 
increased viral loads and lowered CD4 counts (Herbinger et al., 2006; Ssemwanga et al., 
2011). 






Figure 1.6. HIV-1 transmission bottleneck.    Different scenarios proposed during transmission  
in which a single “fit virus” is able to establish productive infection while infection with a less 
fit variant or defective virus cannot establish an infection even after crossing the mucosal barrier. 
Ro indicates the reproductive ratio of the transmitted virus, where Ro <1 indicates terminated 
infection. Taken from Cohen et al., (2011). 
 
This thesis examines and characterise viruses isolated from four high-risk women from the 
CAPRISA 002 cohort in South Africa. In a previous study (Woodman et al., 2011) these 
participants were identified to be infected with two phylogenetically distinct variants at 
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enrolment, suggesting the transmission of more than one variant during early stages of 
infection either simultaneously or within a short time before seroconversion. Moreover, these 
participants were diagnosed to have one or more STIs at enrolment which most likely 
contributed to the disruption of the mucosal barrier and thus increased the susceptibility to 
HIV infection (Woodman et al., 2011). It has been hypothesised that coinfection of highly 
diverse variants would provide the sequence space for rapid selection of fitter variants 
leading to enhanced disease progression. However, there have been conflicting evidence as 
to whether multivariant transmission is associated with increased disease progression 
(Andreani et al., 2011; Grobler et al., 2004; Sagar et al., 2003; Woodman et al., 2011). 
1.6 HIV-1 disease progression  
Advanced techniques enable researchers to detect viral RNA and early immune responses 
within the first few weeks of HIV-1 infection (McMichael et al., 2010). This period is 
associated with impaired early innate immune responses and damage to the genital mucosa 
due to viral cytopathicity (McMichael et al., 2010). 
Viral RNA can be detected 7 to 21 days after HIV-1 transmission and this period is known 
as the “eclipse phase” and refers to the time from virus entry into a cell to production of new 
virions (Figure 1.7) (Cohen et al., 2011; Haase, 2011; McMichael et al., 2010). During this 
time, virus replicates exponentially in the mucosa, submucosa and draining lymphoreticular 
tissues, targeting different cell types including Langerhans’ cells (LCs), dendritic cells 
(DCs), resting CD4+ T cells (Haase, 2011) and activated CD4+ T cells (Cohen et al., 2011). 
In addition, the virus establishes latent infection in long lived resting CD4 cells (Haase, 
2010).  
Following the eclipse phase, the virus and/or virus-infected cells spread to other lymphoid 
tissues and the gut-associated lymphoid tissue (GALT) where activated CD4+CCR5+ 
memory T cells are found in abundance for rapid replication (McMichael et al., 2010). 
Plasma viremia levels can peak at 107 or more copies of viral RNA per millilitre of blood 
(Coffin and Swanstrom, 2013) at around 21-28 days (Haase, 2011; McMichael et al., 2010). 
During this period known as peak viremia, the number of CD4+ T cells are significantly 
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depleted and acute phase symptoms might appear (Haase, 2011) (Figure 1.7). The first 
immune response modulated by DCs and natural killer (NK) cells appear during this stage 
and is characterised by a large burst of inflammatory cytokines (Cohen et al., 2011). In 
addition, CD8+ T cell responses and non-neutralising anti-HIV antibodies (seroconversion) 
have also been detected at peak viremia (Gaines et al., 1988). Tomaras et al. (2008) reported 
the first B cell response in the form of plasma immune complexes 8 days after HIV detection 
and the first anti-HIV-1 antibody 13 days after the appearance of virus. Early events are 
critical to HIV survival and this period is considered a window of opportunity for vaccine or 
early intervention to prevent systemic infection (Fauci, 2007; Haase, 2011). 
After peak viremia, the viral load decreases and stabilises over 21-20 weeks known as viral 
set point. At the same time, CD4+ T cell numbers increase to near normal concentrations in 
blood although counts continue to fall in the GALT. However, blood CD4+ T cell numbers 
begin to decline over time and is a surrogate marker for disease progression (Maartens et al., 
2014). The chronic phase of infection (known also as clinical latency), can extend from 1-20 
years and infected individuals can remain asymptomatic throughout (Coffin and Swanstrom, 
2013). This stage is maintained by a balance between virus turnover and immune responses 
that limit viral replication (McMichael et al., 2010) until viremia increases and the number 
of CD4+ T cells declines to the point at which the immune system cannot control adventitious 
infectious agents (Coffin and Swanstrom, 2013). 
Based on viral loads and CD4+ T cell counts, the clinical course of HIV infection was 
classified into three stages: 1) primary infection or acute phase of infection, when the viral 
load is high, 2) clinical latency, when the viral load is stable, and 3) AIDS-defining stage, 
where the viral load is high and host immunity is destroyed (Figure 1.7) (Mellors, 1997; 
Mylonakis et al., 2001). However, the rate of disease progression is highly variable between 
infected individuals and they are categorised as rapid, typical (or intermediate), slow or long-
term non progressors (LTNPs) (Langford et al., 2007; Pantaleo and Fauci, 1996) and EC  
(Zaunders and van Bockel, 2013).  
Most HIV infected individuals (70-80 %) are typical progressors that follow the clinical 
course of infection described above. Typical progressors have long asymptomatic periods of 
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clinical latency (8-10 years) with CD4+ T cell counts usually higher than 500 cells/µl 
(Jurriaans et al., 1994; Pantaleo and Fauci, 1996). Progression to AIDS-defining illness 
occurs when the CD4+ T cell counts drops and plasma viral load increases (Langford et al., 
2007; Mellors, 1997; Pantaleo and Fauci, 1996; Phillips and Pezzotti, 2004). Initially, ART 
was introduced once CD4+ T cell levels dropped to 200 cell/ul but recently it has been 
debated whether ART should be initiated soon after HIV-1 infection irrespective of CD4+ 
levels (Ying et al., 2016). Rapid progressors on the other hand, comprising 10-15 % of 
infected individuals, progress to AIDS within two to three years. These individuals 
experience prolonged acute infection with no clinical latency transition. The CD4+ T cell 
counts decline very rapidly to less than 350 cell/µl within the first year of infection (Mlisana 
et al., 2014) with a rapid rise in viral load (between 3000 copies/mL to ≥ 300 000 copies/mL) 
(Langford et al., 2007). However, in LTNP, the viral load drops after acute infection and 
their CD4+ T cell counts remain within the normal range for several years (eight to ten) 
(Mandalia et al., 2012; Pantaleo and Fauci, 1996; Zaunders and van Bockel, 2013) whereas 
ECs suppress viral load to below detectable levels (Mandalia et al., 2012). 
Variation in disease progression of HIV-1 infected individuals could be due, in part, to the 
genetic complexity/diversity of infecting viruses impacting the rate of disease progression 
(Sagar et al., 2003). Another study showed that diversification over the course of infection 
also influenced the rate of disease progression (Mani et al., 2002). Thus, the genetic diversity 
of viral populations circulating in infected individuals may play a role in determining the 
severity of the disease.  





Figure 1.7. Time course of HIV-1 infection and disease progression.   Average HIV-1  
disease progression of untreated typical progressors. CD4+ T cells are depleted progressively in 
the gastrointestinal tract (GIT) (green line) and remain low throughout infection while CD4+ T 
cells in blood (blue line) are depleted during acute phase of infection but rise again during the 
asymptomatic period also called “clinical latency”. HIV RNA copies (viral load) (red line) peak 
during acute infection and stabilise during clinical latency before rapid viral replication gives 
rise to a highly diverse viral population (quasispecies) when CD4+ T cells are depleted, and 
AIDS-defining illness appear. Graph adapted from (Maartens et al., 2014). 
 
1.7 Dual infection 
 Grobler et al., (2004) defined dual infection with the same subtype “as an infection with 2 
phylogenetically distinct viruses that are no more closely related to each other than are 
another pair of epidemiologically unlinked viruses, with a mean pairwise DNA distance at 
least as distant as that to a group of unlinked sequences”. Dual infection is classified into two 
groups based on the timing of infection: 1) coinfection of two viral strains occurs prior to 
seroconversion, either simultaneously or within a brief period of time (Jobes et al., 2006), 
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(this usually takes anywhere from a few weeks to a few months), and 2) super-infection, also 
known as reinfection, when an HIV-positive individual becomes infected with a second 
strain after seroconversion (Gottlieb et al., 2004; van der Kuyl and Cornelissen, 2007). 
Super-infection has been the focus of several studies due to its relevance to vaccine design: 
infection of one virus does not protect against infection by others. However, coinfection with 
multiple strains prior to adaptive immune responses might also be relevant to the efficacy of 
vaccine trials (Jobes et al., 2006) and the design of multiple subunit/epitope vaccines (Powell 
et al., 2010). Phylogenetically distinct strains can be transmitted from the same donor or from 
multiple partners (Ssemwanga et al., 2011) and dual infection can occur between CRFs and 
URFs  (Girard et al., 2006; Smith, Richman, et al., 2005) or within subtypes (Artenstein et 
al., 1995), between HIV-1 and HIV-2 (Georgoulias, 1988) as well as between HIV-1 groups 
(De Oliveira et al., 2017).  
 Incidence of dual infection 
The prevalence of CRFs and URFs globally suggests high frequency of dual infections 
(Girard et al., 2006), although identification of dual infections is rare (Smith, Richman, et 
al., 2005) with none detected in studies of chronically infected individuals in more than 1072 
and 215 person-years of study (Gonzales et al., 2003; Tsui et al., 2004). Other studies, 
however, have identified HIV dual infection during chronic infection, (Brenner et al., 2004, 
p. 1; Fang et al., 2004; Grobler et al., 2004; Pernas et al., 2006), suggesting that susceptibility 
to infection with more than one strain is not restricted to early HIV infection.  
The earliest report of dual infection, published in 1987, was on an experimental animal 
model. The aim of the study was to infect chimpanzees with two different strains of HIV-1. 
After the first infection, no AIDS-like syndrome was observed in chimpanzees however, 
after infection with the second strain, high antibody titres to both virus strains were detected 
(Fultz et al., 1987). In 1994, Sala et al., (1994) reported the first human dual infection when 
he isolated two distinct viral strains from LCs of skin  (Sala et al., 1994). Later, in 1995, two 
further reports were documented: The first one identified a patient coinfected with multiple 
strains of subtype B virus (Zhu et al., 1995), and the other reported two patients in Thailand 
who were infected with subtypes B and E variants (Artenstein et al., 1995). In 1996, Janini 
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(1996) reported a case of dual infection during the analysis of 33 samples from Brazilian 
patients, with two distinct HIV-1 subtypes F and D using restriction fragment length 
polymorphism (RFLP). After that, many reports of dual infection (coinfection and 
superinfection) were documented (Table 1.1). In 2002, two cases of superinfection were 
found in Thailand (Ramos et al., 2002) and another case was reported in which a man infected 
with HIV-1 subtype AE became infected with an HIV-1 subtype B virus (Jost et al., 2002). 
Both Smith et al., (2004) and Yerly et al., (2004) indicated approximately 5 % incidence of 
dual infection in IDUs in Geneva and Lausanne, sites of a Swiss Cohort (Smith et al., 2004; 
Yerly et al., 2004). In 2004, Gottlieb et al, (2004) analysed sixty-four patients from two 
different cohorts, the Seattle Primary Infection cohort and the South African female sex 
workers cohort. He found five patients (~8 %) with intra-subtype HIV-1 dual infection, four 
participants were co-infected with two strains of subtype B, and one was superinfected with 
a subtype C variant <3 years’ post-infection with the first virus (Gottlieb et al, 2004). The 
frequency of dual infections has been reported to range from 6 to 56 % (Table 1.1). The 
global variation in the incidence of dual-infections could be due to differences between 
cohorts, intra-subtype infections, timing of infection and the inability to detect variants at 
low frequency or intra-subtype recombination (Burke, 1997; Pacold et al., 2010). 
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Table 1.1 Incidence of dual infections 








Seattle Primary Infection Cohort 
and South African female sex 
workers Cohort 
United states 
(USA) & South 
Africa (SA) 
(Gottlieb et al., 2004) 
Coinfection Intra-subtype 19 
Female sex worker, Durban 
cohort 
SA (Grobler et al., 2004) 









32 Amsterdam cohort (2003-2007) Netherland 








Women's Interagency HIV Study 
(WIHS) 
USA Templeton et al. 2009 
Coinfection intra-subtype 9 
CAPRISA cohort 002 (2006-
2009) 
SA (Woodman et al., 2011) 






San Diego Primary Infection 
high-risk MSM Cohort 







Chinese MSM Cohort China (Luan et al., 2017) 
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 Method of Identification 
Identification of dual infection requires molecular evidence of the co-circulation of two or 
more viral populations with a DNA distance greater than within-host evolution from one 
single founder virus (Pacold et al., 2010). Due to the large genetic differences between 
subtypes, inter-subtype dual infection is easier to detect than intra-subtype dual infection 
because of similarity between infecting strains (Burke, 1997; Pacold et al., 2010). Intra-
subtype dual infection is limited to molecular and serological methods (Jobes et al., 2006). 
Challenges facing the detection and estimation of the incidence of intra-subtype dual 
infection are multifactorial: insufficient longitudinal sampling, insensitive detection methods 
to detect viral strains at low frequency, and the rapid emergence of recombinant viruses. 
Recombination limits the ability to detect initial parent virus based on a single genome 
fragment and thus analysis of partial gene or sub-genomic sequences might lead to an 
underestimation of the number of HIV-1 dual infected individuals (Jobes et al., 2006; Pacold 
et al., 2010).  
In order to overcome sampling limitations, individuals should be enrolled into studies within 
weeks of infection and followed longitudinally for years (van Loggerenberg et al., 2008). 
Moreover, detection of dual infection can be strengthened by applying more than one 
methodology such as heteroduplex mobility assay (HMA) and single genome amplification 
(SGA) (Woodman et al., 2011). HMA is one of the earliest methods for identifying dual 
infection and is considered a reliable method in estimating HIV-1 diversity (Sahni et al., 
2007). It can detect minor variants present at low frequency in a background of distinct 
quasispecies (Delwart et al., 1994). However, the method has limitations such that it probes 
only a fraction of the gene of interest and not the whole gene or genome (Salazar-Gonzalez 
et al., 2008). SGA is based on diluting the cDNA template to an endpoint in which ≤ 30 % 
of subsequent PCR reactions are positive, statistically supporting the notion that each 
amplicon was derived from a single cDNA template (Keele et al., 2008; Salazar-Gonzalez et 
al., 2008). This strategy avoids artefacts induced by recombination between multiple 
templates during PCR (Etemad et al., 2015) and diversity estimates were considered to be a 
true reflection of the viral population. However, this method also has limitations, as it is 
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subjected to sample bias and might also underestimate the number of viruses present in a 
sample (Pacold et al., 2010; Woodman et al., 2011). Next-generation or ultra-deep 
sequencing (UDS) technologies, providing high resolution estimates, seems particularly 
effective for monitoring diversity of rapidly mutating viruses such as HIV-1 (Bushman et al., 
2008; Eriksson et al., 2008). Pacold et al., (2010) showed that UDS was equally or more 
effective than SGA at detecting dual infections, able to detect variants at a frequency of 1 % 
(Pacold et al., 2010). UDS has been used in recent studies to show the prevalence of 
coinfections and superinfection incidence (Luan et al., 2017; Wagner et al., 2014) suggesting 
it might be the method of choice to identify dual infections in future studies. However, 
irrespective of method used, lack of longitudinal sampling and targeting of single genomic 
regions are likely to lead to underestimating the frequency of dual infections (Luan et al., 
2017). The challenge to detect phylogenetically distinct viruses will impact the ability to 
fully characterize the phenotype of variants infecting dual infected individuals. 
 Association between dual infection and increased disease progression 
Most of the reports available to date are mainly on inter-subtype recombination and 
superinfection and there are very few reports on the effect of intra-subtype recombination 
before seroconversion between co-infected phylogenetically distinct HIV strains and their in 
vivo effect on disease progression. It is possible that the timing of recombination and early 
emergence of fitter viruses within the context of host-specific immune responses could 
determine how rapidly the infected individual progresses to AIDS-defining illnesses. 
Therefore, there is a need for longitudinal studies of co-infected individuals to understand 
how viral fitness could contribute to increased disease progression. 
It has been suggested that dual infections influence HIV disease progression, as it is 
accompanied by a rise in plasma viral load and a decline in CD4+ T cell numbers (Gottlieb 
et al., 2004; Grobler et al., 2004; Sagar et al., 2003). One of the first studies that showed how 
recombination between two strains resulted in enhanced pathogenicity involved an in vitro 
study of infected rhesus monkeys. When two attenuated non-pathogenic phylogenetically 
distinct strains of simian immunodeficiency virus (SIV) with deleterious mutations (delta-
vpx/vpr and delta-nef genes) were used to infect rhesus monkeys simultaneously, a full-
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length, proviral DNA of SIVmac239 virus was isolated from PBMCs within two weeks of 
infection. Furthermore, there was a concomitant increase in viral load and decline in CD4+ 
T lymphocyte concentrations (Wooley et al., 1997). 
A number of human studies also reported similar associations between dual infections and 
disease progression: a case of MSM transmission where infection of two phylogenetically 
unlinked viruses was associated with rapid progression to AIDS defining illnesses in less 
than two years  (Liu et al., 1997). Recombination selected for a mosaic virus with increased 
fitness, suggesting that recombinants that emerge from dual infection accelerated disease 
progression in this participant (Liu et al., 2002). Subsequent studies also reported that the 
emergence of recombinant viruses from inter-subtype and intra-subtype recombination was 
associated with increased viral load and decreased CD4+ T count (Fang et al., 2004; Gottlieb 
et al., 2004; Grobler et al., 2004; Nájera et al., 2002; Ramirez et al., 2008).  
A male volunteer from the world’s first Phase 3 HIV vaccine efficacy trial (VAX004) got 
coinfected with two strains of subtype B despite receiving three immunizations. 
Recombination between the two strains resulted in a highly diverse viral population and rapid 
disease progression, leading to the commencement of ART (Jobes et al., 2006). Importantly, 
a recent finding on a dual-infected study participant showed that a recombinant virus 
emerged within 18 mpi with enhanced viral fitness compared to the parent viruses. This 
suggested that recombination facilitated the rapid generation of fitter viruses that could drive 
increased viral load and disease progression (Gordon et al., 2016). 
Sagar at al. (2003) reported on 89 women from Kenya, who were infected with multiple 
variants that lead to rapid disease progression with significantly high viral loads (4.84 log10 
copies/ml) and low CD4+ T-cell counts (median 416 cells/ µl) within the first year of 
infection. In two longitudinal studies on female dual infected sex workers, CD4+ T cell 
counts dropped to below 200 cells/µl within three years post-infection (Gottlieb et al., 2004; 
Grobler et al., 2004). Moreover, a case of intra-subtype superinfection with a “wild type” 
virus after primary infection with a drug resistant virus within the first four months resulted 
in a sharp increase in viral load with concomitant decline in CD4+ cell counts, suggesting 
that the second virus had high in vivo viral fitness compared to the first virus leading to rapid 
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disease progression. Sequence analysis showed that this second viral strain had additional 
polymorphisms (K20R, M36I, L63P) in the protease gene that were not present in the first 
strain, suggesting that these changes could play a role in the higher in vivo fitness of the 
second strain (Koelsch et al., 2003). Recently, UDS analysis of sixty-four HIV-1 early-
infected participants showed that both coinfections and dual infections were associated with 
increased disease progression (Luan et al., 2017). 
On the other hand, other studies have not shown a significant link between dual infections 
and disease progression. In one  study, two individuals were found to be infected with two 
distinct strains of HIV-1 subtype B and were defined as LTNP and remained asymptomatic 
without ART for > 15 years (Casado et al., 2007). Another study, suggested that dual 
infections were not always associated with increased disease progression, but that disease 
outcome dependended on the interplay between viral and host factors (Woodman et al., 
2011). Although a number of reports provide evidence of a significant association between 
dual infection and disease progression, further studies are still required to identify the extent 
of the association and factors that influence this relationship. 
 Dual infection and Drug Resistance 
Besides increased disease progression, dual infections are also linked to drug resistance 
mutations (Figure 1.2). In one study, a lymphoblastoid cell culture was coinfected with a 
mixture of two distinct viruses. One virus was highly resistant to a protease inhibitor (SC-
52151) and the other highly resistant to zidovudine. The recombinant virus isolated was 
resistant to both drugs (Moutouh et al., 1996). After initial infection with a drug sensitive 
virus, superinfection with an intra-subtype, drug resistant virus was associated with high viral 
load and low CD4+ T counts, suggesting enhanced in vivo fitness (Smith et al., (2005). 
Another study of a dual infection between HIV-1 (CFR-02 A/G) and HIV-2 (clade A) (HIV-
1/2) was reported in a young heterosexual man. Both viruses conferred multiclass drug 
resistance mutations that was associated with rapid disease progression (Castro et al., 2012). 
Recently, one case of dual infection (intra-subtype) with multidrug resistant viruses reported 
a participant superinfected with a highly divergent multi-drug resistant strain that lead to 
ART failure and subsequent change in highly active antiretroviral therapy (HAART) (Martin 
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et al., 2016). Most of these cases refer to superinfection, highlighting the lack of studies on 
HIV-1 coinfections. However, it is reasonable to suggest that coinfection with drug resistant 
phylogenetically distinct viruses would also lead to treatment failure and/or enhanced viral 
fitness. 
1.8 HIV-1 Envelope 
The first step in HIV-1 infection begins with virus adhesion to the host cell surface via CD4 
and CCR5 (and other coreceptors) receptors followed by fusion between viral and host cell 
membranes and subsequent delivery of the virus core material to the cell cytoplasm. This 
process is mediated by the viral Env.   
 Structure and function 
HIV-1 Env is a heterodimer of two glycoprotein subunits, the surface glycoprotein gp120 
and transmembrane (TM) gp41 that are non-covalently connected to form a trimer on the 
surface of the HIV virion. Env is co-translationally modified in  the rough endoplasmic 
reticulum (RER) as a gp160 precursor of approximately 845–870-amino acids (Staropoli et 
al., 2000; Wyatt, 1998), with N glycosylation with high mannose carbohydrates (Freed and 
Martin, 1995a). Oligomerization of gp160 monomers also occurs in the RER (Checkley et 
al., 2011). Subsequently, and during transport of the Env precursor to the cell surface, the 
protein undergoes trimerization and modification of high-mannose sugar chains to form 
hybrid and complex-type N-glycans (Freed and Martin, 1995a; Li et al., 2000).  Lastly, gp160 
is cleaved within the trans-Golgi at a K/R-X-K/R-R motif by a cellular protease, Furin 
generating mature gp120 and gp41 subunits. The cleavage process is critical for viral fusion 
and infectivity (Blay et al., 2007; Freed et al., 1989) and the trimers are incorporated into the 
budding virion and displayed as a spike on the surface of viral particles (~ 10–14 
spikes/virion) (Didigu and Doms, 2012; Staropoli et al., 2000; Wyatt, 1998). The three gp120 
and three gp41 subunits form a cage-like structure as was described by Mao et al., (2012) 
using  ~11-Å cryo-electron microscopy (Mao et al., 2012). However, it has also been shown 
that uncleaved gp160 as well as monomers are also incorporated into the virus and these 
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could act as decoys for the immune response as they lack the native, functional structure of 
Env (Herrera et al., 2005; Moore et al., 2006). 
Gp120 consists of five highly conserved regions (C1-C5) that are predominantly located in 
the inner domain of the protein, or the core, and five highly variable regions (V1-V5) that 
are located on the outer domain of the protein (Figure 1.8) (Modrow et al., 1987). The two 
domains are connected by a third domain called the bridging sheet (Koning et al., 2002). The 
first four variable regions are demarcated by disulfide bridges at each end and are important 
mainly in modifying the immunogenicity and antigenicity of gp120 due to their high number 
of N-linked glycosylation sites. In addition, V3 is important for coreceptor binding, viral 
tropism (Hwang et al., 1991) and membrane fusion (Freed et al., 1991). The conserved 
regions play a crucial role in gp120 folding and binding to CD4 (Didigu and Doms, 2012; 
Kwong et al., 1998; Wilen et al., 2012a). Gp41 is about 345 amino acids that are divided into 
three major domains: an ectodomain (or extracellular), a transmembrane domain (TMD), and 
a C- terminal cytoplasmic tail (CT) (Figure 1.8) (Montero et al., 2008). 
The ectodomain contains: 1) an N-terminal, hydrophobic region known as the fusion peptide 
(FP) that inserts into the target cell membrane during the fusion/entry process, 2) two heptad 
repeat regions (HR1 and HR2) which are also known as N-helix and C-helix, respectively, 
connected by a disulfide bridge within a hydrophilic loop, and 3) the membrane-proximal 
external region (MPER) that is found to be a highly conserved and Tryptophan-rich (Didigu 
and Doms, 2012; Montero et al., 2008). The TMD, that anchors the Env in the viral 
membrane, consists of approximately 25 highly conserved amino acids. It was found to play 
a role in Env-mediated membrane fusion (Checkley et al., 2011). 
The CT consists of different motifs: the internalization signal, YSPL; the Kennedy sequence 
(ks); the conserved amphipathic α-helices LLP-1, LLP-2, and LLP-3; and a C-terminal 
dileucine motif (LL) that are involved in endocytosis and intracellular distribution of Env 
(Checkley et al., 2011; Yue et al., 2009). LLP-1 and LLP-2 are found in the central region 
and, at the C-terminal region, respectively of gp41 CT, while LLP-3 is located between the 
other two helices (Figure 1.8A). The first two LLP segments are positively charged regions 
due to the presence of Arginine residues on one face of the α-helix. These regions are 
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Figure 1.8. Schematic of Envelope Structure.  A) Diagram of Envelope showing gp160  
comprising gp120 and gp41 subunits. The variable regions are indicated by grey diamonds, the 
fusion peptide is indicated in red, HR1 and HR2 are in purple and the transmembrane domain 
(TMD) is in yellow. Gp41 consists of the internalization signal (YSPL); the Kennedy sequence 
(ks); the conserved amphipathic α-helices LLP-1, LLP-2, and LLP-3; and a C-terminal dileucine 
motif (LL). B) Gp120 linear structure showing the five variable loops with disulphide bonds 
indicated in grey with the constant regions between the variable loops (Checkley et al., 2011). 
. 
 
1.8.1.1 Entry of CD4+ cells 
Entry of CD4+ cells can be summarized in three steps: 1) gp120 - CD4 binding, 2) gp120–
chemokine receptor binding and 3) membrane fusion facilitated by gp41 (Figure 1.9). Gp120 
binding to the CD4 receptor stimulates conformational changes and rearrangement in gp120, 
that allows exposure of the coreceptor binding sites necessary for gp120 binding to CCR5 or 
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CXCR4 (Wilen et al., 2012b). Initial gp120 conformational changes involve the shifting of 
the V1/V2 stem to expose the V3 loop coreceptor binding site, followed by the formation of 
the bridging sheet, the second coreceptor binding site (Koning et al., 2002; Rizzuto, 1998). 
Binding to the coreceptor involves two interactions: firstly, the crown of the V3 binds to the 
extracellular loop-2 (ECL2) of the CCR5 coreceptor followed by binding of the four-
stranded bridging sheet and the base of V3 with the tyrosine sulfate of the CCR5 N- terminal 
domain (Huang et al., 2007). Then, each gp120 monomer rotates and partially reveals the 
gp41 stalk. Furthermore, Env-CD4 interaction is also associated with changes in the CD4 
receptor which bring the virus and target cell membranes closer (Kwong et al., 1998; Liu et 
al., 2008; Wilen et al., 2012a). 
 
 
Figure 1.9. HIV entry process.  A) HIV-1 Envelope inserts into the membrane via gp41 with  
the cytoplasmic tail facing into the cell. B) The virus entry mechanism is summarized by three 
steps: 1) CD4 binding resulting in conformational change, 2) V3 loop binding to coreceptor 
resulting in insertion of fusion peptide into the host cell membrane, and 3) Formation of the six-
helix bundle drawing the viral and cell membranes close together for fusion. Figure adapted from 
Wilen et al. (2012b). 
 
After gp120 binding to the coreceptor, additional conformational changes in gp120 and gp41 
trigger the exposure of the FP of gp41 that inserts into the cell membrane, destabilizing it 
and resulting in the formation of a fusion pore that culminates in the fusion of host and viral 
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membranes and the delivery of the viral core (capsid) into the cytoplasm (Checkley et al., 
2011; Liu et al., 2008; Yue et al., 2009). The FP of each gp41 then folds and brings the N-
terminal HR-1 together to form a triple-stranded coiled coil structure. Subsequently, the C-
terminal HR-2 from each gp41 subunit folds back and packs into a groove of the triple-
stranded coiled coil. The formation of the 6HB stabilizes and stimulates the fusion pores to 
expand (Markosyan et al., 2003, 2009) and juxtapose the viral and host cell membranes 
leading to fusion (Figure 1.9). Both cell-cell fusion and virus-cell fusion can occur in vivo 
and both processes are mediated by Env (Freed and Martin, 1995a). 
Env coreceptor binding sites have different affinities for CCR5 and CXCR4 which determine 
coreceptor tropism. The V3 region, with its positively charged residues is the main region 
responsible for determining viral tropism. Viruses that utilize CCR5 for entry are called R5 
viruses and have a net V3 charge of +3 to +5. These viruses are usually responsible for virus 
transmission, and are found during the early stage of HIV infection whereas subtype B 
viruses that use CXCR4 i.e. X4 viruses with a net V3 charge of +7 to +10, emerge late during 
infection. Viruses that are able to bind to both CCR5 and CXCR4 for entry are designated as 
dual tropic (Hartley et al., 2005; Koning et al., 2002; Staropoli et al., 2000). The emergence 
of X4 and R5X4 tropic viruses later in infection is associated with a decline in CD4+ T cells 
and increased disease progression (Connor et al., 1997; Schramm et al., 2000). There is an 
important distinction between coreceptor usage and cellular tropism (Gorry and Ancuta, 
2011). Viruses that infect macrophages are called macrophage-tropic viruses (M-tropic), 
while viruses that are able to infect CD4+ T cells are called T-lymphocyte tropic (T-cell 
tropic) even though both M-tropic and T-tropic viruses utilise CCR5. TFs are not M-tropic 
(Nofemela, 2013; Ping et al., 2013) although the ability to infect macrophages over the 
course of infection increases. The distinction between M-tropism and T-tropism is the ability 
of M-tropic variants to bind to low levels of CD4 on macrophages (Gorry et al., 2004; Gray 
et al., 2005) whereas T-tropic virus requires high levels of CD4 associated with T 
lymphocytes (Gorry et al., 2014; Ping et al., 2013). Therefore, viruses that are transmitted 
require high levels of CD4 for infection. 
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1.8.1.2 Envelope role in HIV-1 escape immune responses 
Env is heavily glycosylated (Figure 1.10) carrying about 24 to 28 PNGs defined by the 
sequence motif: NXS or NXT where X is any amino acid other than proline (Lavine et al., 
2012). Some PNGs are highly conserved in most subtypes, such as N241 within C2 on gp120, 
while others are highly conserved in some subtypes and not in others. For example, N339 
within C3 of gp120 is highly conserved in HIV-1 subtype BC and B with 100-83%, 
respectively, but not in subtype AE (Wang et al., 2013). The high density of N-glycans plays 
many significant roles in Env function. N-glycosylation influences Env folding and 
processing and thus Env incorporation, virus entry and infectivity (Wang et al., 2013), 
receptor and coreceptor binding (Pollakis et al., 2001) and provides a “glycan shield”  that 
protects against host immune responses (Moore et al., 2012; Townsley et al., 2016). More 
recently, it has been found that these N glycans are targeted by broadly neutralising 
antibodies (bnAbs) (Doores, 2015). 
Env is under constant selective pressure by the host immune system and the addition and 
deletion of PNGs is a common mechanism to escape neutralisation (Wei et al., 2003) while 
contributing to the high diversity between HIV-1 variants. More recently, a study showed a 
shift in PNG position from 334 to 332 after 6 months of infection to escape early strain-
specific antibodies (Moore et al., 2012), confirming the important role of N-glycosylation in 
evasion of immune responses. The N-glycan at position 332 was mapped to the gp120 outer 
domain within the epitope for a bnAb, 2G12, that is found within the glycan patch (Figure 
1.11) (Lavine et al., 2012; Murin et al., 2014). 
A fraction of HIV-1 infected individuals are able to generate bnAbs against diverse primary 
isolates (Pejchal et al., 2011). These bnAbs take years to evolve a high level of neutralisation 
breadth (Burton and Mascola, 2015). bnAbs target different regions in HIV-1 Env such as 
VRC01 that recognises the CD4-binding site of gp120 and 4E10 and 10E8 bnAbs that target 
the MPER on gp41 (Figure 1.11) (Doores, 2015). Interestingly, 2G12, interacts with multiple 
N-linked glycans, including N295, N332, N339 and N392 within the highly immunogenic 
“mannose patch” (Murin et al., 2014), suggesting that N-glycans contribute to nAb epitopes. 
In fact, the appearance of the PNG at site 332 6 months after infection not only allowed 
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escape from nAb but itself became the target for highly potent bnAb such as mAbs PGT121–
PGT123, PGT125–PGT128, PGT130, PGT131 and PGT135–PGT137 (Moore et al., 2012). 
Therefore,  although Env N-glycans protect the virus from neutralising antibodies, they are 
also the target for highly potent BCN antibodies (Binley et al., 2010). 
 
 
Figure 1.10. HIV-1 Env trimer.  The three heterodimers are distinguished by stick, ribbon and 
grey surface representation on the left and a table of evasion mechanisms are indicated on the 
right. Gp120 is in red and gp41 is multi-coloured (from a blue N terminus to an orange C 
terminus), and crystallographically defined glycans are in green”. The MPER of each 
heterodimer is shown by broken lines juxtaposed along the viral membrane. From “Structure and 
immune recognition of trimeric pre-fusion HIV-1 Env” (Pancera et al., 2014). 
 
Deletion of N332 (and N386) resulted in a significant disruption of entry of YU-2 virus 
subtype B but not of JRFL of the same subtype (Lavine et al., 2012). However, the same 
PNGs were not essential for virus entry of clade BC virus (Wang et al., 2013), suggesting 
that the effect of PNGs on virus entry/infectivity can vary dramatically between subtypes 
and even between isolates of the same subtype. The loss of PNGs at V1/V2 and C1/C2 of 
gp120 resulted in significant loss of virus infectivity (Wang et al., 2013) possibly because 
PNGs maintain the steric conformation of HIV-1 Env (Huang et al., 2012). However, other 
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PNGs were reported to enhance viral activity such as N408 and N411 located in V4 of gp120 
(Wang et al., 2013). Interestingly, deletion of some PNGs, such as N355 in C3 of gp120 and 
N611 in gp41, had no significant effect on viral entry despite causing a significant reduction 
in gp120 incorporation into virions (Wang et al., 2013). Overall, PNGs not only mask 
epitopes as a mechanism to escape the immune system, they also play a crucial role in Env 
entry and viral fitness. 
 
 
Figure 1.11. Location of broadly neutralizing antibody (bNAbs) epitopes on the Envelope 
trimer.  Antibodies are listed on the right that recognise HIV-1 Env epitopes highlighted in 
different colours on the left [CD4bs (red), V1/V2 (blue), V3/Asn332 glycan patch (green), 
gp120/gp41-interface (brown), MPER (denoted as a grey rectangle)]. The surface area of gp120 
and gp41 is highlighted in light grey and in dark grey, respectively. From Zhang et al, (2016). 
(Zhang et al., 2016). 
 
 
1.8.1.3 Env expression and incorporation into viral particles 
During virus assembly, Env trimers are incorporated into viral particles (Lambele´ et al., 
2007), an essential step in the formation of infectious virions (Affranchino and González, 
2014; Freed and Martin, 1996).  
Env glycoproteins are synthesized, processed and glycosylated in the lumen of the RER. 
After oligomerisation of gp160, the trimers traffic through the Golgi complex where N-
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glycans are further modified and proteolytic cleavage of gp160 into gp120 and gp41 occurs 
en route to the plasma membrane (PM) (Freed et al., 1989; McCune et al., 1988) or trans-
Golgi-derived (TGN) secretory vesicles (Moulard and Decroly, 2000). Cleavage of gp160 is 
an absolute requirement for Env fusogenicity. Gp120 and gp41 remain non-covalently 
connected and once at the PM, the heterotrimers are incorporated into viral particles. Studies 
have consistently shown that the number of heterotrimers incorporated per virus is very low: 
~7-14 (Checkley et al., 2011; Murakami, 2008) and ~ 10–14 spikes/virion (Didigu and 
Doms, 2012; Staropoli et al., 2000; Wyatt, 1998).    
Env incorporation requires interaction between gp41 CT and the N-terminus of p55Gag 
precursor- MA (Affranchino and González, 2014; Freed and Martin, 1995b; Murakami, 
2008; Murakami and Freed, 2000a; Postler and Desrosiers, 2013; da Silva et al., 2016; Wyma 
et al., 2000). For instance, a single mutation in MA restored Env incorporation that was lost 
due to a small deletion in the LLP2/LLP3 region of gp41-CT (Murakami and Freed, 2000a). 
Conversely, a mutation in MA that disrupted Env incorporation was reversed by truncating 
a small region of gp41 (Freed and Martin, 1995b; Mammano et al., 1995). Therefore, gp41 
CT is essential for Env incorporation (Affranchino and González, 2014; Da Silva et al., 2013; 
Freed and Martin, 1995b; Murakami, 2008; Murakami and Freed, 2000b; Postler and 
Desrosiers, 2013; Wyma et al., 2000).  
Checkly et al. (2011) summarised several proposed Env incorporation mechanisms: 1) The 
“passive” or “random” incorporation model (Figure 1.12A) suggests that Env trafficking to 
the PM takes place independently of Gag and Env is incorporated into the virion as a result 
of Env expression and virus assembly;  2) The “direct Gag–Env interaction” model (Figure 
1.12B) where a direct interaction between MA and gp41-CT is required for Env 
incorporation; 3) The “Gag–Env co-targeting” model (Figure 1.12C) which describes an 
indirect interaction between Env and Gag in which cellular host factors (lipid rafts) play a 
role in Env and Gag enrichment at the PM enabling virus assembly; and 4) The “indirect 
Gag–Env interaction” model (Figure 1.12D) when other cellular proteins (adaptor proteins) 
link Env and Gag and stimulate Env incorporation (Checkly et al. 2011).  






Figure 1.12. Env incorporation models explains.  A) Passive model where interaction 
between Gag and Env is not required, B) direct interaction between Gag-Env is required; C) co-
targeting of Gag and Env for recruitment to the PM via lipid drafts; D) Gag-Env interaction 
requires an adaptor protein to link Env and Gag together. Env complex spikes, Gag, lipid drafts, 
and the adaptor protein are in indicated by blue, grey, red and pink color, respectively. Figure 
was taken from Checkley et al. (2011). 
 
 
A) Passive Incorporation B) Direct Gag-Env interaction
C) Gag-Env Cotargeting D) Indirect Gag-Env Interaction
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1.9 Viral fitness 
Viral fitness is defined as the ability of the virus to adapt and replicate in a given host 
environment (Domingo and Holland, 1997). Recently it was shown that participants that 
became infected with TFs with high replication capacity, progressed more rapidly to disease 
and carried a larger early latent viral reservoir (Claiborne et al., 2015). As transmitted 
variants tend to be more pathogenic than previously believed, it was suggested that viral 
fitness could be used as a clinical marker for the start of ART given its association with 
disease progression (Arnott et al., 2010).  
 Env as an HIV fitness determinant 
Although Gag has been shown to play an important role in HIV-1 disease progression (Prince 
et al., 2012), there is evidence as to the importance of Env in cell entry and tropism (Hoffman, 
and Doms, 1999; Pastore et al., 2006; Pollakis et al., 2001; Wilen et al., 2012a), transmission 
(Hsu et al., 2003), and virus fitness and disease progression (Lobritz et al., 2007; Quiñones-
Mateu et al., 2000). Moreover, Env plays a key role in escape from immune responses and 
virus survival due to its high glycosylation (Moore et al., 2012; Wang et al., 2013; Wei et 
al., 2003). Rangel et al. (2003) determined a significant correlation (p = 0.002) between the 
fitness of wild-type HIV-1 isolates and the entry efficiency of their corresponding Env using 
an ex vivo competition assay. He also showed in a time course competition assay that virus 
entry had a higher impact on the ability of one virus to outcompete and dominate another 
compared to other steps in the HIV life cycle (Rangel et al., 2003). In another competitive 
study, a primary HIV isolate had similar fitness to its env/NL4-3 chimeric counterpart 
(Marozsan et al., 2005). A more recent study, using a similar approach, compared the fitness 
of an isolate from a multi-drug resistant (MDR) participant to its corresponding env/NL4-3 
chimera and a control construct comprising the isolate’s backbone genome carrying Env 
from pNL4-3. The result showed that both the isolate and its Env had higher fitness than its 
backbone genome only, suggesting that Env is a major determinant in viral fitness (Mohri et 
al., 2015). Similarly, variants resistant to MVC carried a mutation within the CD4 binding 
site that rendered them better at replication than MVC sensitive clones (Ratcliff et al., 2013).  
As Env plays a very important role in immune evasion, variants resistant to neutralisation by 
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VRC01 were tested for changes in host cell entry and replication fitness. CD4-mediated viral 
entry and replicative capacity was diminished in the presence of Env mutations that conferred 
resistance to VRC01 (Lynch et al., 2015). Therefore, the relationship between Env fitness 
and changes in viral replication could be due to variation in the interaction between Env with 
CD4 and/or CCR5 (Marozsan et al., 2005) as well as other receptors. Env binds DCs via 
mannose-binding lectins such as dendritic cell–specific intercellular adhesion molecular 3-
grabbing non-integrin (DC-SIGN) and interacts with α4β7 integrin on CD4 T cells (Arthos 
et al., 2008; Baribaud et al., 2001; Mondor et al., 1998). Binding to these receptors facilitates 
the transfer of infectious virus from the genital tract to the draining lymph nodes, facilitating 
productive, clinical infection. Binding of Env to DC-SIGN and α4β7 has been suggested to 
play an important role in HIV-1 transmission (Arthos et al., 2008; Geijtenbeek et al., 2002). 
Therefore, changes within the structure of Env could influence these interactions and thus its 
transmission fitness. 
 Env fitness and disease progression 
HIV-1 Env fitness was suggested to play an important role in disease progression (Connor 
and Ho, 1994). A study comparing relative fitness of viral isolates from LTNP and rapid 
progressors, demonstrated an association between disease progression and viral fitness 
(Quiñones-Mateu et al., 2000). Similarly, Lassen et al. (2009) showed that Env clones 
derived from elite suppressors displayed low Env entry efficiency compared to Env derived 
from chronic progressors (Lassen et al., 2009). Troyer et al., (2005), showed a strong 
correlation between ex vivo fitness of HIV-1 isolates and both viral diversity and disease 
progression (Troyer et al., 2005) whereas Gordan et al. (2016) reported high ex vivo entry 
efficiency of an env pseudotyped virus potentially associated with rapid disease progression 
(Gordon et al., 2016). Recently, it was suggested that the apoptosis-inducing potential of Env 
might be responsible for the depletion of CD4+ T cells in HIV-1 infection, directly linking 
Env with disease progression (Joshi et al., 2016). Finally, a MDR isolate, shown to have high 
Env entry efficiency, was associated with rapid disease progression (Mohri et al., 2015). 
Therefore, escape from immune responses and antiretroviral therapy could select for 
mutations in Env that enhance entry efficiency which, in turn, drives viral fitness and disease 
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progression. Overall, this review has highlighted the importance of Env, diversity, 
expression, processing and function in viral fitness and disease progression.  
  
1.10 Research Aim and objectives 
Use dual infection as a model to understand the role of Envelope entry efficiency in the in 
vivo outgrowth of variants, the replicative capacity of infectious molecular clones and disease 
progression. 
 Rational 
Dual infected individuals provide a unique model system for the identification of 
determinants of viral fitness as two distinct viruses co-evolve under the same environmental 
pressures culminating in the outgrowth of recombinant variants most likely due to gain of 
fitness mutations. The overall hypothesis tested in this study will be that rapid viral evolution 
in dual-infected individuals results in the rapid generation of recombinants with high 
replication fitness that drive disease progression. Therefore, recombinants with high 
replication fitness that emerge early in infection could carry regions/sites on Env that are 
essential for viral propagation. These regions can be used to guide drug and immunogen 
design. This study aims to identify and characterise determinants of subtype C HIV-1 Env 
fitness in individuals co-infected with two phylogenetically distinct viruses to evaluate their 
impact on viral replication in PBMCs. This is a longitudinal study of the genotypic and 
phenotypic evolution of Env isolated from four HIV-1 subtype C dual-infected South African 
women differing in disease progression. 
 Objectives 
I. Determine the association between in vitro Env entry efficiency and in vivo 
outgrowth of variants infecting dual infected individuals and identify potential 
functional determinants that could be targeted in drug and vaccine design 
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II. Understand how the function of Env fitness determinants could impact the in vivo 
outgrowth of variants isolated from dual infected individuals 
III. Determine whether Env entry efficiency impacts the replicative capacity of chimeric 
infectious molecular clones in PBMCs. 
IV. Describe whether there is an association between Env entry efficiency, IMC 
replicative fitness and disease progression.  
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The Role of HIV-1 Subtype C Envelope Entry Efficiency In In 




In dual infections the presence of two distinct viruses within the same host and under the 
same selection pressures could lead to “in vivo” competition, increasing the probability of 
rapid evolution, high diversity of circulating variants and potentially reducing the efficacy 
of vaccines (Sanborn et al., 2015). Dual infections are also likely to lead to the emergence of 
recombinant variants with advantageous mutations, inherited from the two initial viruses, 
that enhance viral replication fitness (van der Kuyl and Cornelissen, 2007; Peeters, 2000).  
Studies have shown that multiple variant infections were significantly associated with 
increased viral load, CD4+ T cell decline and thus rapid disease progression (Cornelissen et 
al., 2012; Gottlieb et al., 2004; Sagar et al., 2003). A recent study showed that infection with 
multiple variants correlated with a significantly higher viral load after the first year of 
infection compared to patients infected with a single variant  (Janes et al., 2015). It was also 
suggested that the rapid disease progression of a dual infected individual to AIDS defining 
illness was due to the emergence of a recombinant variant within the first year of infection 
with enhanced Envelop (Env) entry efficiency compared to its parental variants. The authors 
suggested that Env might play an essential role in the outgrowth of variants with enhanced 
viral fitness that could potentially increase disease progression (Gordon et al., 2016). 
Env entry efficiency has been reported to be associated with disease progression (Campbell 
et al., 2003; Gordon et al., 2016; Quiñones-Mateu et al., 2000; Troyer et al., 2005). Recently, 
a study showed that Env entry efficiency of transmitted founder (TF) variants impacted viral 
loads during acute infection (Nofemela et al., 2015). HIV Env mediates the first step in virus 
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entry of host cells by interacting with cell-surface receptors e.g. CD4, CCR5 and CXCR4 
(Wilen et al., 2012a). Env is subjected to extensive selective pressure, including host immune 
response [humoral and cytotoxic T-lymphocyte (CTL)] (Troyer et al., 2005), levels of co-
receptor expression (Gorry et al., 2004; Meijerink et al., 2014) and availability of permissive 
host cells (Marozsan et al., 2005). Reports support the hypothesis that Env plays a major role 
in the competitive and adaptive ability of the virus (Ball et al., 2003; Rangel et al., 2003). 
Together, the data suggest that Env entry efficiency (Env fitness) might play an important 
role in the outgrowth and thus the pathogenicity of variants infecting dual infected 
individuals. 
Viral fitness, the ability to survive within a given environment includes the ability of variants 
to evade the host immune system and resist antiretroviral therapy (ART). Therefore, viruses 
able to evade host immunity or carrying drug resistant mutations can result in loss of viremic 
control due to treatment failure or compromised immune system potentially leading to rapid 
disease progression and possibly death of the patient (van der Kuyl and Cornelissen, 2007). 
One solution is to restrict variants from introducing fitness-enhancing mutations by 
designing vaccines and drugs that target sites/regions essential for HIV survival so that any 
amino acid change either leads to loss of fitness or viral clearance (Arenas et al., 2016; Sather 
et al., 2012). However, to accomplish this strategy, we need to identify HIV-1 viral fitness 
determinants.  
Dual-infected individuals provide a unique model system to characterise the evolution of 
Env function over the course of infection as two phylogenetically distinct viruses co-evolve 
under the same environmental pressures. Therefore, we aimed to track Env entry efficiency 
of variants isolated from dual infected individuals and evaluate its impact on virus 
competition and disease progression and thereby identify Env fitness determinants.  
 




2.2 Research Aim and Objectives 
 
Aim 
The overall aim of this study was to investigate whether the entry efficiency of HIV-1 
subtype C Env influenced the outgrowth of variants infecting dual infected individuals and 
to identify potential functional determinants. 
 
Objectives  
Objective 1: Determine the in vivo frequency of viral populations infecting dual 
infected individuals using sequence analysis of longitudinal samples 
Objective 2: Determine in vitro Env entry efficiency of variants over time  
Objective 3: Identify regions/sites within Env involved in replication fitness of viruses 
infecting dual infected individuals. 
 




2.3 Materials and Methods 
 Study cohort and samples used in this analysis 
This study utilized stored PCR products generated as part of the CAPRISA 002 Acute 
Infection study, Durban, South Africa (van Loggerenberg et al., 2008). HIV-positive women 
were enrolled within 3 months of infection and plasma samples were collected at enrolment 
(Phase 2_week/month post-infection_visit), then weekly for three weeks, fortnightly until 3 
months, monthly until a year and quarterly thereafter. Pre-enrolment samples were identified 
by testing samples prior to enrolment for viral RNA (Phase 1, week/month post-
infection_visit) (van Loggerenberg et al., 2008). In this study, we designated the first visit 
from which we obtained samples as 0 months irrespective if it was at enrolment or pre-
enrolment sample. 
Out of 39 individuals screened, only four CAPRISA 002 study participants were identified 
as dual infected (not superinfected): CAP37, CAP84, CAP137 and CAP267  (Woodman et 
al., 2011). One participant, CAP84, was classified as a typical progressor as the CD4+ T cell 
count remained stable; whereas CAP37, CAP137 and CAP267 were classified as rapid 
progressors as their CD4+ cell counts dropped to below 350 cells/µl within the first two years 
of infection (Mlisana et al., 2014). Viral loads were measured using a COBAS 
AMPLICORTM HIV-1 Monitor Test v1.5 (Roche Diagnostics, Rotkreuz, Switzerland) and 
CD4+ T cells counts were assessed using a FACS Calibur flow cytometer (BD Biosciences, 
San Jose, USA (Mlisana et al., 2014).  
The SGA-derived first round, full-length env PCR products were obtained from Professor 
Williamson (Institute of Infectious Diseases and Molecular Medicine, University of Cape 
Town) (Abrahams et al., 2013). Briefly, viral RNA extracted from longitudinal plasma 
samples (0, 3, 6, and 12 months post infection (mpi) of CAP37, CAP84, CAP137 and 
CAP267, was reverse transcribed and cDNA was diluted so that PCR products were 
generated from a single template. Amplicons were directly sequenced and stored at –80°C 
for further analysis.  
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 Analysis of SGA-derived envelope sequences 
In the current study, a total of 295 full-length env sequences from all participants (with an 
average of 20 env sequences per time point) across time points were analysed using BioEdit 
version 7.0. Classification of variants was performed using the DNA pairwise distance 
analyses MEGA-5 (Tamura et al., 2011) in conjunction with recombination analysis using 
Highlighter plot (http://www.hiv.lanl.gov) (Kraft et al., 2012) and Recombinant 
Identification Program (RIP) (http://www.hiv.lanl.gov/content/sequence/RIP). 
2.3.2.1 Identification of parent variants transmitted to dual infected individuals  
Identifying the initial parent viruses transmitted to dual infected individuals was challenging 
due to the potential transmission of multiple variants from donors, early recombination 
between transmitted variants, high genetic diversity and limited detection of variants at low 
frequencies. To reduce the complexity of the number of different viral populations, the 
dominant viral population at enrolment (0 mpi) was designated as population A. Neighbour-
joining trees (MEGA-5) were then constructed to identify variants that clustered separately 
to viral population A and the virus with the greatest DNA maximum distance was classified 
as the second ‘parent’, virus B. These two “parent” viruses were used as master sequences 
in Highlighter plots and all other viruses at 0, 3, 6 or 12 mpi were classified as either A, B or 
AB depending on their position on the Neighbour-joining tree, their DNA distance from each 
“parent” and their similarity compared to the master sequences on the matched Highlighter 
plots (http://www.hiv.lanl.gov), using the “match” setting to visualize the intra-participant 
diversity. In one or two variants, findings from Maximum DNA distance analysis, 
Highlighter plot, RIP and Neighbour-joining trees did not support one another and these 
sequences were classified according to RIP analysis only. 
All recombinants were classified initially as AB even if there were more than one 
recombinant population. As the aim of the study was to track fit variants able to outcompete 
other viruses, we assumed that variants at low frequency were not driving viral loads in these 
participants and that undetectable viruses were not playing an essential role.  
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2.3.2.2 Frequency of variants infecting dual infected individuals over the course 
of infection 
To track variants over the course of infection, viruses at all time points were compared to 
parents A and B using neighbour joining trees of sub-genomic regions, maximum DNA 
distance and Highlighter plots. Outgrowth of A, B or AB variants was determined by 
measuring the frequency of each viral population relative to the total number of sequences 
per time point (%).  
After measuring outgrowth of AB variants, we looked at the recombinant populations in 
more detail to compare relative frequency and fitness of sub-groups. The classification of 
variants into subgroups of AB recombinants was confirmed by Highlighter plots 
(http://www.hiv.lanl.gov), RIP (http://www.hiv.lanl.gov/content/sequence/RIP) and 
Neighbour-joining trees.  
 Cloning functional Env SGA 
2.3.3.1 Env amplicons selected for cloning  
In order to investigate in vitro Env entry efficiency, SGA-derived env amplicons from each 
participant were cloned into mammalian vectors. Selection of env amplicons was based on 
1) representing A, B and AB variants at each time point and 2) cloning representatives of 
populations that changed frequency over time. Where there were two recombinant sub-
populations, representatives were cloned from both. For CAP37, eight functional Env clones 
representing viruses A, B and AB were generated: three clones from enrolment, two clones 
from 6 mpi and three clones from 12 mpi representing two AB populations. For CAP84, four 
functional Env clones were generated: one representing virus A at 0 mpi (84c1), one 
representing virus B at 3 mpi (84c2), and two representing virus A and AB at 12 mpi, (84c3, 
84c4). Ten Env clones were generated representing variants infecting CAP137 over time. 
Two clones represent virus A at 0 mpi, one represents virus B at ~2 mpi, two representing A 
and B viruses at 3 mpi, three representing A, B and AB at 6 mpi, and two representing AB 
sub-population at 12 mpi. Six of the SGA-derived env amplicons sequences were cloned for 
CAP267 and represent A and B viral populations at 0 mpi, 3 mpi and 12 mpi. 
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2.3.3.2 PCR Amplification of env 
Representative SGA env amplicons were amplified using nested PCR performed by an XP 
Thermal cycler (Bioer technology). The env specific primers Env-1A-RX and Env-1M or 
Env-N (Appendix A) were used to amplify rev-vpu-env expression cassettes as previously 
described (Kraus et al., 2010). PCR reactions were carried out according to the Phusion Hot 
Start Polymerase kit instructions (Thermo Scientific, USA) with some modifications 
described in Appendix A. The size of the PCR products was confirmed using 0.8 % agarose 
gel electrophoresis. The DNA band of approximately 3 Kb was excised and extracted from 
the agarose gel using the Wizard® SV Gel and PCR Clean-Up System (Promega, USA) 
following the manufacturer’s instructions. 
2.3.3.3 'A' tailing and Ligation Reaction 
In order to clone the PCR products into a mammalian expression vector, pTargeT™, a poly-
adenosine (poly-A) tail was added to both the 5’ and 3’ ends of the cleaned-up env PCR 
products using SuperTherm Taq polymerase enzyme (JMR- Holdings, UK). The reaction 
was carried out at 72 °C for 10 min and the reagents used for the poly-A tailing reaction are 
listed in (Appendix A). The poly-A-tailed PCR products were cleaned up using the Wizard 
SV PCR Gel clean-up kit (Promega, USA), and ligated with pTargeT™ vector following the 
manufacturer instructions (Promega, USA). The ligation reaction was performed overnight 
at 4 °C using T4 ligase (Promega, USA) at a molar ratio of 1:3 (vector: insert). 
2.3.3.4 Transformation 
The competent E.coli JM109 bacterial cells (Promega, USA) were used for transformation 
as follows: the bacterial cells were allowed to thaw on ice for 10 min and the ligation reaction 
was added to 50 l competent cells at a 1:10 ratio of plasmid:cells. The mixture was 
incubated at 4 °C for 20 min, and then subjected to heat shock for 45 sec at 42 °C and then 
returned to ice for a further 2 min. The bacterial cells were allowed to recover at 37 °C for 1 
hr in 950 µl Luria broth (LB) without Carbenocillin. The bacterial cells were concentrated 
by centrifugation at 5000 rpm for 7 min and the pellet was re-suspended in 50 µl of LB and 
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spread on Luria agar plates (1.5 % agar and 0.1 mg/ml Carbenocillin). The bacterial plates 
were incubated at 30 °C overnight.  
Colony PCR was used to screen colonies for the presence of env in the correct orientation 
downstream the CMV promotor of the pTargeT™ vector (Promega, USA). A T7 primer 
complimentary to the T7 promoter sequence was used as forward primer and the Rev15 
primer complimentary to rev sequence was used as the reverse primer. The Supertherm Taq 
polymerase enzyme (JMR- Holdings, UK) was used to amplify a product of 1 Kb using the 
PCR reaction mixture and cycling conditions listed in (Appendix A). Once the insert was 
verified, LB was inoculated with the bacterial colony and the plasmid was purified using the 
PureYield™ Plasmid Midiprep System (Promega, USA) as per manufacturer’s instructions. 
Plasmids were sequenced at Stellenbosch Central Analytical Facility using an ABI 3000 
genetic analyser (Applied Biosystems, USA). Sequence analysis to verify correct env 
sequence was performed using ChromasPro and compared to the env SGA-derived sequence. 
 Pseudovirus Entry Efficiency 
In order to compare Env entry efficiency, pseudovirus (PSV) was generated using human 
embryonic kidney (HEK-293T) cells and entry efficiency was compared using the TZM-bl 
reporter cell line. 
2.3.4.1 Cell culture 
HEK-293T: Highly transfectable HEK-293T cells were (Graham et al., 1977) maintained in 
T75 flasks at 37 °C with 5 % CO2 in Dulbecco’s Minimal Essential Medium (DMEM) with 
high Glucose (4.5 g/L) obtained from Lonza (Switzerland) or Sigma (Germany). Medium 
was supplemented with 10 % Fetal Calf Serum (FCS) (BiochromGmBH), and 1 U/ml 
Penicillin and 1 µg/ml Streptomycin (Lonza, Switzerland).  
TZM-bl cells: HeLa cell line that stably expresses CD4, CCR5 and CXCR4 and thus 
susceptible to HIV infection (Platt et al., 1998; Wei et al., 2002). It also expresses luciferase 
and β-galactosidase enzymes under the control of a Tat-inducible HIV LTR promoter. Cells 
were maintained as described above.  
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2.3.4.2 Generating pseudovirus and entry efficiency assay 
PSV was generated by co-transfecting HEK-293T cells with 2.5 µg of env plasmid and 5 µg 
of pSG3ΔEnv HIV-1 backbone vector (1:1.5 molar ratio) (NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: from Drs. John C. Kappes and Xiaoyun Wu: pSG3Δenv) 
using 1 mg/ml Polyethylenimine (PEI). PSV supernatant was collected after 48 hr and stored 
at -80 °C in 20 % FCS prior to determining PSV titre using p24 ELISA (section 2.3.4.3). 
Using 96-well plates, (104 cells / 100 µl) of TZM-bl cells (AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH; from Dr. John C. Kappes, Dr. Xiaoyun 
Wu, and Tranzyme Inc.) were infected in triplicate with PSV normalized to 100 ng/ml p24. 
After 48 hrs, medium was replaced with Bright-Glo Luciferase Assay buffer (Promega, 
USA) and relative luciferase units (RLU) were measured using a GloMax-Multi Microplate 
Multimode Reader (Promega, USA). RLU readings of uninfected TZM-bl cells were 
considered as background signal and only RLU readings 2.5-fold higher than background 
was considered as positive infection. PSV generated by transfecting the HIV-1 subtype B 
pSG3ΔEnv backbone vector with pTargeT™ vector only (with no env cloned) was used as 
a negative control. 
2.3.4.3 P24 antigen ELISA 
A modified p24 sandwich ELISA (Aalto Bio reagents) and TROPIX® detection system 
(CDP-Star®, Applied Biosystems) were used to determine PSV titre as previously described 
by Moore et al. (1990) and Mckeating et al. (1991) and adapted by Dr A Trkola 
(McKEATING et al., 1991; Moore et al., 1990; Trkola et al., 1995).  
High binding 96 well plates (Porvair Sciences, UK) were coated with a 100 µl/well of the 
D7320 sheep polyclonal anti-HIV-1 p24 antibody (Aalto Bio reagents, Dublin, Ireland) 
diluted in 0.1 M NaHC03 buffer, pH 8.5 to a final concentration of 2 µg/ml and incubated 
overnight at room temperature. Unbound antibody was removed by washing the plates three 
times with 1 X Tris-buffered saline (TBS). Plates were blocked with 5 % bovine serum 
albumin (PAA, Biocom Biotech), dissolved in TBS for 1-2 hrs at room temperature and 
thereafter stored in blocking agent at -20 °C until needed. PSV was inactivated by 5-fold 
dilution with 1.25 % Empigen detergent (Sigma-Aldrich, MO, USA) in 1 X TBS for one 
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hour at room temperature. Then serial dilutions of PSV were made using 1 % Empigen-TBS. 
A volume of 100 µl diluted samples was added to each well of pre-coated ELISA plates that 
were washed four times to remove the blocking reagent. The p24 standard curve was 
generated by 2-fold serial dilution of recombinant HIV-1 p24 antigen standard (Aalto Bio 
Reagents, Dublin, Ireland) starting at 32 ng/ml and ending at 0.5 ng/ml. Then, each p24 
dilution was loaded in duplicate onto each ELISA plate (100 µl/well). Plates were incubated 
for two and half to three hours at room temperature to allow p24 antigen to bind to the 
antibody coated on the surface of the wells and thereafter washed three times with 1X TBS. 
The secondary anti-HIV-1 p24 conjugate (BC 1017-AP, Aalto Bio Reagents, Dublin, 
Ireland) was prepared by diluting the antibody 1: 64000 with 0.1 % Tween-20 (TBS-T) 
containing 20 % sheep serum (PAA, Biocom Biotech). A volume of 100 µl of the diluted 
antibody was added to each well in the plate. The secondary antibody was allowed to bind 
for one hour at room temperature followed by three washes with (1X TBS-T) and then two 
washes with 1X TROPIX buffer (Appendix C). For detection, 100 µl of CPD-Star® with 
Sapphire II enhancer substrate (Applied Biosystems, CA, USA) diluted 1:4 in 1 X TROPIX 
buffer was added to each well and incubated for 10 min at room temperature in the dark after 
which luminescence (measured in RLU) was read immediately using a Glomax luminometer 
(Promega, MA, USA). 
 Env determinants for viral fitness 
In order to identify functional Env determinants of entry efficiency, chimeras and mutants 
were generated from selected participants.  
2.3.5.1 Generating Chimeras 
The env sequences generated as described in section 2.3.3 were aligned using BioEdit and 
the Gene cutter tool (http://www.hiv.lanl.gov) was used to identify different regions of Env 
(Appendix B).  
CAP84 chimeras were generated by swapping the gp41 region between virus A clone 84c1 
and virus AB clone 84c4 using restriction enzyme digestion (Figure 2.1). Theoretical 
constructs and restriction enzyme mapping were performed using Serial cloner 2.5 software. 
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The plasmid (5 µg) of the 84c1 and 84c4 were sequentially digested using SbfI and XmaI 
restriction enzymes (Thermo Scientific, MA, USA) according to the manufacturer’s 
recommendation. The required DNA bands were excised and gel purified using Wizard SV 
PCR Gel clean-up kit (Promega, USA) following the manufacturer’s instructions. Ligation 
of the fragments was performed overnight by T4 ligase (Thermo Scientific, MA, USA) in 10 
μl final reaction volume. Transformation was carried out using JM109 cells as described in 
section 2.3.3. Restriction enzyme digestion was used to screen colonies for mutagenesis and 
confirmed by sequencing. 
CAP267 chimeras were generated by swapping gp120 between virus B at 0 mpi (267c2) and 
virus B at 12 mpi (267c6) using EcoN1 which cut twice in both clones before gp41 region 
(Figure 2.2). Colony PCR was used to confirm correct directional cloning after ligation 
followed by sequencing to ensure the correct constructs at Stellenbosch Central Analytical 
Facility using an ABI 3000 genetic analyser (Applied Biosystems, Foster City, CA, USA).  
 Site direct mutagenesis 
Potential N-glycan sites (PNGs) were introduced in chimera 84c1/c4 (Figure 2.1) or removed 
from 84c4 and 137c10 (Figure 2.1, Figure 2.2) using a modified Stratagene Quik Change II 
PCR-based protocol (Agilent Technologies, CA, USA). Overlapping primers with silent 
restriction enzyme sites for screening were designed using WATCUT 
(http://watcut.uwaterloo.ca) and SDM-Assist software (Karnik et al., 2013). Briefly, mutated 
PCR-generated plasmids using the Phusion Hot Start Polymerase kit (Thermo Scientific) 
were digested with methyl-specific DpnI- (Thermo Scientific/Fermentas, USA). JM109 
competent cells (Promega, USA) were transformed with the un-methylated PCR products 
and screened using restriction enzyme digestion. Positive colonies were selected and 
plasmids were extracted using PureYield™ Plasmid Midiprep System (Promega, USA) as 
mentioned above and sequenced at Stellenbosch Central Analytical Facility using an ABI 
3000 genetic analyser (Applied Biosystems, Foster City, CA, USA). All Env alignments are 
in Appendix B.






Figure 2.1. CAP84 chimeric Env clones and mutants.    A diagram illustrating the construction 
of env chimeric clones and mutants generated from CAP84. 1) Two chimeras were constructed 
by swapping gp41 between 84c1 and 84c4 indicated by red and red with purple signalling peptide 
(SP) & gp41, respectively. 2) A potential N-glycan site was introduced at 339 using site direct 
mutagenesis (SDM) of gp120 of the chimera 84c1/c4 to generate a mutant 84c1/c4-sdm. 3) The 
































Figure 2.2.  Construction of CAP267 chimeras and CAP137 mutant.   A) Two chimeras were 
constructed by swapping gp120 between 267c2 (representing B virus at 0 mpi) and 267c6 
(representing B virus at 12 mpi) indicated with light blue and dark blue, respectively. These 
chimeras were designated as 267c2/c6 and 267c6/c2. B) CAP137 potential N-glycan site at 332 





















2.4 Statistical analysis 
GraphPad Prism 5.0 software (CA, USA) was used to perform all statistical analysis. One-
way ANOVA with Bonferroni correction for multiple comparisons was used to compare 
entry efficiency between all functional clones. Correlation between in vivo frequency and in 
vitro entry efficiency was evaluated using the non-parametric Spearman rank correlation test. 
All p-values were based on a two-sided test. Significance p value < 0.05. 
 




 Diversity of variants infecting dual infected individuals 
Longitudinal analysis of full-length SGA-derived env sequences of four dual infected 
CAPRISA 002 participants, CAP37, CAP84, CAP137 and CAP267 characterised viral 
evolution over the first year of infection. Changes in diversity over time was determined by 
measuring the mean intra-participant pair-wise DNA distance at each time point as well as 
diversification from the variant with the highest frequency at 0 mpi (Figure 2.3A and C).  
There was an apparent initial peak in viral diversity for all participants; with variants 
infecting CAP137 having the highest mean DNA distance (6.5 %) at 3 weeks post infection 
(Figure 2.3). Diversity of variants infecting CAP84, CAP37 and CAP267 seemed to stabilize 
between 6 and 12 mpi with an average rate of change of 0.035, 0.05 and 0.08 % per month, 
respectively.  Quasispecies’ diversity infecting CAP137 however, continued to decrease after 
the initial peak to 2.2 % at 12 mpi. Mean diversity of variants infecting CAP84 seemed to 
change much slower than the other participants with diversity increasing from 0.07 % at 0 
mpi to 1.7 % at 12 mpi. When the mean DNA distance of total variants at all time points was 
compared between participants, there was a significant difference between CAP137 and 
CAP84 (p < 0.001) (Figure 2.3B), confirming longitudinal data (Figure 2.3A) that variants 
infecting CAP137 had evolved much more rapidly within the first 12 months of infection 
than viruses infecting the other participants although at 12 mpi, all participants were infected 
with variants of similar diversity (range = 1.7 – 3.2 %).  
An alternative measure of HIV evolution is the change in DNA distance relative to a 
reference variant, usually the founder virus (Abrahams et al., 2009). Except for those 
infecting CAP137 for the first 6 months, all variants infecting the dual infected individuals 
diverged from the parent virus at 0 mpi (Figure 2.3C). Overall, divergence and diversification 
followed a similar pattern as outlined by Shankarappa et al. (1999) for early infection 
(Shankarappa et al., 1999). We cannot exclude the possibility of sampling bias resulting in 
detection of only a subset of variants (Salazar-Gonzalez et al., 2008; Troyer et al., 2005). 
However, we hypothesised that if variants were not detected then they were unlikely to 
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influence viral loads and might not be essential to determine the role of Env function in in 
vivo viral outgrowth (Arenas et al., 2016). 
 
 
Figure 2.3. Diversity and Diversification of envelope sequence over time.  A) Mean pairwise 
DNA distance (%) between intra-participant env sequences generated at 0 mpi, three months, six 
months and 12 months’ post-infection was calculated over time for CAP37 (orange), CAP84 (blue) 
and CAP137 (red) and CAP267 (green). B) Average pairwise DNA across all time points was 
compared between participants using Kruskal-Wallis test" with "Dunn's Multiple Comparison 
Test. (*** < 0.001). C) Divergence was calculated as the difference in DNA distance at each time 
point relative to the dominant variant present at 0 mpi. 
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 Frequency of viral populations infecting dual-infected individuals 
The full-length env sequences derived from the four dual infected individuals provided a 
snapshot of the relative frequency of variants present in the viral population over time: 0, 3, 
6 and 12 mpi. We hypothesised that variants at high frequency were most likely driving viral 
loads in dual infected individuals and would have high in vivo replication fitness. Variants 
were tracked over the course of infection and their relative frequency was indicated as a 
percentage of total sequences generated at each time point. The relative frequency was used 
as a surrogate marker of in vivo viral fitness (Salazar-Gonzalez et al., 2011). 
2.5.2.1 Confirmation of dual infection 
Dual infection is defined as infection by variants that group independently from each other, 
separated by phylogenetically unrelated sequences (Grobler et al., 2004). However, when 
full-length sequences of CAP37, CAP267 and CAP84 were aligned with phylogenetically 
unlinked viruses, they did not group separately in Neighbour-joining trees (data not shown). 
This could be due to transmission of multiple related variants from the donor in a single 
transmission event, rapid recombination within the recipient and/or the transmission of 
recombinants derived from the donor. When Neighbour-joining trees of CAP37, CAP84 and 
CAP267 V3 and gp41 sub-genomic regions were drawn with 30-100 unrelated sequences, 
two viral populations carried phylogenetically distinct sequences (Appendix B)  (Kraft et al., 
2012; Pacold et al., 2010; Woodman et al., 2011). This was consistent with the previous 
finding of Woodman et al. (2011) who first identified these individuals as dual infected by 
analysing C3-V3 regions using Heteroduplex Mobility assay (HMA) (Woodman et al., 
2011). It was highly likely that these variants were recombinants of the initial “parents” and 
thus shared genetic information. 
 Identification of phylogenetically distinct master sequences 
In order to track variants over the course of infection we first had to designate variants as 
‘parents’ or master A and B env sequences. To do this we used three approaches: 1) full-
length env sampled at 0 mpi and 2-3 mpi for each participant were analysed by Neighbour-
joining trees (Figure 2.4).  Variants that clustered separately with low bootstrap values were 
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designated A and B while those that clustered with neither group were classified as AB 
recombinants; 2) the maximum DNA distance between viruses A and B were determined to 
identify two sequences that were the least related of all viruses and to verify that the 
maximum DNA distance of variants designated as AB recombinants were equidistant to 
virus A and virus B (Table 2.1); and 3) Highlighter plots using A and B parent sequences as 
masters were used to confirm visually the classification of viruses at early infection (Figure 
2.5). 
Two viral populations, A and B, grouped separately on the neighbour-joining trees of CAP37 
and CAP267 at 0 mpi with maximum DNA distance of 8.3 % and 5.3 %, respectively. 
Population B infecting CAP37 made up only 5 % of the total population present, whereas 
CAP267 total viral population at 0 mpi comprised of 29 % B variants (Table 2.1, Figure 2.4).  
However, CAP84 and CAP137 were infected with homogenous viral populations at the first-
time points. A second viral population was detected at 2 mpi for CAP137 and 3 mpi for 
CAP84. These variants designated B viruses had a maximum DNA distance of 12 % and 3 % 
from the initial variants at 0 mpi of CAP137 and CAP84, respectively.  
Besides populations A and B, two recombinant variants infecting CAP137 were also 
identified at 2 mpi that not only grouped separately from viruses’ A and B but also from each 
other. Despite differing from one another by 12 %, these two distinct recombinant 
populations were both designated AB to make it easier to track variants over time. Once 
variant frequency of AB recombinants was determined, the individual recombined 
populations were investigated in more detail to determine whether dominance of one 
recombinant population over another was due to Env entry efficiency. A, B and AB viruses 
infecting CAP137 had a frequency of 17 %, 50 % and 33 %, respectively at 2 mpi (Table 









Figure 2.4. Phylogenetic analysis of SGA-derived env at early time points.  The full-length 
env sequences of A) CAP37, B) CAP84, C) CAP137 and D) CAP267 from 0 mpi (CAP37, 
CAP267) or 0 mpi and 2-3 mpi (CAP84 and CAP137) were aligned using BioEdit. Later time 
points were included for CAP84 and CAP137 as they were infected with a homogenous viral 
population at 0 mpi and phylogenetically different variants were only detected at later time 
points. Neighbour-joining trees were used to identify A (red) and B (blue) master sequences with 
the highest maximum DNA distance and AB variants (in purple) with equidistant maximum 
DNA distance from both masters.  Sequences from 0 mpi are indicated with a circle and variants 
from later time points are labelled with a square. CAP84 sequences from 0 mpi, 0.5 mpi, 1 mpi, 
and 3 mpi are indicated with circle, triangle, empty red square and filled square, respectively. 
Boot strap values lower than 70 % are not shown. 



















Figure 2.5. Highlighter Plot of sequences generated at early time points.   Highlighter Plot 
of SGA-derived env sequences generated at earlier HIV-positive time points, showing variants 
from each participant: A) CAP37, B) CAP84, C) CAP137 and D) CAP267.  Env sequences with 
the highest maximum DNA distance which grouped separately on Neighbour-joining trees were 
used as master sequences (virus A: red and virus B: blue) to which all other sequences were 
compared. Variants that grouped separately were indicated A and B in CAP37 and CAP267 and 
variants identified at ~2 mpi for CAP137, and up to 3 mpi for CAP84 were designated A, B and 
AB. To simplify diversity, all recombinants were labelled AB irrespective of whether they 
grouped together or not. Red lines represent sequences that match with A and blue lines indicate 
sequences that match with virus B. Black lines indicate sites that are unique to both A and B 
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CAP84 was also infected with a homogenous viral population at initial time points until a 
second variant was detected at 3 mpi that grouped separately from virus A, albeit only within 
gp41. Despite variation limited to gp41 only, to compare evolution of sequences over time, 
this variant was designated virus B as it had the highest DNA distance from virus A (3 %). 
Virus B had a frequency of 20 % at 3 mpi. In addition, two minor sequences (10 % frequency) 
which appeared to be recombinants of A and B was also detected (Table 2.1, Figure 2.4B 
and Figure 2.5B). 
2.5.3.1 The evolution of variants over the course of infection 
Highlighter plots of longitudinal full-length env for each participant indicated ‘parents’ (the 
initial transmitted viruses that were detected), evolved ‘parents’ (accumulation of point 
mutations over time in parent sequences), recombinants (carrying regions of sequence from 
each parent) at the earliest time point or emergent recombinants (appeared during the course 
of infection) (Figure 2.6). Identifying which variants grouped with A, B or AB populations 
was difficult using only Highlighter plots (Figure 2.6) and Neighbour-joining trees 
(Appendix B). To simplify the complexity and thus determine frequency of variants, pair-
wise DNA distance between all sequences and master sequences, A and B were determined. 
If a variant was more similar to virus A than B, it was classified as virus A and those that 
were equidistant were designated AB recombinants (Table 2.1). Evidence of recombination 
was confirmed using RIP analysis (Figure 2.7).  
CAP37 
Highlighter plots suggested that early recombination occurred between variants infecting 
CAP37, (Figure 2.6A). Therefore, variants designated virus B were likely recombinants of 
virus A (or vice versa) and an unidentified phylogenetically distinct parent. Furthermore, 
full-length env sequence analysis indicated that CAP37 viral population A dominated during 
early infection (Figure 2.6A). However, recombinant variants AB, sharing regions (mainly 
in signal peptide, V1 and gp41) from both A and B viruses emerged at 6 mpi with a frequency 
of 17 %, and outgrew all other viruses at 12 mpi with a frequency of 100 % (Table 2.1, Figure 
2.6A, and Figure 2.8A). Neighbor-joining trees and Highlighter Plots showed that the AB 
population at 12 mpi could be divided into two sub-groups that differed by 2.6 % (Figure 
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2.6). One group was more similar to virus A and thus clustered with A virus, while the other 
was more closely related to the other parent as it carried C3 and gp41from B virus (Figure 
2.7 and Appendix B). These two recombinant populations had similar frequency of 45 % and 
55 % at 12 mpi and thus we could not confirm which variant was dominant at this time point.  
CAP84 
Master sequences A and B differed only in gp41 and viral population B remained minor 
throughout the first year of infection. As viruses A and B shared gp120 sequence, virus B 
was likely a recombinant. However, by 12 mpi, virus B had evolved to include regions of 
virus A gp41 sequence as well as unique changes within the signal peptide (Figure 2.6).  This 
viral population had an average DNA distance of 2.8 % and 2.5% from A and B, respectively, 
and was designated as an AB variant. AB virus dominated other viral populations with a 
frequency of 70 % at 12 mpi) (Table 2.1, Figure 2.8), suggesting that evolution in the signal 
peptide and/or gp41 could have conferred a growth advantage to this population. 
CAP137 
CAP137 was infected with highly diverse variants as the three viral populations A, B and 
AB identified by ~2 mpi fluctuated and recombined over the course of infection. Virus A 
evolved to include C3, V4 and/or gp41 regions from virus B resulting in an emergent AB 
population at 12 mpi distinct from the initial recombinant identified at 0 mpi. Similar to 
variants infecting CAP37, the emergent AB population at 12 mpi could be sub-divided into 
two groups with an average DNA difference of 2.1 % due to differences mainly within gp41 
(HR2 and MPER regions). Although, one AB group shared higher similarity with virus A 
(AB/A) and had a frequency of 31 % and the other AB group was more similar to virus B 
(AB/B) (Figure 2.7) with a frequency of 69 %, these sequences did not cluster separately and 
grouped with virus A, albeit with low bootstrap values (Table 2.1, Figure 2.8). The outgrowth 
of population AB/B suggests that recombination selected for a fitter virus in vivo over time 
through recombination within the C3, V4 and gp41 regions.  






Figure 2.6. Sequence diversity over the course of infection.   The full-length env sequence 
alignments of A) CAP37, B) CAP84, C) CAP137 and D) CAP267 were analysed using 
Highlighter plot (www.lanl.gov) with sequences from 0 mpi, 3, 6 and 12 mpi compared to A and 
B masters. A and B viruses are shown by red and blue lines, respectively while black lines 
indicate unique sequence not present in either master sequence. Sequences identical in both 































































Figure 2.7. RIP analysis to determine whether AB variants are recombinants.   A) At 12 mpi CAP37 AB/A sub-population was more 
similar to virus i) A and AB/B variant was more similar to virus ii) B due to additional C3 and gp41 virus B regions. B) CAP84 AB env at 
12 mpi carried regions in gp41 that were of both A and B viruses. C) At 12 mpi CAP137 AB viral population could be separated into two 
sub-groups with i) AB/A more similar to virus A carrying C3 and V4 from virus B, and ii) AB/B was more similar to virus B as it carried 
both C3, V4 and gp41 of this variant.  D) CAP267 viral population B at 12 mpi was similar to virus B only. Virus A is shown in red and 
virus B is indicated in green and the top line is the query sequence. The x-axis (k) represents the query sequence position at the centre of 
the moving window of 400 bp. The y-axis, s(k), shows the similarity between that window of query sequence and virus A and virus B. 
Relative positions of variable loops indicated in blue lines along x-axis. 




Table 2.1. Characterisation of viral populations over time in dual infected individuals 
Participant 
ID 
aVisit Time post-infection 
(weeks) b(months) 
Average Population 
Diversity (%) from 
master 
Max DNA distance from A/ 










CAP37 1_18 2 (0) 0 0.00/8.3 2 A 95 37c1 






    
8.25/0.00 
 
B 5 37c3 
 
2_05 13 (3) 3.24 
 
2 A 82 N/A 
      
B 18 N/A 
 
3_08 21 (6) 3.00 2.24/8.4 3 A 73 37c4 
    
5.5/3.1 
 
B 10 37c5 
    
4.9/4.4 
 
AB 17 N/A 
 
3_16 56 (12) 4.62 3.7/7.10 2 AB/A 45 37c6 
    
5.4/3.9 
 
AB/B 55 37c7 
    
5.4/3.9 
 
AB/B 55 37c8 
CAP84 1_00 1 (0) 0 0.00/2.8 1 A 100 84c1 
 
f2_00 3 (0.75) 0.78 
 
1 A 100 N/A 
 
2_01 4 (1) 0.26 0.00/2.8 2 A 86 N/A 
    
1.9/2.9 
 
AB 14 N/A 
 
2_05 10 (3) 0.34 0.00/2.8 3 A 70 N/A 
    
2.84/0.00 
 
B 20 84c2 
    
1.3/2.3 
 
AB 10 NA 




3_08 19 (6) 1.04 
 
2 A 71 N/A 
      
B 29 N/A 
 
3_16 54 (12) 2.38 1.07/3.84 2 A 30 84c3 
    
2.53/2.37 
 
AB 70 84c4 
CAP137 1_13 2 (0) 
 
0.00/0.00 1 A 100 137c1 
    
2.72/12.85 
 
A 100 137c2 
 
f2_00 7 (2) 8.97 0.7/12.2 3 A 17 N/A 
    
12.24/0.00 
 
B 50 137c3 
    
5.2/7.9 
 
AB 33 N/A 
 
2_04 12 (3) 7.10 0.86/12.68 3 A 34 137c4 
    
10.59/1.59 
 
B 48 137c5 
      
AB 17 N/A 
 
2_05 14 10.82 
 
1 B 100 N/A 
 
3_08 23 (6) 5.45 4.50/8.45 3 gA 65 137c6 
    
10.31/2.28 
 
B 22 137c7 
    
5.10/7.50 
 
AB 13 137c8 
 
3_15 52 (12) 5.63 3.8/9.2 2 AB/A 31 137c9 
    
5.62/7.56 
 
AB/B 69 137c10 
CAP267 f2_01 6 (0) 
 
0.00/5.32 3 A 71 267c1 
    
5.32/0.00 
 
B 29 267c2 
 
2_04 10 (3) 3.20 0.19/5.36 2 A 42 267c3 
    
5.35/0.63 
 
B 58 267c4 




3_08 20 (6) 3.76 
 
2 A 23 N/A 
      
B 77 N/A 
 
3_15 52 (12) 4.03 1.13/5.48 2 A 24 267c5 
    
5.39/1.4 
 
B 76 267c6 
a Time of sampling is phase of study_visit number 
b To simplify the comparison between sequences from different participants, the visit from which we got the first sample was classified as 0 
months post-infection (mpi), 3, 6 and 12 mpi even though number of weeks at sampling differs slightly between participants.  
c The number of viral populations that grouped separately according to Neighbour-joining trees or had different similarities to A and B viruses 
based on max DNA distance 
d Initial, phylogenetically distinct viral populations were designated A and B and variants that emerged after 0 mpi were classified as AB if 
they differed equally from both A and B viruses. Some AB populations comprised sub-groups where one was more similar to virus A and one 
was more similar to virus B and this is indicated with /A or /B, respectively. 
e Clone ID: Participant ID number clone name in chronological order for each participant 
f Samples from enrolment to the CAPRISA002 study. 











Viral populations A and B were identified at 0 mpi with a max DNA distance of 5.3 %. Virus 
A dominated the quasispecies with a frequency of 71 %. Although, viral population B was a 
minor variant at 0 mpi, it evolved over time with changes mostly in gp41 and became the 
major population at 12 mpi with a frequency of 76 % (Figure 2.6, Figure 2.8 and Table 2.1). 
Although there was no clear evidence of recombination between A and B viruses over the 
course of infection (Figure 2.7), it is highly likely that virus B was a recombinant of A (or A 
was a recombinant of B), suggesting that recombination occurred early within this participant 
(Figure 2.6) and that there was apparently no further recombination between the two viruses 
over 12 months of infection (Figure 2.7), most likely because further events did not confer a 
growth advantage to the virus (Arenas et al., 2016). 
At a glance, recombination, common to most participants, occurred mainly within C3 (n=2) 
and gp41 (n=3) although a number of other regions also recombined (Figure 2.7).  Overall, 
even though viruses infecting dual infected individuals evolved along dissimilar pathways, 
recombinant variants tended to dominate the population by 12 mpi (Figure 2.6). CAP137 AB 
variants that emerged (or were detected) at 12 mpi had the highest frequency one year after 
infection. Variant B infecting CAP37, CAP84 and CAP267 were likely recombinants of 
virus A and an unidentified parent and thus recombination had probably occurred close to 0 
mpi or within the donor. Virus B of CAP267 and AB, viruses generated through further 
recombination between viruses A and B, infecting CAP37, CAP84 and CAP137 became the 
dominant viruses at 12 mpi. This suggests that recombination plays an important role in the 
generation of variants able to out-compete other viruses. 







Figure 2.8. In vivo frequency of viral populations over time. The in vivo frequency of viral 
populations over time in each participant: A) CAP37, B) CAP84, C) CAP137 and D) CAP267 
showing change in frequency of viruses A (red), B (blue) and AB (purples) and outgrowth at 12 
mpi. In vivo frequency (%) of variants was determined by calculating the relative proportion of 
sequences at each time point for each participant. Viruses not detected at 0 mpi had 0 % frequency. 
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 Changes in Env Entry efficiency of viruses infecting dual infected individuals 
over time 
We showed previously that Env entry varied over the course of HIV-1 dual infection  
(Gordon et al., 2016). Furthermore, it has been shown that Env diversity via mutation and 
recombination influenced in vitro HIV-1 fitness (Arenas et al., 2016; Gordon et al., 2016; 
Haddox et al., 2016). In order to investigate whether changes in Env entry efficiency was 
influenced by diversification, SGA-derived env amplicons, representing viral populations, 
A, B and AB were cloned into a mammalian expression system. PSVs were generated and 
entry efficiency was compared between clones using the TZM-bl cell line. To compare entry 
efficiency of PSVs over the course of infection, across independent experiments, all 
measurements were calculated relative to virus A at 0 mpi. 
2.5.4.1 Association between pseudovirion entry efficiency and Env evolution 
CAP37 
Eight functional Env clones representing viruses A, B and AB were generated: three clones 
from 0 mpi, two clones from 6 mpi and three clones from 12 mpi. The three 12 mpi clones 
represented the two sub-groups of AB virus, with two from population AB/B (37c7 and 37c8) 
(Table 2.1; Appendix B). CAP37 was infected with highly diverse variants and this was 
reflected in the variation in entry efficiency between PSVs (range = 23 – 141 %). PSVs 
representing virus A had 0.5-fold lower entry efficiency than B-associated PSVs at 0 mpi 
although this difference was not significant.  At 6 mpi virus A entry efficiency did not change 
but there was an apparent decrease in virus B PSV entry. At 12 mpi there was no significant 
increase in entry efficiency of all AB recombinants compared to PSVs of virus A and B at 
previous time points. Despite extensive recombination within AB/B, PSVs had the lowest 
entry efficiency suggesting that recombination was associated with a fitness cost. On the 
contrary, the AB/A subgroup had significantly higher entry efficiency compared to AB/B 
PSV (p < 0.001), suggesting that some recombination events over the course of infection had 
selected for variants with higher Env entry efficiency. 
 




Due to the low viral diversity of variants infecting CAP84 only four functional Env clones 
were generated representing viral population A at 0 mpi (84c1), virus B at 3 mpi (84c2) and 
viruses A and AB at 12 mpi (84c3; 84c4). PSV entry efficiency of virus A was significantly 
higher than that of B-associated PSV (p = 0.01), although at 12 mpi, virus A PSV entry had 
significantly declined, suggesting that diversification within population A had come with a 
fitness cost (Figure 2.9). Comparison of Env sequences between clones representing virus A 
at 0 mpi and 12 mpi indicated that they differed in 39 amino acids, with most changes 
occurring within the gp41, suggesting that these changes were responsible for the decrease 
in entry efficiency of virus A over time. At 12 mpi virus A and virus AB Env sequences were 
nearly identical except for point mutations within gp120 and recombination within gp41 that 
incorporated regions of virus B (Figure 2.6). As virus AB had the same entry efficiency as 
PSV A sampled at 0 mpi, and significantly higher entry efficiency than PSV A at 12 mpi, 
introduction of virus B gp41 sequence apparently rescued Env fitness. Therefore, 
diversification of virus A over the course of infection led to a less fit variant but 
recombination within gp41 might have restored fitness. 
CAP137 
A total of ten Env clones were generated representing variants infecting CAP137 over time. 
Two clones represented viral population A at 0 mpi, one representing virus B at ~2 mpi, two 
representing A and B viruses at 3 mpi, three representing A, B and AB at 6 mpi, and two 
representing viral population AB at 12 mpi (Table 2.1). The variation in entry efficiency 
between the clones was high, ranging from 10 % to 239 %. There was no significant 
difference in the entry efficiency between A and B PSVs at all time points and their entry 
efficiency decreased over 12 months of infection, suggesting that diversification had reduced 
Env fitness. However, further recombination between A and B viruses in C3, V4 and gp41 
regions resulted in the emergence of recombinants at 12 mpi with significantly higher PSV 
entry than virus A at 0 mpi and virus B at 2 mpi (p < 0.001) (Figure 2.9). Viral population 
AB at 12 mpi comprised of two subgroups with one, AB/B, carrying additional gp41 
sequences from virus B and having significantly higher entry efficiency than all other Env 
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clones except AB/A. This could suggest that sequential recombination events, incorporating 
virus B regions, first in gp120 (C3 and V4 regions) and then in gp41 rescued the loss of virus 
A Env fitness. 
CAP267 
To compare the entry efficiency of viruses from CAP267, six of the SGA-derived env 
sequences were cloned with two clones representing A and B viral populations at 0 mpi, 3 
mpi and 12 mpi. At 0 mpi, PSV generated from viral population A had higher entry efficiency 
than PSV B although this difference did not reach significance. However, diversification of 
B virus over time was associated with a significant increase in entry efficiency as PSV B at 
12 mpi was 4.7-fold more efficient at entering TZM-bl cells than that of PSV B at 0 mpi. 
Unlike, the other participants, there was no apparent recombination between viruses A and 
B over 12 months of infection (Figure 2.7) and it seemed as though B variants evolved to 
higher entry efficiency through point mutations.  
 
2.5.4.2 Selection of Env with high pseudovirion entry efficiency 
This study hypothesized that high diversity in dual-infections would facilitate the emergence 
of fitter recombinant viruses. Highlighter plots and phylogenetic analysis suggested that 
CAP37, CAP84 and CAP267 were infected with recombinants at or soon after enrolment in 
the study. However, without the identification of phylogenetically distinct parents, we were 
unable to confirm that early recombination had occurred. We were able to confirm that 
additional recombination events occurred between virus A and virus B for CAP37, CAP84 
and CAP137 and of these, CAP137 was infected with recombinants at 12 mpi with increased 
entry efficiency compared to virus A and virus B at early time points. Furthermore, 
recombinant variants infecting CAP37 and CAP84 at 12 mpi had significantly higher entry 
efficiency than other viruses detected at the same time point. Therefore, recombination 
within the first year of infection seemed to contribute to improved Env entry efficiency of 
variants 12 mpi. However, there was no overall correlation between maximum Env diversity 
at each time point and corresponding entry efficiency of the dominant Env at that time point 
(data not shown) (p = 0.08). This suggests that high diversity of populations does not translate 
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into the emergence of variants with increased Env entry efficiency, but that rapid selection 
of recombinants conferred a survival advantage. 
Despite fluctuations in entry efficiency within time points and over the course of infection, 
at 12 mpi, CAP37, CAP84, CAP137 and CAP267 were consistently infected with variants 
that had higher entry efficiency than other variants at the same time point.  Escape from 
antibody and CTL immune responses occurs mostly during early infection characterised 
initially by rapid shuffling and toggling of polymorphisms within hypervariable regions and 
CTL epitopes until fixation of escape mutations and slowing of diversification (Abrahams et 
al., 2013). This is apparent in the initial high diversity of variants followed by convergence 
and plateauing of diversity and divergence for all four dual infected individuals at 12 mpi 
(Figure 2.3). Some CTL epitopes previously linked to disease progression and targeted by 
HLA alleles of CAP37, CAP84, CAP137 and CAP267 were analysed for emergence of 
polymorphisms over the course of infection (Appendix B). The analysis indicated fixation 
of putative escape mutations by 12 mpi. Thus, during the first months of HIV infection, there 
could be rapid sampling of polymorphisms forming a heterogeneous population with varied 
abilities to escape from immune responses with random Env entry efficiency. Ultimately, 
however, fixation of mutations that not only allows immune escape but also confers Env 
phenotypic traits that best facilitate viral survival are selected, resulting in the selection of 
variants with high viral fitness. Therefore, it is interesting to speculate that the entry 
efficiency of variants fluctuated seemingly randomly during the first months of infection 
until immune escape and optimal replicative fitness was reached.  
 
2.5.4.3 Association between Entry efficiency and variant frequency 
This study hypothesised that viral outgrowth in dual infected individuals was due to 
enhanced Env entry efficiency. In order to evaluate the relationship between the in vivo 
outgrowth of variants in dual infected individuals and in vitro Env entry efficiency, we 
compared the entry efficiency of clones representing populations A, B and AB to the relative 
frequency of each viral population per time point. 
 




Virus A was the dominant population at 0 mpi, but PSV entry efficiency was lower than 
virus B although this difference was not significant (Figure 2.9A). Furthermore, despite 
emergent AB/B recombinants having marginally higher frequency than virus AB/A at 12 
mpi, it had significantly lower entry efficiency (p < 0.001), suggesting that viral outgrowth 
in CAP37 was not due to Env entry efficiency. However, at the population level, the 
outgrowth of recombinants tended to coincide with enhanced average Env entry efficiency 
of AB viruses (Figure 2.10A). The discrepancy between sub-population frequency and PSV 
entry efficiency could be due to the Env clones not representing the viral fitness of the 
population. Alternatively, fluctuating frequency of viral populations during early infection 
could be due to immune escape masking a clear relationship between viral outgrowth and 
Env entry efficiency. Interestingly, CTL escape mutations were identified approximately 12 
wpi (Appendix B) whereas Abrahams et al, (2013) showed that CTL escape in Env occurred 
2-5 wpi. The authors suggested that immune responses were the driver of early HIV-1 
diversification in mono-infections in vivo and the introduction of escape mutations could 
randomly influence Env entry efficiency (Abrahams et al., 2013). This could suggest that 
CTL escape occurs earlier in mono-infections than dual infections. However, further analysis 
of the dual-infection sequences needs to be carried out to confirm this suggestion and whether 
recombination plays a role in selection of CTL escape.  
CAP84 
The entry efficiency of PSV B was significantly lower than PSV A (p < 0.01) at 0 mpi which 
correlated with variant frequency. At 12 mpi, virus A entry efficiency was significantly 
reduced compared to enrolment and this coincided with a drop in frequency to 30 % (Figure 
2.9B). Whereas virus A seemed to lose fitness, virus AB had significantly higher entry 
efficiency and frequency than virus A at 12 mpi. Therefore, there was an association between 
entry efficiency and frequency at each time point with the recombinant having the highest 
frequency and entry efficiency relative to virus A (Figure 2.9B). This trend was confirmed 
at the population level when the entry efficiency was compared to variant frequency (Figure 
2.10B). As Env representing virus A and the AB recombinant at 12 mpi differed due to 
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changes within gp41, it is possible that virus B gp41 contributed to enhanced Env entry 
efficiency of AB. 
CAP137 
While PSV B entry efficiency varied according to its population in vivo frequency over time, 
the decrease in entry efficiency of PSV A did not correlate with its in vivo frequency. At 6 
mpi virus A made up 65 % of the viral population but the entry efficiency of PSV A was 
similar to that of the other variants at that time point. Similar to CAP37, PSV entry efficiency 
did not always track changes in population frequency during early infection possibly due to 
the influence of CTL escape mutations on Env fitness (Abrahams et al., 2013) noting that 
sequences as early as 2-3 mpi showed putative escape within the HLA B*5802 epitope HF9 
(Appendix B). However, entry efficiency could be impacting outgrowth of the recombinants 
as the average entry efficiency of AB/A and AB/B coincided with change in population 
frequency (Figure 2.10C). Further, analysis of individual clones at 12 mpi indicated that 
PSVs representing the AB/B sub-group had marginally higher entry efficiency than AB/A 
that could be responsible for the 2–fold higher in vivo frequency (Figure 2.9C). The 
genotypic difference between AB/A and AB/B is the presence of additional virus B gp41 
sequence, suggesting that changes in gp41 might have contributed to enhanced entry 
efficiency and in vivo outgrowth.  
CAP267 
Viruses A and B entry efficiency fluctuated over time and not all changes corresponded with 
changes in in vivo frequency. There was no evidence of putative CTL escape to explain the 
lack of association as there was no evidence of polymorphisms within and adjacent to the 
HLA B*5802 epitope, HF9 (Appendix B). However, at 12 mpi virus B dominated with a 
frequency of 76 % and had significantly higher entry efficiency than all other Envs (Figure 
2.9D). This trend was also apparent when PSV entry efficiency was plotted alongside 
population frequency (Figure 2.10D).  This could suggest that virus B evolved into a variant 
with enhanced entry efficiency which then contributed to in vivo outgrowth.  
 





Figure 2.9. Pseudovirion Entry Efficiency over 12 months of infection.  The entry efficiency 
of pseudovirus (PSV) representing virus A (red), B (blue) and AB (purple) infecting A) CAP37, 
B) CAP84, C) CAP137, and D) CAP267 was compared over time (0, 3, 6 and 12 mpi). TZM-bl 
cells were infected with PSV equivalent to 100 ng/ml p24 and entry efficiency was measured as a 
percentage (%) relative luminescent units (RLU) to PSV A at 0 mpi after subtracting background: 
PSV lacking Env. The in vivo frequency (%) of each virus is indicated at the top of each bar. 
Results represent three independent biological repeats with error bars indicating standard 
deviation. One-way ANOVA with Bonferroni correction for multiple comparisons was used for 
statistical analysis (p < 0.05: *, p < 0.01: **, p < 0.001: ***, and p < 0.000: ****). 
A) CAP37 B) CAP84










































































































































































































Of the four participants, three were infected with variants at 12 mpi with high in vivo 
frequency and increased entry efficiency, suggesting that Env fitness was enabling some 
variants to outcompete others. Overall, there seemed to be a tendency for recombinant 
variants with high average entry efficiency to have high relative frequency at 12 mpi (Figure 
2.10) although correlation analysis showed that this relationship was not significant across 
all time points (p = 0.37, r = 0.19) (data not shown). Similarly, populations that dominated 
at each time point, whether A, B or AB, did not always have the highest entry efficiency (p 
= 0.2, r = 0.38) (data not shown). This apparent lack of association between frequency and 
Env entry efficiency could be due to the dependence of variant survival and outgrowth on 
immune escape during early infection rather than Env entry efficiency (Abrahams et al., 
2013). Finally, for 2/4 participants Env with higher entry efficiency seemed to have 
recombined within gp41, suggesting that gp41 could play an important role in determining 
Env fitness and thus virus outgrowth in vivo. 
 





Figure 2.10. Overall relationship between “in vivo” frequency and Env entry efficiency over 
time.  Changes in in vivo population frequency (right y-axis) and PSV entry efficiency (left y-
axis) of variants infecting A) CAP37, B) CAP84, C) CAP137 and D) CAP267 are shown over 
months post infection (mpi). In vivo frequency (%) of populations was determined by calculating 
the proportion of sequences relative to total sequences at each time point. The frequency of AB 
subgroups was not included. PSV entry efficiency is indicated relative (%) to PSV A at 0 mpi. The 
frequency of A, B, and AB viruses are indicated in red, blue and purple lines, respectively. Entry 
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2.5.4.4 Association between Entry efficiency and disease progression 
Studies have shown that increased Env entry efficiency is associated with both an increase 
in viral load (VL) and/or a decrease in CD4+ T cell count (Gordon et al., 2016; Lassen et al., 
2009; Mohri et al., 2015; Troyer et al., 2005). Therefore, we determined whether the Env 
entry efficiency of viral populations A, B and AB infecting dual infected individuals 
impacted disease progression and whether the entry efficiency of the dominant virus was a 
determining factor. 
For all participants, peak viremia was apparent at the earliest time point and for CAP37, 
CAP84 and CAP137, the increased VL coincided with the highest entry efficiency of ‘parent’ 
viruses A and B compared to later time points. There was a similar trend between VL and 
PSV entry efficiency across all time points in general, with high VL at 12 mpi coincident 
with high entry efficiency of AB recombinants (Figure 2.11A-C).  Entry efficiency of viruses 
infecting CAP267 was not linked with VL during the first-year of infection: when Env entry 
efficiency was low, VL was high and vice versa (Figure 2.11D).  However, the increased 
entry efficiency of CAP267 viruses at 12 mpi coincided with a decrease in CD4 count (Figure 
2.11D). This relationship was similar for the other participants where CD4 count levels either 
increased or plateaued at initial time points before dropping at 12 mpi, concomitant with an 
increase in entry efficiency of AB viral populations (Figure 2.11A-C). 
Despite the apparent association between changes in PSV entry efficiency and VL in 3/4 
participants (Figure 2.11) there was no significant correlation between VL and average entry 
efficiency of all variants at each time point. When a similar analysis was carried out 
comparing VL to the entry efficiency of the dominant variant only, the relationship still did 
not reach significance. However, there was a correlation of CD4+ T cell count loss with 
increased average PSV entry efficiency (p = 0.046, r = -0.59) (Figure 2.12A) and this 
relationship strengthened when CD4 count was compared to the entry efficiency of the 
dominant variant only (p = 0.02, r = -0.71) (Figure 2.12B). Therefore, there seems to be an 
overall association between Env entry efficiency and disease progression with three of the 
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study participants progressing to CD4 levels associated with AIDS-defining illness within 
the first year of infection (CAP37, CAP137 and CAP267). 
 
 
Figure 2.11. Env entry efficiency and disease markers (viral load and CD4 count) over time. 
Entry efficiency and markers of disease progression, viral load (VL) and CD4+ T cell count were 
plotted over time. Entry efficiency of PSV A, B and AB is indicated in red, blue and purple, 
respectively. PSV entry efficiency of all clones was normalised to the entry efficiency of virus A 
at 0 mpi and indicated as percentage. Changes in VL and CD4 count decline over months post 
infection (mpi) are shown by black circles and squares, respectively. VL and CD4 counts were 
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Figure 2.12. Association between pseudovirion entry efficiency and CD4+ T cell count. The  
entry efficiency of pseudovirus from independent experiments across participants was normalised 
to the background control and indicated as fold higher than background (-fold). A) The entry 
efficiency of viruses at each time point per participant, irrespective of population, was averaged 
and compared with CD4+ T cell count. B) To determine whether the entry efficiency of the viral 
population dominant at each time point was influencing CD4 counts, the entry efficiency of the 
virus with the highest frequency was compared to CD4 counts of all participants. If more than one 
clone represented a viral population that dominated at a particular time point then the entry 
efficiency of the clones was averaged. The association between relative in vitro Env efficiency and 
disease progression was analysed by Spearman r correlation test. Spearman r test is indicative of a 
negligible, weak, moderate, high and very high relationship based on previous reports (Hinkle et 
al., 2003) and a p value of < 0.05 was considered significant. GraphPad Prism 5.0 software (CA, 
USA) was used for statistical analysis.  
 
 
 Env Fitness determinants 
The relationship between in vivo variant frequency and Env entry efficiency suggests that 
Env function influences viral fitness. We hypothesized that the better the virus is able to enter 
host cells, the faster they would replicate. Therefore, identifying determinants of Env fitness 
could provide novel targets for vaccine and drug design that if targeted, could lead to 
attenuation of viral replication and reduced risk of transmission. To identify Env fitness 
determinants that could potentially impact viral outgrowth, Env sequences were aligned and 
mismatches were compared across Env with varying entry efficiency. Results revealed 
putative sites that could play a role in influencing Env structure and function.  
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At 3 mpi CAP84 was infected with two variants that differed primarily in gp41, suggesting 
that the gp120 of the second parent (virus B) was not detected. Virus A (84c1) had 
accumulated a number of mutations by 12 mpi, with 84c3 carrying a cluster of 9 amino acid 
changes within the signal peptide and putative CTL escape mutations within CAP84 HLA 
restricted epitopes. These changes seemingly reduced 84c3 entry efficiency significantly 
compared to 84c1 (Figure 2.9). However, after recombination introduced virus B regions 
within gp41 of virus A, the entry efficiency of virus AB (84c4) was significantly higher than 
84c3 coincident with increased frequency (70 %).  Virus A and virus AB at 12 mpi comprised 
very similar gp120, suggesting that gp41 might be influencing their PSV Env entry efficiency 
and thus driving in vivo viral outgrowth.  
To investigate whether gp120 mutations lowered and gp41 increased PSV entry efficiency, 
we generated two chimeric Env clones, (84c1/c4 and 84c4/c1) by swapping the gp41 of virus 
A at 0 mpi for that of virus AB and vice versa. The chimera (84c1/c4) with gp41 of virus B 
was 3- to 4-fold significantly more efficient than PSV A at entering TZM-bl cells (p = 0.005). 
Despite high sequence similarity with 84c3, 84c4/c1 had lower entry efficiency than 84c1 
and 84c4 although this difference did not reach significance (Figure 2.13 A and B). This 
suggested that recombination in gp41 may have resulted in a fitter virus but that mutations, 
present in gp120 of virus AB, attenuated Env function. 
When gp120 sequence of virus A was compared to that of virus AB, a potential N-
glycosylation site (PNG) at position 339 was identified in AB sequences that appeared in 
19/20 sequences at 12 mpi. The introduction of N339 by SDM into the 84c1/c4 chimera with 
high entry efficiency decreased PSV entry 2.4-fold (p < 0.05), suggesting that an N-glycan 
at this position had a negative effect on Env function. We thus hypothesized that a PNG at 
position 339 of virus AB could counter the positive effect of recombination in gp41 on Env 
function. However, when N339 was deleted in 84c4, the entry efficiency did not increase as 
expected (Figure 2.13C), suggesting that the putative CTL escape mutations also had a 
deleterious effect on PSV entry efficiency.   
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A closer analysis of CAP84 sequences indicated that the introduction of N339 was 
concomitant with adjacent amino acid changes that flanked the CTL epitope recognized by 
HLA B*1503 (Appendix B). Mutations flanking CTL epitopes can prevent processing and 
presentation of peptides to CD8+ T cells facilitating immune escape (Milicic et al., 2005). 
Not only has the introduction of PNGs been linked to escape from neutralizing antibodies 
(Moore et al., 2012) and decreased Env fitness (Wang et al., 2013), it has also been linked to 
processing and presentation of CTL epitopes (Wood and Elliott, 1998). As CAP84 is HLA 
B*1503 positive and additional mutations appeared within and adjacent to other B*1503 
epitopes (Appendix B), it is possible that the emergence of mutations and an N-glycan at 
N339 flanking the epitope VY9 contributed to immune escape at 12 mpi. However, these 
mutations might also have synergistically influenced Env structure and function within the 
context of 84c4 gp41.  Therefore, deletion of N339 without altering the mutations flanking 
VY9 in 84c4 might not have resulted in a change in Env entry efficiency (Figure 2.13C). 
Collectively, this data suggests that the introduction of mutations in gp120 could have 
reduced Env fitness that was then rescued by recombination in gp41 and highlights the 
complex relationship between Env function and viral evolution. 
CAP137 
The outgrowth of virus AB at 12 mpi was associated with enhanced entry efficiency of PSV 
137c10, a representative of the AB viral population. Therefore, in order to identify fitness 
determinants, AB sequences were compared to the master sequences representing virus A 
and virus B. Sequence analysis showed that virus AB had inherited regions/sites from both 
initial infecting viruses and could be sub-grouped into recombinants AB/A and AB/B due to 
the presence of additional gp41 sequence of virus B (Figure 2.6). Although, the difference in 
entry efficiency between recombinants AB/A and AB/B was not significant, with the 
concomitant 2-fold higher frequency of AB/B it seemed likely that this region in gp41 played 
an important role in virus AB/B PSV entry efficiency.  
Further sequence analysis also identified a PNG at position 332 (according to HXB2 
numbering) of virus B, AB/A and AB/B gp120. The PNG at N332 was identified as the 
epitope for broadly cross-neutralizing (BCN) antibodies that emerged during late stages of 
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infection (Moore et al., 2012). As the PNG elicits some of the most potent BCN antibodies 
and was inherited from virus B that had poor PSV entry efficiency, we wanted to know 
whether introduction of this PNG in AB virus was accompanied by a change in Env entry 
efficiency.  When the PNG at N332 was deleted in 137c10, there was a significant 2.3-fold 
decrease in entry efficiency compared to wild-type (p < 0.001), suggesting that a PNG at 
position 332 might not only play a role in escape from neutralising antibodies but also 
enhance viral entry efficiency (Figure 2.14). However, noting that virus B had poor entry 
efficiency despite carrying the PNG, the affect that a PNG at 332 might have on Env entry 
efficiency is most likely dependent on the presence of other sequence changes. Therefore, it 
is impossible to predict whether immune responses that drive the loss or incorporation of 
PNGs will lead to less fit variants as fitness is likely highly dependent on the interplay 
between a number of structural factors. 
CAP267 
Based on the entry efficiency results, the evolution of virus B over time coincided with an 
increase in PSV entry efficiency. PSV representing virus B (267c6) at 12 mpi had 4.2-fold 
higher entry efficiency than PSV carrying virus B Env (267c2) at 0 mpi. These sequences 
differed by eighteen amino acids in gp120 and five amino acids in gp41. To determine 
whether gp120 or gp41 changes were responsible for the difference in entry efficiency, gp120 
(excluding C5 region) was swapped between the two clones and entry efficiency was 
compared. The chimera having C5 and gp41 of virus B (267c6) at 12 mpi had 4.5-fold 
increase in entry efficiency, similar to that of PSV B (267c6) (Figure 2.15). This suggested 
that either the one a.a. in C5 and/or the five a.a. changes in the gp41 of virus B at 12 mpi 
could be responsible for the increase in entry efficiency of the B population over time.





Figure 2.13. Entry efficiency of CAP84 Envelope chimeras and mutants.  A) Schematic  
diagram of CAP84 clones, chimeric and mutant constructs made for CAP84. Red and blue bars 
indicate virus A and virus B sequences, respectively, stars indicate point mutations and N indicates 
the potential N-glycan site (PNG) N339. B) Two chimeras were constructed from 84c1 and 84c4 
by swapping gp41 between the two clones. CAP84 virus A (84c1) at 0 mpi and virus AB (84c4) 
at 12 mpi are indicated in red and purple, respectively. The chimera 84c1/84c4 comprises of the 
gp120 region of 84c1 and the gp41 of 84c4 and is indicated by a pink bar. Chimera 84c4/c1 
comprises of gp120 of 84c4 and gp41 of 84c1and is indicated by the pale purple bar. C) Site-
directed mutagenesis (SDM) was used to introduce a PNG site at position 339 in the chimera 
84c1/c4. The mutant is indicated by the pink striped bar. D) PNG site at position 339 was removed 
from 84c4 using SDM and is indicated by purple blocks. Entry efficiency is indicated as percentage 
relative to that of virus A (84c1).  Data represents the average of three independent experiments. 
One-way ANOVA with Bonferroni correction for multiple comparisons was used for statistical 







































































































































Figure 2.14. Identification of CAP137 Envelope determinants. A) Schematic diagram of 
CAP137 clones and mutant construct. Red and blue bars indicate sequences from virus A and virus 
B, respectively with recombined regions indicated. The N indicates the PNG, N332.  B) A PNG 
was removed from virus AB/B (137c10) at position 332 (HXB2) and the entry efficiency was 
compared using the TZM-bl cell line. Virus A (137c1), virus AB (137c10), and the 137c10-sdm 
mutant are indicated by red, purple and purple blocks, respectively. Bars represent the average of 
three independent biological repeats with error bars representing standard deviation. One-way 
ANOVA with Bonferroni correction for multiple comparisons was used for statistical analysis 

























































Figure 2.15. Entry efficiency of CAP267 chimeras.   A) Schematic diagram of CAP267 clones 
and chimeras. Red and blue indicate the sequences of viruses A and B, respectively with stars 
indicating point mutations. B) Gp120 of virus B at 0 mpi (267c2) (blue bar) was swapped with that 
of virus B at 12 mpi (267c6) (blue bar). Two chimeras were generated using restriction enzymes 
and entry efficiency was compared to virus A at 0 mpi (267c1) indicated with a red bar.  The first 
chimera (267c2/c6) comprises the gp120 of virus B at 0 mpi and gp41 of virus B at 12 mpi (blue 
striped bar). The second one (267c6/c2) comprises gp120 of virus B at 12 mpi and gp41 of virus 
B at 0 mpi (indicated by blue blocks). One-way ANOVA with Bonferroni correction for multiple 
comparisons was used for statistical analysis using Prism 5.0. Data represent the average of three 
independent biological repeats with standard deviation (p < 0.05 = *, p < 0.01 = **, p < 0.001 = 


























































Env is an important determinant of viral fitness and can impact disease progression 
(Quiñones-Mateu et al., 2000). We aimed to determine whether the in vivo outgrowth of 
variants infecting dual infected individuals was related to the in vitro Env entry efficiency of 
the dominant viruses at 12 mpi.  
In order to track viral evolution and monitor fluctuations in viral populations, we first needed 
to identify the initial transmitted viruses. Identification of viral populations via sequencing 
is limited by sampling and as we analysed ~20 sequences per time point, we were most likely 
only detecting variants at a frequency greater than 15 % (Salazar-Gonzalez et al., 2008). 
Furthermore, although we had samples as early as 2-12 wpi, rapid recombination or 
transmission of recombinants, complicated the identification of full-length parent envs at the 
earliest time point of sampling (Wooley et al., 1997). To overcome this limitation, we 
determined the maximum DNA distance between the dominant variant at the earliest time 
point, virus A and all other variants. We hypothesised that the variant most dissimilar to virus 
A, would most closely resemble the second parent, virus B. Based on Highlighter plots; 
however, it was highly likely that the sequence we classified as virus B was a recombinant 
of A. Therefore, we suspected that recombination had occurred before the earliest time of 
sampling for all the dual-infected individuals.  As we aimed to determine whether viral 
outgrowth was due to Env fitness, we hypothesised that viruses below detectable frequency 
would not significantly influence determining the relationship between in vivo viral 
outgrowth and Env entry efficiency. We identified two variants, virus A and virus B, most 
closely resembling the two phylogenetically distinct parents, tracked their relative frequency 
over time and determined whether Env function was driving viral outgrowth. 
Viruses A and B from all participants differed with a DNA distance ranging between 3 – 
12 %. In CAP84, env representing virus B was only detected at 3 mpi with a max DNA 
distance of 3 % while env classified later as a recombinant of viruses A and B was already 
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present at ~1 mpi. The inability to detect virus B variants at earlier time points suggested low 
in vivo frequency likely due to poor replication fitness.  
Further recombination events between viruses A and B were confirmed using Highlighter 
Plot and RIP tools. The timing of the emergence of new recombinant viruses varied between 
participants. In two participants, recombinants emerged at 2 and 6 mpi (CAP37 and CAP137, 
respectively) whereas in CAP84, an apparent recombinant of viruses A and B was present at 
1 mpi, before the detection of virus B and there were no detectable recombinants of virus A 
and virus B infecting CAP267.  Despite differences in timing between participants, the in 
vivo frequency of recombinants increased over time and outgrew other variants at 12 mpi in 
CAP37, CAP84 and CAP137.  
Based on previous definitions, the four dual-infected participants were classified as rapid 
(CAP37, CAP137, CAP267) and typical (CAP84) progressors based on their CD4+ T cell 
levels (Mlisana et al., 2014). In our study, the in vivo frequency of emergent recombinants 
in two rapid progressors at 12 mpi confirmed previous reports that showed an association 
between recombination and disease progression (Fang et al., 2004; Gordon et al., 2016; 
Nájera et al., 2002; Ramirez et al., 2008). Interestingly, no emergent recombinants were 
detected in the other rapid progressor (CAP267) although virus B, a putative recombinant, 
had the highest frequency at 12 mpi. However, in the typical progressor (CAP84), the early 
presence of recombinant variants and the in vivo outgrowth of emergent recombinants were 
not associated with disease progression. Although the sample size is small, and we cannot 
exclude the impact of limited sampling, these results could suggest that recombination is not 
always linked to disease progression (Liu et al., 1997). 
Our results showed variation in PSV entry efficiency (ranged from 10 – 230 %) across 
participants. At early time-points, there was no consistent relationship between PSV entry 
efficiency and viral outgrowth. The entry efficiency of PSV representing variants at 12 mpi 
infecting CAP37 and CAP84 did not increase significantly compared to viruses at 0 mpi, 
suggesting that diversification had not selected for fitter Env. However, at 12 mpi 3/4 
participants were infected with variants with high frequency (dominant) with significantly 
higher entry efficiency than other variants at the same timepoint, suggesting that Env fitness 
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was playing a role in viral outgrowth within later time points. The only exception was 
CAP37, where recombinant AB/B, with the highest entry efficiency at 12 mpi had similar 
frequency to recombinant AB/A at 12 mpi.  
Whether outgrowth was due to gain of fitness of Env or whether recombination triggered the 
emergence of escape mutants that enhanced viral survival, required further analysis 
(Mostowy et al., 2011). As detailed analysis of immune escape fell outside the objectives of 
this study, we only looked at the emergence of polymorphisms within previously identified 
CTL epitopes recognised by the HLA alleles of the individuals. There seemed to be some 
evidence of toggling of polymorphisms during early infection with subsequent fixation of 
CTL escape mutations for CAP37, CAP84 and CAP137 by 12 mpi (Abrahams et al., 2013). 
It is interesting to speculate that the seemingly random changes in entry efficiency during 
early infection could be due to immune pressure selecting escape mutations that either 
favoured or lowered Env entry efficiency. However, based on CTL epitope analysis the 
recombinants at 12 mpi had not only escaped early immune responses but also gained fitness 
mutations favouring in vivo outgrowth although without further analysis no clear conclusions 
can be drawn. In our cohort, there was no increase in PNGs frequency over time, suggesting 
that bnAB might not play a role within the first year of infection as previously suggested 
(Abrahams et al., 2013).  
CAP84 PSV representative of the emergent recombinant that outgrew at 12 mpi did not have 
enhanced entry efficiency compared to the parents despite apparent positive selection for 
changes in the signal peptide and gp41.  When we generated gp120/gp41chimeras of virus 
A and virus AB, the gp41 of virus AB fused to the gp120 of virus A led to enhanced PSV 
entry, suggesting that the positive selection of virus B gp41 should have resulted in a virus 
with a fitter Env. Further sequence analysis identified a PNG at position 339 present in virus 
AB and absent in virus A. Changes in Env N-glycosylation in reaction to host immune 
responses has been linked to changes in Env fitness and we thus wanted to test whether the 
presence of a PNG at 339 affected CAP84 PSV entry efficiency. The introduction of N339 
into the chimera, decreased PSV entry efficiency, suggesting that the lack of increased entry 
efficiency of CAP84 emergent recombinants could be due to a fitness cost associated with 
N339 (Liu et al., 2007). However, deletion of the PNG in virus AB at 12 mpi (84c4) did not 
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yield the expected increase, suggesting that the impact of mutations on Env fitness is variant 
specific.  
The appearance of the PNG at position 339 was also co-incident with mutations flanking the 
VY9 epitope recognized by HLA B*1503, an allele frequents in subtype C sequences and 
associated with slow disease progression in subtype B but not subtype C infected individuals 
(Frahm et al., 2006). It is thus possible that the concomitant emergence of the PNG at N339 
and potential CTL escape mutations was required for changes in entry efficiency. This has 
ramification for vaccine design as PNGs that help escape from neutralizing antibody 
recognition and potentially CTL escape could increase the fitness of one variant in one host 
but attenuate Env in another.  This is especially noteworthy given that N-glycans are the 
target for potent neutralizing antibodies (Lavine et al., 2012). We propose that recombination 
within gp41 increased the fitness of emergent recombinants but that due to immune pressure 
a PNG site was introduced at position 339 which then attenuated viral replication.  The lack 
of overall enhanced entry efficiency over the first 12 months of infection could be responsible 
for the typical disease progression of this participant (Ball et al., 2003; Quiñones-Mateu et 
al., 2000). 
Similarly, for CAP37 the entry efficiency of PSV representing variants at 12 mpi was similar 
to that at 0 mpi, suggesting no overall increase in viral fitness. However, the entry efficiency 
of viruses A and B declined over time and were supplanted by the emergent recombinants 
AB/A and AB/B, most likely due to escape from immune responses (Barouch and Letvin, 
2002; Costa et al., 2004; Moore et al., 2002). AB/A had the highest entry efficiency at 12 
mpi, suggesting that recombination had selected for a fitter virus at 12 mpi but escape from 
immune responses compromised Env entry efficiency.  There was evidence of putative CTL 
escape mutations within epitopes recognized by HLB*5301.   
In the other two participants, CAP137 and CAP267, PSV entry efficiency increased over 
time coinciding with in vivo outgrowth of variants. Env entry efficiency was reported to be 
linked with disease progression (Gordon et al., 2016; Lassen et al., 2009; Quiñones-Mateu 
et al., 2000; Trkola et al., 2003). Here, we showed that PSV entry efficiency correlated 
significantly with faster CD4+ T cell decline (p = 0.046) and therefore, Env entry efficiency 
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could be a driving factor in the disease progression of CAP137 and CAP267. A similar 
relationship between PSV entry efficiency and VL was not observed but CD4+ T cell decline 
can be an independent marker of disease progression and in vivo variant frequency 
(Claiborne et al., 2015). Furthermore, when the entry efficiency of the dominant variant at 
each time point was correlated to CD4 counts, the association was strengthened, supporting 
the relationship between Env fitness and disease progression.  
Interestingly, gp41 was identified as a potential fitness determinant of variants infecting 
CAP137, CAP267 and CAP84, at 12 mpi, suggesting that gp41 could play a very important 
role in Env entry efficiency by determining virus-to-cell membrane fusion (Checkley et al., 
2011; Wilen et al., 2012).  However, Env fitness of CAP137 AB/B was also influenced by a 
PNG at position 332.  It has been shown that broadly neutralising antibodies recognised an 
N-glycan at position 334 and that escape involved the shifting of the PNG from position 334 
to 332. However, shifting of the PNG to position 332 resulted in broadly cross-neutralising 
(BCN) antibodies so it was unclear how a PNG at 332 benefitted the virus (Moore et al., 
2012). When we deleted N332, the enhanced entry efficiency of the emergent AB/B 
recombinant dropped significantly, suggesting that a PNG at position 332 might not only 
play a role in immune responses but also Env fitness which is consistent with a previous 
finding (Lavine et al., 2012) where N332S also reduced virus entry of HIV-1JR-FL. Thus, 
this could explain the benefit of a shift of PNG from 334 to 332 although whether a PNG at 
position 334 also influences Env function still needs to be determined.  
Conclusion 
In this study, we showed that recombinants were dominant at 12 mpi with better entry 
efficiency compared to other viruses at the same time point. The increased entry seemed to 
be associated with recombination within gp41 for 3/4 individuals. However, for CAP84 and 
CAP137 changes in gp41 were linked to changes in PNGs at positions 339 and 332 of the 
immunogenic C3 region (Moore et al., 2008), suggesting that interplay between immune 
escape and changes in Env function could determine the outgrowth of fitter variants. As Env 
entry efficiency could play a very important role in CD4 T cell loss, vaccines that target Env 
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N-glycans could select for the loss or gain of PNGs resulting in the emergence of a more 
pathogenic variant that increases disease progression.   
 




Longitudinal, Phenotypic Characterisation of Hiv-1 Subtype C 
Envelope Isolated from Dual Infected Individuals 
 
3.1 Introduction 
In this study, recombination events, which mapped mainly to gp41 in association with N-
glycan site changes in the C3 region, were associated with in vivo outgrowth of viruses 
(Chapter 2). Outgrowth of recombinants was associated with enhanced Env entry efficiency 
in 2/4 dual infected individuals and mutagenesis showed that changes within C3 and gp41of 
¾ individuals conferred phenotypic advantages that enhanced Env entry efficiency. We 
hypothesised that changes in Env phenotype mediated by C3 and gp41 could translate into 
high replicative fitness which might increase disease progression. Env phenotypic changes 
that have been associated with HIV-1 pathogenicity include: (i) switching of R5-tropism to 
X4 tropism (Gorry et al., 2014; Gorry and Ancuta, 2011), ii) enriched macrophage (M)-
tropism and high replicative capacity in monocyte derived macrophages (MDM)  (Blaak et 
al., 2000; Li et al., 1999), (iii) increased ability to utilize low levels of CD4 (Gorry et al., 
2014) and CCR5 (Gray et al., 2005; Tuttle et al., 2002) with greater susceptibility to 
inhibition by CCR5 antagonists (Koning et al., 2003; Lobritz et al., 2007; Olivieri et al., 
2007), and (iv) enhanced Env entry efficiency and viral fitness (Marozsan et al., 2005; Rangel 
et al., 2003).  We therefore wanted to determine how recombination in gp41 and/or the 
presence of PNGs influences Env entry efficiency and thus viral fitness. As gp41 seemed to 
be the most common fitness determinant across participants, we focused on phenotypes 
related to gp41 function. However, as PNGs at sites 332 and 339 were adjacent to V3, 
involved in R5 tropism and binding to CCR5 (Bagnarelli et al., 2003; Hwang et al., 1991), 
we also investigated differences in co-receptor and cellular tropism. 
   
94 
 
Following Env interaction with CD4 and CCR5, a series of conformational changes in gp41 
occur that result in the fusion of the viral and cell membranes (Chan et al., 1997; Pancera et 
al., 2010, p. 41).  Previous studies showed that differences in fusion capacity of HIV-1 
variants impact virus entry (Lobritz et al., 2007; Marozsan et al., 2005), and the sensitivity 
to fusion inhibitor (T-20) (Lobritz et al., 2007; Reeves et al., 2002). These differences in 
fusion capacity were mapped to variable loops (V1-V3) in gp120 (Cavrois et al., 2014; 
Etemad et al., 2009; Lobritz et al., 2007) and the T-20 binding site on the HR1 domain of 
gp41 (Reeves et al., 2005; Wei et al., 2002). Moreover, previous studies also revealed an 
association between fusion capacity and post-translational processing and incorporation of 
cleaved Env into virions (Blay et al., 2007; Cavrois et al., 2014) resulting in enhanced Env 
entry efficiency (Bachrach et al., 2005). Env incorporation into virions was mapped to gp41 
(Blay et al., 2007; Da Silva et al., 2013; Murakami and Freed, 2000), emphasising the 
important role of gp41 in Env fitness.    
Therefore, we compared Env phenotypes between clones that varied in PSV entry efficiency 
to determine one or more Env properties that could provide variants with a functional 
advantage over another in dual infected individuals. 
 




3.2 Research Aim and Objectives 
 
Aim 
To determine the phenotype of Env driving changes in pseudovirus entry efficiency over 12 
months of dual infection. 
  
Objectives 
Objective 1: Compare changes in Env tropism, fusion capacity, expression and 
incorporation into virions over the course of infection. 
Objective 2: Identify Env phenotype(s) responsible for changes in pseudovirus entry 
efficiency.  
Objective 3: Determine the impact of fitness determinants on changes in Env 
phenotypes. 
 




3.3 Materials and Methods 
 Samples used in this study 
A subset of clones isolated from CAP84, CAP137 and CAP267 with changes in entry 
efficiency between enrolment and 12 mpi were selected. 
 Coreceptor phenotype 
To determine Env viral tropism in our cohort, envs were co-transfected with the 
luciferase-encoding pNL4-3.Luc.R–E– backbone (NIH AIDS Reagent Program, Division 
of AIDS, NIAID, NIH: pNL4-3.Luc.R–E– from Dr. Nathaniel Landau, USA). U87 cell 
lines expressing CD4 receptor and either CCR5 or CXCR4 were infected with PSV with 
a titre equivalent to 100 ng/ml of p24 and luciferase activity was measured after 48 hours. 
Viruses that could infect the U87CD4+CCR5+ cells (NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: U87CD4+CCR5+ cells from Dr. HongKui Deng and 
Dr. Dan R. Littman) were classified as R5-tropic, and viruses that infected 
U87CD4+CXCR4+ (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
U87 CD4+CXCR4+ from Dr. HongKui Deng and Dr. Dan R. Littman) were classified 
as X4-tropic. In order to control for R5 and X4 tropism, we included the Env clones, 
QHO (Li et al., 2005) to control for R5 tropism and RPI (Cilliers et al., 2005) for X4 
tropism. Transfection with the pNL4-3.Luc.R–E– backbone and medium only was used 
as negative controls. Coreceptor usage was also confirmed using the bioinformatics tool, 
Position-Specific Scoring Matrices (PSSM) 
(https://indra.mullins.microbiol.washington.edu/webpssm/) (Jensen et al., 2003), that 
predict R5 and X4 usage based on the V3 positive charge. 
 Cellular tropism  
HEK293T- Affinofile cells, donated by Benhur Lee (UCLA) are dual inducible so that 
the addition of minocycline (Sigma-Aldrich, MO, USA) and ponesterone (PonA) (Sigma-
Aldrich, MO, USA) induces CD4 and CCR5 levels in a dose dependent manner. These 
cells were used to measure whether Envs were macrophage-tropic (M-tropic) or T 
lymphocyte tropic (T-tropic) based on the ability of PSVs to enter cells expressing low 
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CD4 and high CCR5 levels resembling macrophages or high CD4 and low CCR5 levels 
similar to T cells (Table 3.1) (Johnston et al., 2009). Briefly, Affinofile cells (104 cells 
per well) were seeded in 6 well plates, CD4 expression was induced with a concentration 
range of minocycline (0-5 ng/ml) and CCR5 expression was induced with a range of 
PonA (0-4 µM).  After inducing for 24 hours, cells were collected and stained with either 
phycoerythrin (PE)-labelled anti-human CD4 or PE-labelled anti-human CCR5 
(BioLegend, US) for 30 minutes at room temperature. Cells were fixed with 
paraformaldehyde and CD4 and CCR5 density was measured using flow cytometry. 
Quantibrite beads (BD Biosciences, USA) were used for CD4 and CCR5 quantification 
according to the manufacturer’s instructions. The number of antibody sites/cell 
(ABS/cell) was equivalent to molecules per cell (Joseph et al., 2014). Data acquisition 
and flow cytometry analysis was done using Cellquest and Flowjo software, respectively.  
Cellular tropism was measured by seeding Affinofile cells (104 cells/well) in a 96-well 
plate and incubated at 37 °C for 24 hrs.  Three different combinations of antibiotics were 
used to induce different densities of CD4 and CCR5 (Table 3.1). T-lymphocyte tropism 
was determined by inducing cells with the required concentration of minocycline and 
PonA to express high CD4 (~70,000 molecules/cell) and low CCR5 (~2,000 
molecules/cell), respectively.  Affinofile cells were also induced with the required 
concentration of minocycline and PonA to express low CD4 density (~2,500 
molecules/cell) and high CCR5 (~31,000 molecules/cell) to resemble macrophage levels 
(Ping et al., 2013). Affinofile cells were also induced to express high density of CD4 
(~110,000 molecules/cell and a range of levels of CCR5 from (2,000 – 31,000 
molecule/cell).  The cells were incubated for 24 hours before infection with PSV 
equivalent to 100 ng/ml p24 and entry efficiency was determined after 48 hrs using a 
Briteglo kit (Promega, USA) according to the manufacturer’s instructions and 
luminescence was measured on a luminometer (Turner Biosystems® Modulus 
Microplate).  JR-CSF (obtained from Lynn Morris, NICD, South Africa) was included as 
a representative of T-tropic variants. Cells-only (mock infection) was used as 
background. 
 





Table 3.1. Density of CD4 and CCR5 induced by Minocycline and Ponesterone A 
a Refers to concentration of CD4 and CCR5 on T-lymphocytes and Macrophages (Johnston et al., 2009; Lee et al., 1999; Platt et al., 1998)  
b (Johnston et al., 2009; Ping et al., 2013)  
NF = not found; N/A: not applicable 
Cell Type 
CD4 CCR5 




















































N/A 1.1x104 2x103 – 1x105 N/A N/A 
U87 CD4+/CCR5+ N/A 2.0x105 NF N/A 6.0x103 NF N/A N/A 




 Env sensitivity to entry inhibitor T-20  
PSVs generated as previously described in section 2.3.3, were pre-incubated with five-fold 
serial dilution of T-20 (0.00032 – 5 µg/ml) (NIH AIDS Reagent Program (ARP), Division 
of AIDS, NIAID, NIH: T-20, (Enfuvirtide)) in DMEM for 1 hr at 37 °C prior to infection of 
TZM-bl cells (104 cells per well). Pseudotyped viruses were produced by co-transfecting the 
env clones with pSG3∆env as previously described in Chapter 2. Luciferase activity was 
measured after 48 hours. RLU versus drug concentration were plotted to determine the 50 % 
inhibitory concentration (IC50) values for each PSV using the GraphPad Prism software 5.0 
(CA, USA). 
 Expression and incorporation of Envelope into pseudovirus 
To evaluate Env expression by HEK 293T cells and Env density on the surface of pseudoviral 
particles, cells expressing Env and pseudovirus were prepared, lysed and resolved on SDS 
PAGE followed by quantitative analysis using immunoblotting as described below. 
3.3.5.1 Pseudovirus preparation  
PSVs were generated as previously described in (Section 2.3.4.2, Chapter 2) with the 
following exceptions: 2X106 cells/ml HEK 293T cells were plated in 10 cm tissue culture 
dishes (Corning, Sigma-Aldrich, MO, USA) and incubated at 37 °C with 5 % CO2 for 24 hr 
after which cells were co-transfected with 5 μg of Env and 10 μg of the subtype B HIV-1 
backbone, pSG3∆env. Forty-eight hours later, pseudovirus supernatant was harvested and 
filtered through 0.2 µm filter and the cells were washed with 1X Phosphate-buffered saline 
(PBS). PSV was pelleted by centrifugation at 26000 X g for 2 hrs using a 20 % glycerol 
cushion at 4 °C in a RW55 rotor (Beckman Coulter, GER). The pelleted PSV was re-
suspended in 50 µl PBS and stored at -80°C for further analysis. 
Cells were lysed in 250 µl RIPA lysis buffer (Appendix C) for 5 - 10 min at 4 °C before 
centrifugation at 14000 rpm for 2 min. The supernatants were stored at -20 °C. Protein 
concentration was determined using a Bradford assay (Bio-Rad, USA) according to the 
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manufacturer’s instructions. Bovine serum albumin (BSA) was used to construct a standard 
curve. 
3.3.5.2  Immunoblotting 
An equal volume of pelleted PSV and 80 µg of protein lysate was resolved using 8 % and 10 
% SDS PAGE, respectively. Following electrophoresis, the proteins were transferred to 
polyvinylidene difluoride (PVDF) membrane (Immun-Blot®, Bio-Rad, USA) using the wet 
transfer system (Bio-Rad) and blocked overnight with 5 % blocking buffer (Appendix C) at 
4 °C.  
For the detection of pseudovirus-associated Env, the membrane was cut into two and the 
upper part was probed with sheep anti-gp120 (Table 3.2) for 1 hr and the lower section 
incubated with rabbit anti-p24 (Table 3.2) for 2 hr at room temperature. For detection of cell-
associated Env, the lower section of the membrane was probed with mouse anti-actin 
antibody (Sigma-Aldrich, MO, USA) for 1 hour at room temperature. The membranes were 
washed three times with TBS-T, each for 15 min intervals, before incubation with secondary 
antibodies for 1 hr at room temperature (Table 3.2). Membranes were washed three times 
with TBS-T followed by one extra wash with TBS only as tween was found to interact with 
the detection reagent, LumiGlo chemiluminescent substrate (KPL) before visualisation using 
autoradiography film (Santa Cruz Biotechnology®, USA). Recombinant gp120 (NIH AIDS 
Reagent Program (ARP), Division of AIDS, NIAID, NIH: HIV-1 IIIB gp120 Recombinant 
Protein from ImmunoDX, LLC) was used as a positive control whereas mock-transfected 
cells and pseudovirus lacking Env were used as negative controls. The relative integrated 
intensity of Env, p24 and β-actin were determined using GelAnalyzer 2010 program and 
background was user defined.  
 Data analysis 
Data represents the average of two independent Western blots. Based on the relative intensity 
of each band given by GelAnalyzer 2010, the expression and incorporation of Env into PSVs 
were calculated as described in (Blay et al., 2007; Provine et al., 2009) using the following 
formulae: 




(The band intensity of gp120 + band intensity of gp160) / (band intensity of β-actin). 
 
 Env expression and cleavage into gp120 and gp41 
 (Band intensity of gp120) / (band intensity of gp120 + band intensity of gp160) 
 
Env incorporation into PSV 
 (The band intensity of gp120 + band intensity of gp160) / (band intensity of p24). 
 
 
Table 3.2. Antibodies used in Western blot 
 
a The antibody was obtained through the NIH AIDS Reagent Program (ARP), Division of AIDS, 
NIAID, NIH: Antiserum to HIV-1 gp120 from Dr. Michael Phelan (ARP) 
b Antiserum to HIV-1 p24, ARP432 (ARP432, NIBSC Centralised Facility for AIDS Reagents, 
Hertfordshire, UK) 
c Horseradish Peroxidase (HRP) conjugate. 
 
 
 Statistical analysis  
One-way ANOVA test was used to compare the mean values of PSV Affinofile entry and 
fusion capacity between Env clones within each participant with Bonferroni test for multiple 
comparisons. In addition, Kruskal-Wallis test with Dunn's multiple comparisons test was 






Env gp160 and 
gp120 
Primary 1:10 000 aARP 
Rabbit anti-p24 
ARP432 
Gag/ p24 Primary 1:10 000 bARP 




c Sheep IgG 
antibody 




c Rabbit IgG 
antibody 




c Mouse IgG 
antibody 
Secondary 1:4 000 Santa Cruz  
Biotechnology® 
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performed to compare mean Env expression and incorporation within each participant.  
Spearman correlation test was performed to determine the relationship between entry 
efficiency and all other phenotypes properties of Envs using GraphPad Prism 5.0 software 
(CA, USA). Correlation co-efficient (r) was determined as indicative of a negligible, weak, 
moderate, high and very high relationships based on previous reports (Hinkle et al., 2003) p 
value of  < 0.05 was considered significant. 





 Coreceptor phenotype 
Coreceptor switch from CCR5 to CXCR4 was reported to be associated with an increase in 
viral load, CD4+ T cell depletion, Env fitness and therefore, disease progression (Connor et 
al., 1997; Gorry and Ancuta, 2011). We selected clones at 0 mpi and at 12 mpi from each 
participant to determine whether the coreceptor switch played a role in changes in Env entry 
efficiency of variants isolated from dual infected individuals. As the entry efficiency of PSVs 
at 3 and 6 mpi did not vary significantly from 0 mpi these clones were excluded from the 
analysis.  All PSVs were only able to infect U87 cells expressing CD4 and CCR5 and not 
CD4 and CXCR4 (Figure 3.1). This was confirmed by the positive charge of V3 sequences 
using the PSSM tool (Data not shown). Variation between CAP37 and CAP137 clones 
infecting U87 cells expressing CD4 and CXCR4 could be due to experimental error as 
background values ranged from 50-300 RLU, suggesting inherent intra- and inter-assay 
variability (data not shown) similar to previous report (Whitcomb et al., 2007). Therefore, 
there was no change in coreceptor tropism over time, suggesting that co-receptor tropism did 
not contribute to changes in PSV entry efficiency.  
 
 Differences in cellular tropism 
T-tropic viruses are able to infect cells with high CD4 and low CCR5 numbers while M-
tropic have the ability to infect cells with low CD4 and high CCR5 levels (Gorry et al., 2002; 
Ping et al., 2013; Schnell et al., 2011).  Recent studies have reported that transmitted founders 
(TFs) are T-tropic (Ping et al., 2013) but R5 viruses might evolve to M-tropism and infect 
host cells with low levels of CD4 (Beauparlant et al., 2017; Chikere et al., 2013). This will 
expand the range of HIV-permissible host cells, facilitating replication which could 
culminate in increased viral load and disease progression (Blaak et al., 2000; Chikere et al., 
2014; Joseph et al., 2014). Therefore, to determine whether variants infecting the four dual 
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infected individuals were able to infect cells with low levels of CD4, PSV Env co-
dependency on CD4 and CCR5 levels was measured by inducing 293 Affinofile cells to 
express different levels of CD4 and CCR5 simultaneously and independently (Johnston et 




Figure 3.1. Determine coreceptor tropism over time.  The coreceptor usage of pseudovirus 
(PSV) representing virus A, B and AB infecting CAP37, CAP84, CAP137, and CAP267 was 
compared over time (0, and 12 mpi except 137c3 at 2 mpi) in A) U87-R5 cell line and B) U87-X4 
cell line. The coreceptor usage of PSV A, B and AB are indicated in red, blue and purple, 
respectively. Coreceptor usage was compared between PSVs normalised to 100 ng/ml p24 and 
displayed as log of relative luminescent units (RLU). Results represent the mean of two 
independent biological repeats with error bars indicating standard deviation. QHO (Li et al., 2005) 
(white bar), RPI (Cilliers et al., 2005) (gray bar) are laboratory strains that were used to control for 
R5, and X4 tropism, respectively. Cell control (Cell ctrl) indicated in black represents background 
of cells without virus (Mock). 
 
Previous studies induced Affinofile cells to express a range of CD4 levels from low (~2,000 
molecules/cell) to high (~70,000–110,000 molecules/cell) to mimic macrophages or 
activated T-lymphocytes, respectively, (Johnston et al., 2009; Ping et al., 2013). Affinofile 
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cells were also induced to express a range of CCR5 from low (2,691 molecules/cell) (Joseph 
et al., 2014) to high (~30,000 molecules/cell) (Ping et al., 2013) levels to mimic T-
lymphocytes and macrophages, respectively (Table 3.1). In this study, Affinofile cells were 
induced to express (i) high levels of CD4 (~70,000 molecules/cell) and low levels of CCR5 
(~2,000 molecules/cell) to mimic T-lymphocyte (CD4high/CCR5low), and (ii) low levels of 
CD4 (~2,600 molecules/cell) and high levels of CCR5 (~31,000 molecules/cell) similar to 
macrophages (CD4low/CCR5high) (Table 3.1).  
To validate our Affinofile system, we used JR-CSF, as a T-tropic virus. JR-CSF infected 
Affinofile cells expressing high CD4 and low level of CCR5 (CD4high/CCR5low) efficiently 
and could not infect cells expressing low CD4 and high CCR5 (CD4low/CCR5high), 
suggesting that our Affinofile system was representative of T- cells and macrophages.  
All PSVs from the four participants could enter and infect cells expressing high levels of 
CD4 despite low levels of CCR5 (CD4high/CCR5low) (Figure 3.2A-D). However, when the 
CD4 level was lowered to 2,600 molecules/cell and CCR5 levels were high 
(CD4low/CCR5high) (31,000 molecules/cell), RLU was not significantly higher than 
background. This data indicated that all Env clones required high levels of CD4 to enter cells 
and thus, were all T-tropic (Ping et al., 2013).  





Figure 3.2. Cellular tropism using dual inducible 293 Affinofile cells.  Pseudovirus (PSV) 
representing virus A, B and AB of A) CAP37, B) CAP84, C) CAP137, and D) CAP267 was 
compared over time (0, and 12 mpi except 137c3 at 2 mpi) using dual inducible Affinofile cells 
lines induced to express receptor levels that mimic T-lymphocytes (CD4 = 70,000 molecules/cell 
and CCR5 = 2000 molecule/cell) and macrophages (CD4 = 2,600 molecules/cell and CCR5 = 
31,000 molecules/cell). High CD4 and Low CCR5 levels (T-tropism) are indicated by blue bars, 
Low CD4 and High CCR5 levels (M-tropism) are indicated in red. The entry efficiency was 
compared between PSVs normalised to 100 ng/ml p24 and displayed as log relative luminescent 
units (RLU). Results represent two independent biological repeats with error bars indicating 
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 Validity of TZM-bl cells to compare Pseudovirion entry efficiency 
In this study, TZM-bl cells were used to represent viral entry in vivo and U87-CCR5+ cells 
(Figure 3.3) and Affinofile cells (Figure 3.4) were utilised to characterise different PSV 
phenotypes. The TZM-bl assay required pSG3delenv HIV-backbone whereas the other two 
assays utilised pNL4-3.Luc.R–E–.  As cell lines might not be physiologically relevant and 
viral-viral protein interactions might be important we compared the entry of clones in all 
three cell lines (Table 3.3). CD4 and CCR5 utilisation efficiencies have been shown to 
influence virus entry and infectivity (Chikere et al., 2013; Gray et al., 2005; Lee et al., 1999; 
Platt et al., 1998) but as CD4 levels were high across all cell lines, we did not consider that 
a limiting factor.  We therefore, hypothesized that changes in the relative ranking of the 
clones between cell lines would indicate whether PSV entry efficiency differed due to HIV 
backbone and/or utilization of CCR5.  
 
Table 3.3. Ranking of PSV entry efficiency according to cell type 









CAP37 c3>c1≈c6 c3>c1≈c6 c1≈c6>c3 c3  
CAP84 c1≈c4 c4>c1 c1≈c4 c4 
CAP137 c10>c9≈c1>c2≈c3 c10≈c9≈c1≈c2≈c3 c10≈c9≈c1>c2>c3 c2, c3,c10 
CAP267 c6>c5≈c1>c2 c5>c6>c2>c1 c6>c5≈c1>c2 c1, c5 
a High CCR5 levels 
b Same HIV backbone: pNL4-3.Luc.R–E– 
*Identity of the Env clone(s) that differed in ranking in 1/3 cell lines 
 
 





Figure 3.3. PSV entry efficiency in U87 CD4+CCR5+ cell line. The entry efficiency of 
pseudovirus (PSV) representing virus A, B and AB infecting A) CAP37, B) CAP84, C) CAP137, 
and D) CAP267 was compared over time (0 and 12 mpi and 2 mpi for 137c3) using U87 
CD4+CCR5+ cell line. The entry efficiency of PSV A, B and AB are indicated in red, blue and 
purple, respectively. PSV entry efficiency was normalised to 100 ng/ml p24 and displayed as a 
percentage (%) relative luminescent units (RLU) to PSV A at 0 mpi. Results represent two 
independent biological repeats with error bars indicating standard deviation. Significant difference 
is indicated by stars. One-way ANOVA with Bonferroni correction for multiple comparisons was 
used for statistical analysis (p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***, and p < 0.0001 = ****). 
All Env clones were functional as PSV entry efficiency was higher than the background control 
when no PSV was added to the cells. Infection with PSV generated by transfecting HIV-1 
pNL4.3luc+E-R- backbone with an empty vector was used as negative control for infectivity and 
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Figure 3.4. PSV Entry Efficiency in Affinofile cells expressing CD4high/CCR5low.  Entry 
efficiency of pseudovirus (PSV) representing virus A, B and AB infecting A) CAP37, B) CAP84, 
C) CAP137, and D) CAP267 was compared over time (0, 2, and 12 mpi) using the Affinofile cell 
line expressing CD4high/CCR5low. The entry efficiency of PSV A, B and AB are indicated in red, 
blue and purple, respectively. The entry efficiency was compared between pseudoviruses 
normalised to 100 ng/ml p24 and displayed as a % relative luminescent units (RLU) to PSV A at 
0 mpi. Results represent three independent biological repeats with error bars indicating standard 
deviation. One-way ANOVA with Bonferroni correction for multiple comparisons was used for 
statistical analysis (p < 0.0001= ***, p < 0.001=** and p < 0.01=*). GraphPad Prism 5.0 software 
(CA, USA) was used. All Env clones were functional as PSV entry efficiency was higher than the 
background control when no PSV was added to the cells. Infection with PSV generated by 
transfecting HIV-1 pNL4.3luc+E-R- backbone with an empty vector was used as negative control 
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Of the fourteen clones tested, PSV entry efficiency of seven differed in at least one cell line 
(Table 3.3). PSVs 37c3 and 137c3 relative entry efficiency was different in Affinofiles than 
the other two cell lines, suggesting that the low levels of CCR5 might be influencing entry 
of these clones. When Affinofiles were induced to express high levels of CD4 and varying 
levels of CCR5 (2,000 molecules/cell to ~31,000 molecules/cell molecules/cell), the ranking 
of PSVs from high to low entry efficiency was consistent across all CCR5 levels, suggesting 
that CCR5 levels were not influencing relative PSV entry efficiency (Figure 3.5).  
 
 
Figure 3.5. Pseudovirus entry efficiency relative to changes in CCR5 levels.   Affinofile cells 
were induced to express high CD4 levels (4 ng/µl Minocycline) and varying levels of CCR5 using 
concentrations of Ponesterone that ranged from (0.13 to 4 µM). Pseudovirus (PSV) of CAP137 
clones (c1, c2, c9 and c10 represented by circles, square, tringle, and upside-down triangles, 
respectively) was normalised to the equivalent of 100 ng p24 and entry was measured by relative 
light units (RLU). One biological repeat is indicated with error bars representing standard deviation 
of triplicate values. 
 
If PSV entry efficiency differed in only TZM-bl cells then HIV backbones might be 
influencing Env entry efficiency. Only one clone, 137c10 had higher entry efficiency than 
other clones when tested in TZM-bl cells, suggesting that this clone might be influenced by 
-1 0 1 2 3 4
0
3 0 0 0 0
6 0 0 0 0
9 0 0 0 0
1 2 0 0 0 0
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differences between pSG3delenv and pNL4-3.Luc.R–E–. The relative entry efficiency of the 
rest of the clones varied seemingly randomly across cell lines, suggesting that other 
physiological factors might play a role. It has been shown that differences in Env N-
glycosylation has a discordant impact on virus transmission and infectivity depending on cell 
type (Shen et al., 2014). Correlation analysis showed a significant association (p = 0.049) 
between PSV entry efficiency in T-lymphocyte-like Affinofiles and TZM-bl cells (Figure 
3.6), suggesting that the TZM-bl cell line can be used as a model for in vivo Env entry 
efficiency. However, differences between Affinofile (CD4high/CCR5low) cells and T 




Figure 3.6. Correlation between PSV entry efficiency of TZM-bl and T-lymphocyte like 
Affinofile cells.  Correlation analysis between the relative PSV Env entry efficiency in TZM-bl 
and T-lymphocyte was determined. To compare the entry efficiency of PSVs from independent 
experiments, RLU values were normalised to the background control when PSV was not added. 
Correlation co-efficient (r) was determined as indicative of a negligible, weak, moderate, high and 
very high relationship based on previous reports (Hinkle et al., 2003). p value of < 0.05 was 
considered significant. GraphPad Prism 5.0 software (CA, USA) was used. 
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 Pseudovirus Fusion Capacity  
Previous studies showed that viruses became less susceptible to entry inhibitors over time 
and this was associated with a significant increase in viral fusogenicity and infectivity 
(Etemad et al., 2009; Repits, 2005; Sterjovski et al., 2007). The fusion inhibitor, T-20, binds 
to the HR1 domain of gp41 and blocks host-viral membrane fusion (Reeves et al., 2005).  In 
our study, increased entry efficiency for CAP137 and CAP267 seemed to be associated with 
changes within gp41, suggesting that gp41 might be an important determinant of Env 
function. As T20 inhibits gp41-mediated viral-host membrane fusion, T20 IC50 can be a 
surrogate marker for PSV fusion capacity (Cavrois et al., 2014; Reeves et al., 2005). The 
better the Env clone can mediate fusion the greater the concentration of T-20 needed to 
inhibit PSV entry and thus the higher the IC50, and vice versa. PSVs will be more susceptible 
to T-20 inhibition if Env has poor fusion capacity (Cavrois et al., 2014; Etemad et al., 2009; 
Lobritz et al., 2007; Reeves et al., 2002). Contrary to CAP137, TZM-bl entry efficiency of 
CAP37 and CAP84 PSVs did not increase over 12 months of infection but as Env 
fusogenicity might be more sensitive to changes in gp41 (Diaz-Aguilar et al., 2013) it might 
be easier to detect variation in fusion capacity than entry efficiency. We thus determined 
whether changes in gp41 altered T20 susceptibility without influencing Env entry efficiency.  
CAP37 
In CAP37, the fusion capacity between the Env clones varied 15 – 100 % but there was no 
overall change in the fusion capacity of variants infecting CAP37 over time. PSVs 
representing AB/B variants at 12 mpi (37c7) was ~7-fold more sensitive to T20 compared to 
virus A at enrolment (37c1) which could explain the low entry efficiency of this PSV. 
Overall, changes in PSV T20 IC50 reflected Env entry efficiency in TZM-bl cells, with both 
phenotypes fluctuating over 12 months infection (Figure 3.7A).   
CAP84 
In CAP84, virus A at 0 mpi (84c1) had a higher T-20 IC50 value compared to the 
recombinant virus AB at 12 mpi (84c4) (Figure 3.7B). This was similar to the difference in 
PSV entry efficiency.   
 




Two clones were generated at enrolment for CAP137 representing virus A: 137c1 and 137c2. 
The latter Env was 3.6-fold more susceptible to T-20 than 137c1, similar to the 2-fold 
difference in entry efficiency between the two clones.  Sequence analysis revealed that they 
differed by 33 amino acids (a.a) in gp120 and 4 a.a in gp41.  Moreover, 26/33 a.a were within 
V1/V2, previously reported to impact Env fusogenicity and thus Env entry (Cavrois et al., 
2014). Therefore, these polymorphisms might contribute to the stronger fusion capacity of 
137c1 PSV (Figure 3.7C).  
The recombinant variants AB at 12 mpi (137c9 and 137c10) had higher fusion capacity 
compared to virus A at 0 mpi by 4- and 3-fold, respectively, mimicking entry efficiency data.  
However, even though PSV 137c10 entered TZM-bl cells (Table 3.2) more efficiently than 
137c9, there was no significant difference in T-20 IC50 between 137c9 and 137c10 and, in 
fact, 137c9 was more fusogenic than 137c10. Although, sequence analysis showed that 
137c9 and 137c10 varied mostly in gp41 (9 a.a in the HR2 region, 8 a.a in MPER and one in 
LLP-1 region) these polymorphisms might not only affect Env viral-host cell membrane 
fusion but other structural or phenotypic properties such as the interaction between gp41 and 
gp120 during entry (Etemad et al., 2009). It has previously been suggested that the influence 
of gp41 on entry efficiency and fusogenicity is highly clone specific (Yi et al., 2015).  
However, overall, variation in fusion capacity over the course of infection tracked that of 
PSV entry efficiency, suggesting that gp41 could be a major determinant in the entry 
efficiency of CAP137 PSV. 
CAP267 
Sequence analysis and mutagenesis suggested that five a.a. changes within gp41 were 
responsible for the 4-fold higher entry efficiency of 267c6 at 12 mpi compared to 267c2 at 
enrolment (Figure 2.12, Chapter 2). The fusion capacity of 267c6 PSV was also higher than 
that of 267c2, (28-fold higher), suggesting that the five a.a. that mapped to the cytoplasmic 
tail (CT) region (two a.a between Kennedy region and LLP-2, one in LLP-3 and two in LLP-
1), might be influencing the fusion capacity of Env and potentially entry efficiency and in 
vivo frequency.  Comparison between gp41 of CAP267 sequences aligned to HXB2 indicated 
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that 2/5 a.a. were conserved with consensus carrying an Asparagine (N) at position 750 and 
an Arginine (R) at position 845. However, 267c2 had an Aspartic acid (D) at position 750 
and a Serine (S) at position 845 that might have reduced Env fitness. When D750 and R845 
reverted to consensus in 267c6, this might have rescued the fitness cost. Reversion has been 
shown to come with a gain of fitness, potentially contributing to higher fusogenicity of 267c6 
(Crawford et al., 2007; Song et al., 2014). As far as we know, none of these amino acids have 
been documented to have a direct effect on Env entry efficiency but the CT and LLP1 regions 
do play a role in fusogenicity (Da Silva et al., 2013; Kalia et al., 2003). Differences in Env 
entry efficiency of some variants infecting CAP267 was not directly related to changes in 
gp41 function, similar to previous studies, as virus A at 12 mpi (267c5) had 1.5-fold higher 
fusion capacity than 267c6, but 2-fold lower PSV Env entry efficiency (Diaz-Aguilar et al., 
2013). However, this difference in fusion capacity was not statistically significant.  
 





Figure 3.7. Pseudovirion sensitivity to the entry inhibitor, T20.  The sensitivity to entry 
inhibitor (T-20) of pseudovirus (PSV) representing virus A, B and AB infecting A) CAP37, B) 
CAP84, C) CAP137, and D) CAP267 was compared over time (0, 2, and 12 mpi). The fusion 
capacity of PSV A, B and AB are indicated in red, blue and purple, respectively. The IC50 was 
compared between PSV and displayed as a relative luminescent units (RLU) to PSV A at 0 mpi 
(%). Results represent two independent biological repeats with error bars indicating standard 
deviation. The mean of T-20 IC50 of each Env is indicated at the top of each bar and used for 
statistical analysis. Significant difference is indicated by stars. One-way ANOVA with Bonferroni 
correction for multiple comparisons was used for statistical analysis (p < 0.0001= ***, p < 
0.001=** and p < 0.01=*). 
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 Association between PSV entry efficiency and fusion capacity 
In some cases, T20 IC50 values did not support variation in entry efficiency between 
CAP137 and CAP267 clones similar to a previous study that showed the association between 
fusion and changes in entry efficiency was Env specific (Diaz-Aguilar et al., 2013). The 
authors suggested that there are mechanistic differences between Env entry efficiency and 
fusogenicity. Despite inconsistencies between PSV fusion capacity and entry efficiency in 
TZM-bl for some Env clones, analysis showed a significant correlation between fusion 
capacity and entry efficiency (p = 0.02, r = 0.59) (Figure 3.8). The moderate positive 
correlation suggests that any change in the membrane fusion step of viral entry might alter 
Env entry efficiency. 
 
 
Figure 3.8. Correlation between pseudovirus entry efficiency and fusion capacity.  The 
association between fusion capacity and corresponding Env entry efficiency of PSVs were 
analysed using Spearman r correlation test. Correlation co-efficient (r) was determined as 
indicative of a negligible, weak, moderate, high and very high relationship based on previous 
reports (Hinkle et al., 2003), p value of < 0.05 was considered significant. GraphPad Prism 5.0 
software (CA, USA) was used for statistical analysis. 
 


















p value       = 0.02
Spearman r = 0.59
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 Envelope Expression and cleavage 
HIV-1 infectivity is influenced by many factors, including the incorporation of functional 
trimers into virus particles, Env processing and cleavage of gp160 into gp120 and gp41 
(Bachrach et al., 2005; Blay et al., 2007; Provine et al., 2009; Yuste et al., 2004). The 
outgrowth of variants infecting CAP137 and CAP267 was associated with increased PSV 
entry efficiency (Figure 2.9, Chapter 2) and fusogenicity potentially due to changes within 
gp41. Gp41 has been linked to Env cell-surface expression (Lebigot et al., 2001) which might 
lead to increased Env incorporation and enhanced entry efficiency (Bachrach et al., 2005). 
To determine whether the impact of gp41 on PSV entry efficiency was by enhancing Env 
expression levels, HEK293T cells were transfected, and the relative level of Env expression 
was compared by Western blotting.  Env gp160 and gp120 band intensities were normalized 
to β-actin and virus A at enrolment was used as reference clone.  
CAP137 
Western blotting of 4/5 Envs showed that both cleaved and uncleaved gp160 were present in 
cell lysates (Asmal et al., 2011; Yu et al., 1993). Although bands representing 137c2 gp160 
was 1.7-fold more intense than that of 137c1 gp160, gp120 levels were lower (Figure 3.9). 
There was no consistent relationship between gp160 expression and gp120 levels, supporting 
an earlier suggestion that Env over-expression may lead to inefficient cleavage of Env (Blay 
et al., 2007). As PSV entry efficiency is most likely influenced by gp120 density, we 
compared Env cleavage between clones.  
Virus B at 0 mpi (137c3) had the lowest cleavage of gp160 compared to all other Envs, 
suggesting that low gp120 incorporation into PSV could be driving its poor entry efficiency 
and low fusion capacity. On the contrary, Env expression/cleavage was not a contributing 
factor to the higher entry efficiency of PSV 137c10 compared to 137c9 in the TZM-bl cell 
line, as they had similar expression levels and gp160 cleavage. However, relative changes in 
cell-associated gp120 tracked PSV entry in Affinofile cells suggesting that, for some clones, 
cleavage of gp160 might be a determinant of Env entry efficiency. Despite a general trend 
between variation in PSV entry efficiency and Env cleavage, this relationship was not 
supported when comparing individual Envs using the TZM-bl reporter cell line.  





Figure 3.9. CAP137 Env Expression.  Env expression of variants infecting CAP137 was 
determined by transfection of HEK293 T cells followed by quantitative Western blotting of cell 
lysates. A) One representative Western blot of two biological repeats. A total of 80 ng of protein 
was loaded per well and anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated 
anti-sheep antibody (Santa-Cruz Biotechnology) were used for detection. Β-actin was used as a 
loading control and gp120+ is a recombinant purified HIV-1 gp120 (HIV-1 IIIB gp120 
Recombinant Protein) from (ARP) was used as a positive control. Untransfected cells were used 
as a negative control (-ve control). B) Densitometry analysis using gel analyzer programme. Cell-
associated gp160 and gp120 expression levels were normalized to β-actin. Results represent two 
independent biological repeats with error bars indicating standard deviation. Viruses A, B and AB 
are indicated with red, blue and purple bars, respectively. Gp160 and gp120 are indicated by solid 
and empty bars, respectively. C) Cleavage level of cell-associated gp120 relative to total Env 
(gp120/(gp160+gp120) *100) with viruses A, B and AB indicated by red, blue and purple bars, 
respectively. Kruskal-Wallis test with Dunn's multiple comparisons test was performed to compare 













































































Both 267c2 gp160 and gp120 bands migrated slightly lower than other Env clones which 
could be due to variation in Env glycosylation.  Sequence analysis showed that 267c2 carried 
26 PNGs, 6 less than 267c1 and 2 less than 267c6 which might have influenced its migration. 
There seemed to be a consistent relationship between gp160 and gp120 expression levels for 
all Envs (Figure 3.10). Env 267c5 had the highest expression: 1.3-fold and 1.9-fold better 
than 267c1 gp160 and gp120, respectively. This variation coincided with changes in PSV 
fusion capacity but not entry efficiency as 267c1 entered TZM-bl cells more efficiently. 
There were 18 a.a differences between 267c1 and 267c5 of which 4 mapped to the CT of 
gp41 previously reported to impact Env expression and incorporation (Jiang and Aiken, 
2007). Virus B, 267c2, had the lowest gp120 expression, with levels 3-fold lower than 267c1, 
suggesting that expression could play a role in the low PSV entry efficiency and fusogenicity 
of this Env. Over time, virus B gp120 expression increased until 267c6 had 1.7-fold higher 
expression than 267c2, suggesting that point mutations within Env had increased expression 
and cleavage over the course of infection (Figure 3.10). Comparison between gp160 cleavage 
and Env entry efficiency suggested that the more cell-associated gp120, the higher the PSV 
entry. However, this relationship did not hold true for 267c6 that had the highest PSV entry 
efficiency but not the highest cell-associated gp120.  
Correlation analysis showed a moderate positive correlation between the percentage of 
gp160 cleaved to gp120 and PSV entry efficiency (r = 0.65). However, this correlation was 
not statistically significant (p = 0.07) (Figure 3.11). Similarly, although the pattern of 
association between Env cleavage and fusogenicity was very similar, the moderate 
correlation was not significant (p = 0.06, r = 0.65). The lack of significance could be due to 
the samples size.  Overall, this data suggests that the better gp160 is cleaved, the better fusion 
and thus entry (Bachrach et al., 2005; Blay et al., 2007; Provine et al., 2009; Yuste et al., 
2004). Therefore, the variation observed in entry efficiency of most Env could be due to 
expression levels and cleavage, possibly by influencing the number of functional trimers 
incorporated into PSV. 





Figure 3.10. CAP267 Env Expression.  Env expression of variants infecting CAP267 was  
determined by transfection of HEK293 T cells followed by quantitative Western blotting of cell 
lysates. A) One representative Western blot of two biological repeats. A total of 80 ng of protein 
was loaded per well and anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated 
anti-sheep antibody (Santa-Cruz Biotechnology) were used for detection.  β-actin was used as a 
loading control and gp120+ is a recombinant purified HIV-1 gp120 (HIV-1 IIIB gp120 
Recombinant Protein) from ARP was used as a positive control. Untransfected cells were used as 
a negative control (-ve control). B) Densitometry analysis using gel analyzer 2010 programme. 
Cell-associated gp160 and gp120 expression levels were normalized to β-actin. Results represent 
two independent biological repeats with error bars indicating standard deviation. Virus A and virus 
B are indicated with red and blue bars, respectively. Gp160 and gp120 are indicated by filled and 
empty bars, respectively. C) Cleavage level of cell-associated gp120 relative to total Env 
(gp120/(gp160+gp120) *100) with viruses A and B indicated by red and blue bars, respectively.  
Kruskal-Wallis test with Dunn's multiple comparisons test was performed to compare cell-











































































Figure 3.11. Correlation of gp160 cleavage with Env entry efficiency and fusion capacity. 
Correlation analysis between percentage cleavage of CAP137 and CAP267 gp160 into gp120 in 
the cell line and A) the relative PSV entry efficiency in TZM-bl and B) fusion capacity was 
performed using Spearman r correlation test.  To compare the entry efficiency of PSVs from 
independent experiments, RLU values were normalised to the background control when PSV was 
not added. PSV fusion capacity was measured as the IC50 of T-20 inhibitor in TZM-bl. Level of 
cell-associated gp120 relative to total Env (gp120/(gp160+gp120) *100) was determined. 
Correlation co-efficient (r) was determined as indicative of a negligible, weak, moderate, high and 
very high relationship based on previous reports (Hinkle et al., 2003), p value of < 0.05 was 
considered significant. GraphPad Prism 5.0 software (CA, USA) was used for statistical analysis. 
 
 Env incorporation  
Bachrach et al. (2005) suggested that slight increases in Env incorporation into viral particles 
profoundly increased infectivity (Bachrach et al., 2005). However, incorporated Env 
consisted of immature, uncleaved gp160, gp120 monomers, gp120-gp41 trimers and gp41 
(Moore et al., 2006) with only incorporation of mature gp120 and gp41 trimers required for 
viral infectivity (Lodermeyer et al., 2013). It was suggested that density of mature trimers is 
dependent on Env expression and varies widely across HIV variants (Chertova et al., 2002). 
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We thus compared the relationship between Env expression, incorporation into viral particles 
and PSV entry efficiency. 
CAP137 
Western blot analysis could not resolve incorporated 137c1, 137c2 (in both biological 
repeats) and 137c9 (in one biological repeat) Env into clear bands corresponding to gp160 
and gp120, most likely due to overloading and N-glycosylation (Figure 3.12). As virus 
infectivity is determined by gp120 incorporation (Bachrach et al., 2005; Blay et al., 2007; 
Stieh et al., 2015), we were unable to assess the relationship between gp120 incorporation 
and PSV entry efficiency. Env 137c3 was resolved into gp160 and gp120 bands and had the 
lowest levels of PSV-associated gp120 which could explain its poor ability to enter TZM-bl 
cells. However, PSV 137c10 with the highest entry efficiency of all the clones had similar 
PSV-associated gp120 levels to137c3, suggesting that for these clones, gp120 density was 
not influencing PSV entry.  
CAP267 
Despite the variation in Env gp160 and gp120 incorporation, there was no difference in the 
total amount of Env incorporated between virus A and virus B over time (data not shown). 
PSV 267c1, had the highest level of gp120 incorporated compared to the other clones (Figure 
3.13). The ratio of gp160:gp120 decreased over time with 267c1 PSV carrying 4-fold greater 
gp120 than gp160 while an equal number of gp160 and gp120 seemed to be incorporated 
into 267c6 PSVs. Furthermore, 267c1 PSV-associated gp120 was 2.5-fold greater than 267c6 
PSV.  As 267c6 PSV entered TZM-bl cells with the highest efficiency compared to the other 
clones, it is unlikely that Env incorporation influenced PSV entry efficiency in TZM-bl.  
As incorporation of gp120 into PSVs are essential for infectivity we tested whether cell-
associated gp120 levels correlated with gp120 density on the surface of PSVs. Correlation 
analysis did not show any significance (Figure 3.14). Next, correlation analysis was 
performed between gp120 incorporation, and corresponding Env entry efficiency in TZM-bl 
using Spearman r correlation test. No significant correlation was found between gp120 
incorporation and Env entry efficiency (p = 0.3, r = 0.6), suggesting that gp120 incorporation 
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did not impact entry efficiency (Figure 3.15). However, because we were unable to determine 




Figure 3.12. CAP137 Env incorporation into PSVs.  Env incorporation of variants infecting 
CAP137 was determined by transfection of HEK293 T cells followed by quantitative western 
blotting of cell lysates. A) One representative Western blot of two biological repeats. Gp120 was 
detected using Anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated anti-
sheep antibody (Santa-Cruz Biotechnology) were used for detection. P24 was detected using anti-
p24 antibody (ARP432).  p24+ and gp120+ are recombinant purified HIV-1 proteins (HIV-1 IIIB 
p24 Recombinant Protein and HIV-1 IIIB gp120 Recombinant Protein) obtained from ARP and 
used as a positive control.  Viral particles without env were used as a negative control (-ve control). 
B) Densitometry analysis using gel analyzer 2010 programme. PSV gp160 and gp120 
incorporation levels were normalized to p24 of corresponding virus. Results represent two 
independent biological repeats with error bars indicating standard deviation. Virus A, B and AB 
are indicated with red, blue, and purple colour, respectively. Gp160 and gp120 are indicated by 
filled and empty bars for each virus, respectively. Kruskal-Wallis test with Dunn's multiple 

























































Figure 3.13. CAP267 Env incorporation into PSVs.  Env incorporation of variants infecting 
CAP267 was determined by transfection of HEK293 T cells followed by quantitative Western 
blotting of cell lysates. A) One representative Western blot of two biological repeats. Gp120 was 
detected using anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated anti-sheep 
antibody (Santa-Cruz Biotechnology). P24 was detected using anti-p24 antibody (ARP432). p24 
control and gp120 +ve are recombinant purified HIV-1 proteins (HIV-1 IIIB p24 Recombinant 
Protein and HIV-1 IIIB gp120 Recombinant Protein) obtained from ARP and used as a positive 
control.  B) Densitometry analysis using gel analyzer 2010 programme. PSV gp160 and gp120 
incorporation levels were normalized to p24 expression of corresponding PSV. Result represent 
one biological repeat. Virus A and B are indicated with red and blue bars, respectively. Gp160 and 

















































Figure 3.14. Correlation between Env gp120 expression and gp120 incorporation.   
Correlation analysis between levels of cell associated gp120 and gp120 incorporated into 
pseuodvirions of CAP137 and CAP267 was performed using Spearman r correlation test.  To 
compare the entry efficiency of PSVs from independent experiments, RLU values were normalised 
to the background control when PSV was not added.  Gp120 incorporation band intensity was 
normalized to p24 and the mean of two independent biological repeats was determined. Correlation 
co-efficient (r) was determined as indicative of a negligible, weak, moderate, high and very high 
relationship based on previous reports (Hinkle et al., 2003), p value of < 0.05 was considered 
significant. GraphPad Prism 5.0 software (CA, USA) was used for statistical analysis. 
 
 























p value       = 0.5
Spearman r = 0.3






Figure 3.15. Correlation between Env entry efficiency and gp120 incorporation.  
Correlation analysis between PSV entry efficiency of TZM-bl and Env gp120 incorporation level 
of CAP137 and CAP267 was performed using Spearman r correlation test.  To compare the entry 
efficiency of PSVs from independent experiments, RLU values were normalised to the background 
control when PSV was not added.  Gp120 incorporation band intensity were normalized to p24 
and the mean of two independent biological repeats was determined. Because gp120 could not be 
resolved, three clones of CAP137 were excluded from the analysis. Correlation co-efficient (r) was 
determined as indicative of a negligible, weak, moderate, high and very high relationship based on 
previous reports (Hinkle et al., 2003), p value of < 0.05 was considered significant. GraphPad 
Prism 5.0 software (CA, USA) was used for statistical analysis. 
 
 Characterisation of Env fitness determinants 
 Analysis of Env phenotypic change over 12 months of infection indicated that, in general, 
Env fusogenicity was associated with variation in overall PSV entry efficiency.  This 
relationship supported the apparent selection of changes in gp41 over the course of infection 
for viruses infecting CAP137 and CAP267. To confirm the importance of gp41 function, we 
determined whether sequence changes were not only linked to changes in entry efficiency 
but also Env fusogenicity, expression and incorporation (Cavrois et al., 2014; Lebigot et al., 
2001; Reeves et al., 2005). 



























p value       = 0.3
Spearman r = 0.6




3.4.8.1 Fusion capacity of Env determinants 
CAP84 and CAP137 variants with recombination in gp41 seemed to be selected at 12 mpi 
although only CAP137 PSV entry efficiency increased over time. Gp120/gp41 chimeras of 
CAP84 PSVs had enhanced entry efficiency, however, also suggesting that gp41 was 
important for changes in PSV entry. Although there was no obvious selection of CAP267 
gp41 recombinants, chimeras suggested that gp41 could play a role in PSV entry efficiency 
increasing over time. As we had shown that Env fusogenicity was an important determinant 
of PSV entry efficiency, we wanted to confirm whether the PSV entry efficiency of the 
gp120/gp41 chimeras was similarly influenced by Env fusogenicity. 
CAP84  
Although 84c1 and 84c4 had similar entry efficiency, PSV of 84c1/c4 chimera with gp41 of 
virus 84c4, had 4-fold higher entry efficiency than PSV 84c1, suggesting that gp41 could 
play a role in the entry efficiency of this chimera.  However, PSVs of both chimeras 84c1/c4 
and 84c4/c1 had similar fusion capacity to each other and only 0.5-fold lower than wild-type 
Env clones (Figure 3.16A). This difference was not statistically significant suggesting that 
fusion capacity was not the major factor accounting for differences in Env entry efficiency 
of CAP84 chimeras.  
CAP267 
When comparing virus B variants infecting CAP267, PSV 267c6 at 12 mpi had 4.2-fold 
higher entry efficiency than 267c2 at 0 mpi.  When the gp41 region was swapped between 
the two Envs, the PSV, carrying the gp41 of 267c6 had 4.5-fold higher entry efficiency, 
suggesting that gp41 could be driving the changes in Env entry efficiency and thus potentially 
viral outgrowth.  Chimera 267c2/c6 also had enhanced fusion capacity similar to 267c6 while 
PSV 267c6/c2 fusion capacity was similar to virus B at enrolment 267c2 (Figure 3.16B). 
Therefore, the five a.a. changes within the CT of gp41 might be responsible for the increase 
in fusion capacity as well as the entry efficiency of virus B over time. Therefore, point 
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mutations within the CT of gp41 could be the major Env determinant for enhancing Env 





Figure 3.16. Fusion capacity of CAP84 and CAP267 chimeras.  A) The fusion capacity of the  
two chimeras generated from 84c1 and 84c4. Cap84 virus A (84c1) at enrolment and AB (84c4) 
Env clone at 12 mpi are indicated in red and purple, respectively. The chimera 84c1/c4 comprises 
of the gp120 region of 84c1 and the gp41 of 84c4 and is indicated by a pink bar. The other chimera 
84c4/c1 comprises of gp120 of 84c4 and gp41 of 84c1 and is indicated by a purple bar. Fusion 
capacity was compared to 84c1. B) The fusion capacity of the two chimeras generated from 267c2 
and 267c6. Virus B at enrolment (267c2) is indicated by a light blue bar and virus B at 12 mpi 
(267c6) shown by a blue bar. The fusion capacity was compared to virus A at enrolment (267c1) 
indicated with a red bar. The first chimera (267c2/c6) comprises the gp120 of virus B at enrolment 
and gp41 of virus B at 12 mpi and indicated with a blue striped bar. The second one (267c6/c2) 
comprises of gp120 of virus B at 12 mpi and gp41 of virus B at enrolment indicated by blue 
checkered bar. One-way ANOVA with Bonferroni correction for multiple comparisons was 
performed using Prism 7.0. Data represent the average of two independent biological repeats with 
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3.4.8.2 Determine the potential mechanism of CAP267 Env fitness determinant 
Fusogenicity and PSV entry efficiency could be driven by levels of Env expression and 
incorporation into viral particles. Therefore, quantitative Western blotting of cell and 
pseudoviral lysates were performed to determine whether the five a.a. in gp41 was 
influencing fusion capacity by modulating Env expression and incorporation into viral 
particles. Visually, Western blotting of cell lysates of 267c6/c2 indicated very poor 
expression of gp120 and densitometry analysis could not detect the faint band corresponding 
to the molecular weight of gp120 (Figure 3.17A). However, Western blotting indicated that 
PSV-associated 267c6/c2 gp120 levels were only slightly lower than other PSVs (Figure 
3.18).  
Gp160 and gp120 expression of the chimera 267c2/c6, comprising gp41 of virus B at 12 mpi 
(267c6), was 1.6-fold and 1.1-fold, respectively, higher than that of 267c6 and had 2-fold 
higher gp160 and gp120 expression compared to 267c2 (Figure 3.17B). However, the 
percentage of gp160 cleaved into gp120 and the fraction of PSV-associated gp120 (Figure 
3.18) did not vary between this chimera and 267c2 and 267c6 (Figure 3.17C). Overall, it 
would seem that the gp41 of 267c6 was not influencing Env entry efficiency by changing the 
density of PSV- associated gp120.  






Figure 3.17. Env Expression and cleavage of CAP267 chimeras.  Env expression of CAP267  
chimeras was determined by transfection of HEK293 T cells followed by quantitative Western 
blotting of cell lysates. A) Representative Western blot of two biological repeats. A total of 80 ng 
of protein was loaded per well and anti-gp120 antibody (AIDS Reagent Programme, ARP) and a 
conjugated anti-sheep antibody (Santa-Cruz Biotechnology) were used for detection.  β-actin was 
used as a loading control and gp120+ is a recombinant purified HIV-1 gp120 (HIV-1 IIIB gp120 
Recombinant Protein) from (ARP) was used as a positive control. Untransfected cells were used 
as a negative control (-ve control). B) Densitometry analysis using gel analyzer 2010 programme. 
Cell-associated of gp160 and gp120 expression levels were normalized to β-actin. Results 
represent two independent biological repeats with error bars indicating standard deviation. Virus 
A at 0 mpi and virus B at 12 mpi are indicated with red and blue bars, respectively. The first 
chimera (267c2/c6) comprises the gp120 of virus B at 0 mpi and gp41 of virus B at 12 mpi and is 
indicated with a blue striped bar. The second chimera (267c6/c2) comprises of gp120 of virus B at 
12 mpi and gp41 of virus B at 0 mpi indicated by blue checkered bar. Gp160 and gp120 are 
indicated by filled and empty bars, respectively. C) Cleavage. Level of cell-associated gp120 
relative to total Env (gp120/(gp160+gp120) *100).  Kruskal-Wallis test with Dunn's multiple 


















































































Figure 3.18. CAP267 Env incorporation of the chimeras.  Env incorporation of CAP267  
chimeras was determined by transfection of HEK293 T cells followed by quantitative Western 
blotting of pseudovirus lysates. A) Representative Western blot of two biological repeats. Anti-
gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated anti-sheep antibody (Santa-
Cruz Biotechnology) were used for detection. P24 was detected using anti-p24 antibody 
(ARP432). p24+ and gp120+ are recombinant purified HIV-1 proteins (HIV-1 IIIB p24 
Recombinant Protein and HIV-1 IIIB gp120 Recombinant Protein) obtained from ARP and used 
as positive controls. B) Densitometry analysis using gel analyzer 2010 programme. PSV gp160 
and gp120 incorporation levels were normalized to p24 expression of corresponding virus. Results 
represent one biological repeats. Virus A and B are indicated with red and blue bars, respectively. 
The first chimera (267c2/c6) comprises the gp120 of virus B at 0 mpi and gp41 of virus B at 12 
mpi is indicated with a blue striped bar and the second chimera (267c6/c2) comprises of gp120 of 
virus B at 12 mpi and gp41 of virus B at 0 mpi is indicated by a blue checkered bar. Gp160 and 



















































3.4.8.3 Determine the potential mechanism of CAP137 Env fitness determinant 
A potential N-glycan at position 332 in gp120 has been linked to escape from BCN Ab 
(Moore et al., 2012). Analysis of CAP137 Env indicated that a PNG at position 332 appeared 
in 137c10 at 12 mpi. As 137c10, a representative of virus AB/B had the highest entry 
efficiency we determined the impact of a PNG at this site on Env function. Deletion of the 
PNG at N332 reduced PSV 137c10-sdm entry efficiency and to determine how a potential 
N-glycan at this position could influence Env function, we compared gp120 expression and 
incorporation into PSVs. On average, there was no difference in both overall Env expression 
(gp160+gp120) and gp120 levels of 137c10-sdm compared to wild type (Figure 3.19). 
Furthermore, although the incorporation of gp120 into 137c10-sdm PSVs tended to be lower 
than wild-type (1.5-fold) this relationship did not reach significance (Figure 3.20). Therefore, 
it is unlikely that the increase in entry efficiency observed for 137c10-sdm was due to a PNG 
at 332 enhancing Env expression and/or gp120 incorporation. 






Figure 3.19. CAP137 Env Expression.  Env expression of CAP137 wild type and CAP137-SDM 
with the N332S mutation was determined by transfection of HEK293 T cells followed by 
quantitative Western blotting of cell lysates. A) Representative Western blot of two biological 
repeats. Anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated anti-sheep 
antibody (Santa-Cruz Biotechnology) were used for detection. Β-actin was used as a loading 
control and gp120+ is a recombinant purified HIV-1 gp120 (HIV-1 IIIB gp120) from ARP was 
used as a positive control. Untransfected cells were used as a negative control (-ve control). B) 
Densitometry analysis of Env expression. Cell-associated gp160 and gp120 levels were normalized 
to β-actin. Results represent two independent biological repeats with error bars indicating standard 
deviation. Gp160 and gp120 are indicated by solid and empty bars, respectively. C) Cleavage of 
gp160 was measured by determining cell-associated gp120 relative to total Env 
(gp120/(gp160+gp120) *100). Virus A (137c1), AB (137c10) and AB mutant (137c10-sdm) are 
indicated by red, purple and checkered purple bars, respectively.  Kruskal-Wallis test with Dunn's 

















































































Figure 3.20. CAP137 mutant incorporation.  Env incorporation of CAP137 mutant clone 
(137c10-sdm: N332S) and its wild type Env clone was determined by transfection of HEK293 T 
cells and ultra-centrifugation followed by quantitative Western blotting of pelleted pseudovirus 
lysates. A) One representative Western blot of two biological repeats. A total of 80 ng of protein 
was loaded per well and anti-gp120 antibody (AIDS Reagent Programme, ARP) and a conjugated 
anti-sheep antibody (Santa-Cruz Biotechnology) were used for detection. P24 was detected using 
anti-p24 antibody (ARP432). p24+ and gp120+ are recombinant purified HIV-1 proteins (HIV-1 
IIIB p24 and HIV-1 IIIB gp120) obtained from ARP and used as a positive control. Viral particles 
without Env were used as a negative control (-ve control). B) Densitometry analysis of 
pseudovirus-associated Env. PSV gp160 and gp120 incorporation levels were normalized to p24 
of the corresponding virus. Results represent two independent biological repeats with error bars 
indicating standard deviation. Virus A (137c1), AB (137c10) and AB mutant (137c10-sdm) are 
indicated by red, purple and checkered purple bars, respectively. Gp160 and gp120 are indicated 
by solid and empty bars for each virus, respectively. Unpaired nonparametric Student’s t-tests, 
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 Summary of results 
Table 3.4. Overall relationship between PSV entry efficiency, in vivo viral outgrowth and 


























CAP37 No No Yes ND ND ND N/A 
CAP84 No Yes Yes ND ND ND gp41/N339 
CAP137 Yes *Yes *Yes Yes* Yes* No gp41/ N332 
CAP267 Yes Yes *Yes No* No* No gp41 
* Association was not apparent for all clones 
 
Table 3.5.  Phenotypic characterisation of Envelope fitness determinants 
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Yes Yes No No 
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3.5 Discussion  
The study of in vivo competition between variants infecting dual infected individuals 
provides insight into the selection of variants with specific characteristics/phenotypes or 
biological properties of Env that provide advantages to the survival and pathogenesis of HIV-
1. Understanding advantageous Env characteristics can provide targets for viral control and 
attenuation if not clearance.  Therefore, this study describes the evolutionary changes in Env 
phenotypes, such as receptor/coreceptor preferences, fusion capacity, incorporation and 
expression, over the course of infection that might influence entry efficiency of Env clones, 
viral fitness and thus disease progression of dual infected individuals.  
In this study PSV entry of the reporter cell line TZM-bl was used as a measure of Env fitness 
and U87-CD4+CCR5+ and Affinofile cells were used for phenotypic characterisation. 
However, lab-adapted cell lines might not be the ideal replacement for T-lymphocytes, the 
natural host of HIV-1. Thus, the first objective of the study was to compare PSV entry 
efficiency of all three cell lines. We hypothesised that if PSVs entered TZM-bl cells, U87-
CD4+CCR5+ cells and Affinofiles induced to express T-lymphocyte-like levels of CD4 and 
CCR5 with the same relative efficiency, they would most likely infect T-lymphocytes (in 
vivo) similarly.   
CD4 density was similar for TZM-bl and U87-CD4+CCR5+ cells and approximately 3-fold 
higher than Affinofile CD4high/CCR5low cells. There was greater variation in CCR5 levels 
with Affinofile CD4high/CCR5low, U87-CD4+CCR5+ and TZM-bl expressing 2000, 6000 
and 11000 molecules/cell, respectively. Although most PSVs entered the three cell types 
similarly, there were instances when clones infected one cell type better than another. 
Comparison between cell types indicated that these differences could be due to CCR5 levels, 
HIV backbone differences as well as other unidentified cell-specific characteristics. 
However, there was a significant correlation between entry of Affinofile CD4high/CCR5low 
and TZM-bl cells, suggesting that overall, TZM-bl cell entry was a good indicator of in vivo 
Env fitness. Furthermore, seeing that CCR5 levels, and Env fitness, differed between 
individuals (Garg et al., 2016) utilising PBMCs to compare Env entry might also have 
disadvantages. 
   
137 
 
The efficiency by which HIV-1 utilises CD4 and CCR5 during entry impacts viral infectivity, 
pathogenesis and thus disease progression. Studies have reported that some R5 viruses 
evolve to macrophage tropism and can infect cells with low CD4 levels, thus expanding the 
number of cells permissive to HIV infection (Blaak et al., 2000; Chikere et al., 2014; Joseph 
et al., 2014). Our data showed that all PSVs, isolated at 0 mpi and at 12 mpi, required high 
levels of CD4 to enter cells, consistent with previous studies that showed no difference in 
receptor/coreceptor utilisation over time (Parrish et al., 2012; Ping et al., 2013). It is possible 
that evolution to macrophage tropism is restricted to specific compartment such as CNS 
where the neutralizing antibody pressure is low (Beauparlant et al., 2017; Ping et al., 2013).  
Previously, it was hypothesised that the genetic bottleneck at transmission selected for single 
variants that were R5 and T-tropic as it provided the transmitted founder with a survival 
advantage (Ping et al., 2013). However, variants transmitted to dual infected individuals were 
also R5 and T-tropic, suggesting that phenotypic selection was not restricted to single 
infection events. Overall, neither viral tropism nor cellular tropism contributed to the 
differences observed in Env entry efficiency over time and thus these Env phenotypes are 
unlikely to be the driving factor for variant outgrowth in dual infected individuals. 
Our data showed that PSV entry efficiency was significantly influenced by the fusion 
capacity of Env for all participants (p = 0.02). Env fusogenicity of CAP37 and CAP84 
tracked changes in PSV entry efficiency and therefore did not increase over time. Env fusion 
capacity increased over time in two participants, CAP137 and CAP267 consistent with 
enhanced PSV entry efficiency (Table 3.4). Increased resistance to T20 of longitudinally 
isolated viruses during chronic stages of infection was previously reported, suggesting that 
increased Env fusogenicity provided a survival advantage over the course of infection 
(Chatziandreou et al., 2012; Etemad et al., 2009; Repits, 2005).  
CAP37, CAP84, CAP137 and CAP267 Env sequence analysis suggested that gp41 might be 
under positive selection. Furthermore, gp120/gp41 chimeras of CAP84 and CAP267 
indicated that gp41 might be an important fitness determinant of PSV entry efficiency. The 
main function of gp41 is mediating viral-host membrane fusion however studies have shown 
that it’s important in a number of other processes. The CT is involved with the viral cycle at 
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numerous steps including: Env incorporation, expression and stability of the gp41/gp120 
heterodimer and viral fitness (Da Silva et al., 2013). Mutations in LLP1 of the CT decreased 
the fusion capacity of Env leading to decreased viral infectivity (Kalia et al., 2003). While 
some studies proposed that truncation of LLP1 stimulated changes of the helical structure of 
LLP-2 and/or changes in the structure of the Env ectodomain, (Jiang and Aiken, 2007; Kalia 
et al., 2003; Wyma et al., 2004), other studies suggested that the interactions of LLP1with 
LLP2 and the cell membrane (Wyss et al., 2005) and/or with regions of the gp41 ectodomain, 
particularly the HR1-HR2 6-helix bundle was responsible for changes in viral infectivity 
(Abrahamyan et al., 2005). The CT was also documented to interact with Gag during virus 
assembly and alter the conformation of gp41 which in turn impacted Env incorporation into 
virions and influenced viral infectivity (Davis et al., 2006).  
For CAP137 and CAP267, a.a. changes within gp41 sequences mapped mainly to HR and 
LLP1/LLP3, respectively. As the C5 region only differed in one a.a. we proposed that the 5 
a.a. in the CT of CAP267 Env influenced PSV entry efficiency over time (Chapter 2) and 
therefore CAP267 Env chimeras were tested for changes in fusion capacity. When gp41 was 
swapped between virus B at enrolment and virus B at 12 mpi Env fusogenicity increased, 
suggesting that Env fusion capacity was influencing PSV entry efficiency. Closer analysis 
of the CT indicated that two of the five a.a., N750 and R845, were highly conserved 
indicating positive selection pressure. However, 267c2, carried D750 and S845, suggesting 
that these a.a. might have lowered PSV entry efficiency and when they reverted to consensus 
in 267c6, entry efficiency increased (Song et al., 2014). Therefore, we showed that the CT 
of gp41 could be important for enhancing Env entry efficiency of viral population B over 
time in CAP267, consistent with previous studies (Jiang and Aiken, 2007; Kalia et al., 2003).  
The entry efficiency of CAP37 and CAP84 decreased over time, similar to changes in Env 
fusogenicity, suggesting an association between the two phenotypes. However, when gp41 
was swapped between CAP84 variants with different entry efficiency and fusion capacity 
the two chimeras had similar susceptibility to fusion inhibitor, suggesting that gp41 was not 
important for changes in Env fusogenicity for these clones. As the chimeras differed in Env 
entry efficiency but not fusogenicity, clone specific differences most likely influenced the 
effect of gp41 (Yi et al., 2015).  
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Previous studies reported that CT mutations influenced Env expression, processing, 
incorporation and virus infectivity (Bhakta et al., 2011; Kalia et al., 2003). In our study there 
was no association between PSV entry efficiency and fusogenicity with expression, and 
incorporation. Despite the moderate positive correlation between the cleavage of gp160 and 
both Env entry efficiency (p = 0.07, r = 0.65) and fusion capacity (p = 0.06, r = 0.67), the 
relationship was not statistically significant. Reports have been conflicting with some 
showing a correlation between gp120 incorporation and viral infectivity (Blay et al., 2007; 
Parrish et al., 2013) whereas another study did not (Jiang and Aiken, 2007).  Bachrach et al., 
(2005) had suggested that Env density no longer influenced infectivity once levels increased 
above a certain threshold so it is possible that our PSVs carried excess Env (Bachrach et al., 
2005). Viral populations consist of three subgroups: virus carrying 1) functional, 2) non-
functional and 3) mixed functional and non-functional Env and the first group makes up the 
bulk of the population (Blay et al., 2007; Moore et al., 2006; Stieh et al., 2015).  It is expected 
that poor Env cleavage would increase the level of incorporation of non-functional forms of 
Env (Blay et al., 2007; Herrera et al., 2005) which non-native Western blotting would not be 
able to distinguish. Therefore, even though 137c3 and 137c10 PSV carried similar gp120 
levels, it is possible that the number of functional molecules incorporated per viral particle 
might differ between clones. However, in our study, there was no correlation between the 
percentage of cell-associated gp120 and the level of gp120 incorporated into PSVs. It is 
possible that changes in gp41 LLP1 altered incorporation of gp120 without influencing Env 
expression and/or processing as previously reported by Kalia et al., (2003) (Kalia et al., 
2003).  
When we analysed the phenotypes of potential Env fitness determinants our data from the 
two chimeras of CAP267 supported the lack of association between gp120 incorporation and 
PSV entry efficiency as the density of gp120 did not vary between 267c2/c6, 267c2 and 
267c6. Despite the PNG at 332 of CAP137 showing an effect on PSV entry efficiency, it had 
no significant impact on Env expression or Env incorporation but could play a role in other 
Env phenotypes, such as the affinity to CD4 or/and CCR5. Structural modelling (Figure 3.21 
showed that this PNG (C3 region) was located near the V3 loop that plays a crucial role in 
coreceptor binding. Therefore, N332S could play a role in stabilizing the V3 loop and 
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modulating coreceptor binding and thus Env entry efficiency (Wang et al., 2013). However, 
the effect of this N-glycan varied between different HIV-1 variants as it caused significant 
disruption of Env function of virus YU2 but not of JR-FL (Lavine et al., 2012). Therefore, 
further mutational analysis of other clones should be carried out to confirm the influence of 
this PNG on viral fitness. 
Furthermore, the PNG at 339 (C3 region) in CAP84 viruses that affected PSV entry 
efficiency for some clones, was also located in a region neighbouring the V3 loop involved 
in coreceptor binding. Therefore, introduction of a PNG at 339 could indirectly affect Env 
entry efficiency by causing a shift in the variable V3 loop, decreasing the binding affinity for 
CCR5 (Wang et al., 2013).  However, further analysis is still required.    
Conclusion 
In summary, our data suggests that gp41 is an important determinant of Env function by 
modulating Env fusion capacity. Thus, Env fusion capacity plays a very important role in 
PSV entry efficiency and potentially in vivo viral outgrowth in dual infected individuals.  






Figure 3.21.  Structural modelling of potential N-glycans at positions N332 and N339.    
Homology model of a complex trimer of Env gp120 (in purple) and gp41 (in red) showing the 
positions of N332 and N339 relative to theV3 loop (in cyan colour), a CCR5 binding site, and the 
bridging sheet (in green). The structure was modelled using UCSF Chimera 1.11.2 software based 
on BG505 SOSIP.664 trimer in complex with the broadly neutralizing antibody 3BN117 (PDBe 













Viral load set-point and CD4 T cell decline are surrogates for disease progression and it has 
been suggested that viral genotype and thus HIV-1 traits, contribute to the heritability of viral 
loads (Bertels et al., 2017). Replication capacity (RC) of HIV-1 viruses was found to 
correlate with high viral load and disease progression (Selhorst et al., 2017; Williamson and 
Swanstrom, 2015). We showed earlier that in dual infected individuals, Env entry efficiency 
tend to play an important role in the outgrowth of recombinant viruses. Furthermore, there 
was a significant association between loss of CD4 count and PSV entry efficiency suggesting 
that Env was playing a role in disease progression. Although, PSV-based assays have been 
extensively used to estimate Env entry efficiency and suited for high throughput, it measures 
only a single cycle of viral replication (Etemad et al., 2009; Quiñones-Mateu and Arts, 2001).  
Multiple cell culture assays have been used to assess viral replication capacity and fitness in 
vitro (Dykes and Demeter, 2007; Quiñones-Mateu and Arts, 2001). In multiple cycle assays, 
(i) the same culture can be co-infected with different variants in a competition assay or (ii) 
replication of viruses can be compared independently in parallel culture (Dykes and Demeter, 
2007; Quiñones-Mateu and Arts, 2001). Growth competition assays were potentially limited 
by recombination between the two infecting/competing variants (Song et al., 2012) at high 
multiplicity of infection (MOI) (Ball et al., 2003; Lanxon-Cookson et al., 2013) and 
distinguishing between viruses usually required expensive methods of quantification such as 
deep sequencing or real-time PCR. On the other hand, parallel growth kinetics assays were 
less expensive and successfully used to evaluate Env function, phenotype and RC of HIV-1 
variants in the absence (Chatziandreou et al., 2012; Etemad et al., 2009; Quiñones-Mateu 
and Arts, 2002; Selhorst et al., 2017; Weber et al., 2011) and presence of drugs (Selhorst et 
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al., 2017; Weber et al., 2011). The outcome of replication assays can be influenced by cell 
type  and donor-derived peripheral blood mononuclear cells (PBMCs) is considered a more 
relevant measure of virus replication than cell lines that have adapted to laboratory conditions 
(Quiñones-Mateu and Arts, 2002; Salazar-Gonzalez et al., 2009; Troyer et al., 2005).  
Therefore, to confirm that Env influenced viral RC similar to that of PSV entry efficiency, 
chimeric infectious molecular clones (IMCs) were generated using HIV-1 NL4-3 proviral 
genome backbone and parallel replication in PBMCs monitored by p24 ELISA.  
Furthermore, we evaluated whether Env determinants influenced viral replication as these 
did not consistently affect Env entry efficiency, fusion, expression, cleavage and 
incorporation into PSVs.  




4.2 Research Aim and Objectives 
 
Aim 
Determine the relationship between RC of variants isolated from dual infected individuals 
and in vivo outgrowth of variants over the course of infection and the effect of Env fitness 
determinants on viral RC. 
 
Objectives 
Objective 1: To determine the RC of chimeric IMCs and compare RC with in vivo 
outgrowth of variants and Env phenotypes. 
Objective 2: Compare RC to PSV-entry efficiency to understand the role of Env in 
virus replication. 









4.3 Material and Methods  
 Samples  
 CAP137 and CAP267, both classified as rapid progressors were selected to generate 
IMCs from Env isolated at 0 mpi and 12 mpi. In addition, IMCs were also generated for 
the mutant clones 137c10sdm, 267c2/c6 and 267c6/c2. 
 Plasmids used in the assay 
The shuttle plasmid pCMV-NL4-3-PBS→LTRΔGp160 with the HIV NL4-3 subtype B 
genome (without the 5’LTR) and the helper plasmids pCMV-NL4-3-LTR→Gag4 that 
carries the NL4-3 5′ LTR were generous gifts from Dr. Manish Sagar, Brigham and 
Women’s Hospital, Harvard Medical School, US (Figure 4.1). Plasmid construction was 
as described before (Chatziandreou et al., 2012; Dudley et al., 2009). Briefly, the subtype 
B NL4-3 full-length genome was inserted into the multiple cloning site (MCS) of pRS315 
using the yeast gap-repair homologous recombination (pRS315-NL4-3) prior to replacing 
the primer binding sequence (PBS) of NL4-3 5’LTR sequence with URA3 gene to form 
pRS315-NL4-3∆5'end to prevent the expression of the entire genome of NL4-3. 
Subsequently, the CMV promoter was amplified from pCDNA3 and inserted into the 
pRS315-NL4-35' to form pCMV-NL4-3-PBS-3'LTR, placing genes of NL4-3 under the 
control of the CMV promoter. Finally, env was replaced with the URA3 gene amplified 
with primers that introduced a unique restriction enzyme PacI site to form pCMV-NL4-
3-PBS/LTR∆Gp160. Yeast gap-repair homologous recombination was used to insert env 
to form the final shuttle vector. For constructing the helper plasmid, the yeast centromere 
sequence (CEN6) and LEU2 gene were amplified from pRS315 and inserted into MCS 
of pcDNA3 to generate pcDNA-Leu. The 5’LTR to gag sequence was also inserted into 
pcDNA-Leu to form CMV-NL4-3-LTR -Gag4 (Helper).  




Figure 4.1. Map of shuttle vector and helper plasmid used in yeast recombination assay.   A) Shuttle vector: pCMV-NL4-3-
PBS/LTR∆gp160 in which the URA3 gene replaced the env gene in the NL4-3 genome with a unique restriction enzyme PacI allowing 
other env genes to be inserted into this plasmid using yeast homology recombination. B) Helper plasmid: pCMV-NL4-3-LTR→Gag4 





CMV-NL4-3 PBS-LTR delta env160
14173
A) B)




 Yeast recombination assay 
In order to generate IMCs, yeast homologous recombination was used as described 
previously (Chatziandreou et al., 2012; Dudley et al., 2009). 
4.3.3.1 Env gene amplification 
Full-length HIV-1 env was amplified from 137c1, 137c2, 137c3, 137c9 and 137c10 (Table 
2.1, Chapter-2).  PCR was carried out using the Phusion Hot Start Polymerase kit (Thermo 
Scientific, USA) with the two primers, Env IF and Env IR (Appendix A) using the parameters 
in (Appendix A).  
The PCR product (3 kB) was excised from the 1 % agarose gel and purified using the 
Wizard® SV Gel and PCR Clean-Up System following the manufacturer’s instructions 
(Promega, USA). The purified PCR product was sequenced at Stellenbosch Central 
Analytical Facility using an ABI 3000 genetic analyser (Applied Biosystems, Foster City, 
CA, USA) and BigDye terminator reagents. The shuttle vector, pCMV-NL4-3-
PBS/LTR∆Gp160 (3 µg) was linearized with 3 µl of FastDigest PacI restriction enzyme (1U/ 
µl), (Thermo Scientific, USA) and cleaned up with the Wizard® SV Gel and PCR Clean-Up 
Kit (Promega, USA) following the manufacturer’s instructions.  
4.3.1.2 Yeast gap-repair recombination  
The yeast were transformed with the amplified env genes as previously described 
(Chatziandreou et al., 2012; Dudley et al., 2009). Briefly, yeast [(Saccharomyces cerevisiae 
Hanson (MYA-906), MAT α ade6 can1 his3 leu2 trpl URA3)] cells were made competent 
using 10 % glycerol and stored in 100 µl aliquots at -80 °C. The yeast cells were thawed at 
room temperature and centrifuged at 13000 rpm for 30 seconds and the supernatant was 
removed. A mixture of the linear env PCR product (1 µg/µl) and the linear vector (200 ng/µl) 
in a ratio of 5:1 (env:vector) that made up to a total volume of 74 µl with distilled water was 
added to the yeast cells. Transformation was performed by adding 240 µl of 50 % 
polyethylene glycol (PEG3350) (Sigma Aldrich, USA) (Appendix C), 10 µl of 10 mg/ml 
salmon sperm (Invitrogen), and 36 µl of 1M lithium acetate (Appendix C). The 
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transformation mixture was incubated at 30 °C for 30 min, followed by heat shock at 42 °C 
for 15 minutes. The cells were centrifuged for 30 seconds at 13000 rpm and resuspended 
gently with 100 µl of sterile distilled water before plating on Complete Supplement Mixture 
(CSM) – Leucine + 5 –Fluoroorotic acid (CSM-LEU + 5’FOA) selective plates (Appendix 
C). Only transformed yeast should grow as 5’FOA is toxic to cells expressing URA3. The 
plates were incubated at 30 °C for 3-4 days till colonies became visible. Yeast cells 
transformed with distilled water instead of DNA and/or yeast cells transformed with digested 
vector only were used as negative controls. Yeast cells transformed with PRS315 plasmid 
and plated on Leucine-only agar plates controlled for transformation efficiency. 
4.3.3.2 Yeast plasmid extraction  
To extract the recombinant plasmid, two to three colonies were selected from CMS- Leu/5-
FOA selective plates and cultured in 2 ml of CMS-leucine broth (Appendix C) at 30 °C with 
shaking overnight. Zymoprep™ Yeast Plasmid Miniprep II kit from (Zymo Research, USA) 
was used to extract the recombinant plasmid from the yeast following the manufacturer’s 
instructions. PCR amplification with two primers, env-y F and env-y R (Appendix A) was 
used to confirm the successful cloning of the env gene into the recombinant plasmid. These 
primers were designed specifically for the subtype C env used in this study. The PCR product 
(approximately 1 kb in size) was confirmed on 1% agarose gel. Moreover, the recombinant 
plasmids were sequenced at the Stellenbosch Central Analytical Facility using an ABI 3000 
genetic analyser (Applied Biosystems, Foster City, CA, USA) and BigDye terminator.  
4.3.3.3 Yeast plasmid transformation into bacterial competent cells 
The commercial 10 Beta E. coli electro-competent cells from (New England BioLabs, UK) 
were transformed with a volume of 1-2 µl of yeast-extracted plasmids using a Gene Pulsar 
II electroporator (Bio-Rad, USA) following the manufacturer’s instructions. After 
electroporation, the cells were incubated at 30 °C for 1 hour with SOC medium (provided by 
manufacturer) before plating on ampicillin selective Luria agar plates and incubated at 30 °C 
overnight. The PureYield™ Plasmid Miniprep System (Promega, USA) was used to extract 
the recombinant plasmid from the bacterial culture as per manufacturer’s instructions. 
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 Generation of Infectious Molecular Clones  
HEK 293T cells were co-transfected with 2 µg of the recombinant plasmid (pCMV-NL4-3-
PBS/LTR + env) and 2 µg of the helper plasmid (CMV NL4-3 Gag4) at a molar ratio of 1:1.8 
using polyethyleneimine (PEI) (Sigma-Aldrich). Briefly, 4x105 cells/ml were plated in 6 well 
plates and incubated overnight at 5 % CO2, 37 °C before transfection. A ratio of 1:3 
(DNA:PEI) was vortexed in 400 µl of DMEM (Sigma, Germany) for 10 seconds and 
incubated at ambient temperature for 15 min before adding dropwise to HEK 293T cells in 
2 ml supplemented DMEM (Section 2.3.4.1, Chapter 2). The supernatant containing viral 
particles was collected after 48 hours, clarified through 0.45 um filter, and a volume of 600 
µl was aliquoted into cryotubes and stored at -80 °C till used. 
 Virus Titre  
An aliquot of viral stock was thawed at room temperature and serial diluted with 
supplemented DMEM medium in 1:3 or 1:5 dilution series in triplicate in 96 well plates in a 
total volume of 200 µl. A volume of 100 µl aliquot of each dilution was transferred to TZM-
bl cells plated at a concentration of 104 cells per well in 100 µl supplemented DMEM media 
in 96 well plates (Costar; Promega). Cells were incubated at 37 °C, 5 % CO2 for 48 hours.   
Volume of 150 µl of the medium was removed and 100 µl Bright-Glo Luciferase substrate-
buffer mix (Promega, USA) was added to the TZM-bl cells, incubated for 2 min to lyse the 
cells before 100 µl were transferred into a white opaque 96 well plate and relative light units 
(RLU) measured by a GloMax-Multi Microplate Multimode Reader (Promega, USA). RLU 
readings of uninfected cells were considered as background signal and infection was 
considered successful if RLU was > 2.5-fold higher than background. In the case of titrating 
viruses expanded in PBMCs, Dextran (40 µl per 10 ml supplemented DMEM, 20 µg/ml final 
concentration) was added to the supplemented DMEM of TZM-bl prior to plating the cells. 
This was used to maximize virus infectivity. The 50 % tissue culture infectivity dose 
(TCID50) was calculated based on Reed-Muench method (Reed and Muench, 1938). 
 IMC Replication  
4.3.6.1 Virus expansion  
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Ficoll-gradient centrifugation was used to isolate PBMCs from HIV-negative donors. Cells 
were maintained at 37 °C with 5 % CO2 in RPMI 160 medium supplemented with 10 % Fetal 
Calf Serum (BiochromGmBH), 25 mM HEPES (Lonza, Basel, Switzerland), 1 U/mL 
penicillin and 1 µg/mL streptomycin (Whitehead Scientific) antibiotic mixture, and 2 mM 
L-glutamine (Lonza, Basel Switzerland).  PBMC proliferation was stimulated with IL-2 
(Gentaur, Belgium) (200 U/ml final concentration) and phytohemagglutinin-P (PHA-P) 
lectin (Remel, Thermo Scientific, MA, USA) (0.5 µg/ml final concentration) in RPMI 160 
for 72 hours before virus expansion or virus replication.  
In order to produce high virus titre, the recombinant viruses generated from HEK 293T cells 
were expanded in PBMCs. Activated PBMCs were plated in 6 well plates at a concentration 
of 5 x 106 cells per 2 ml RPMI supplemented with IL-2 only and 500 µl of each virus stock 
was added. Spinoculation was performed by centrifugation at 1500 g for 2 hours at room 
temperature to enhance virus infectivity. The infected cells were then transferred to T25-
tissue culture flasks and medium was topped up to 5 ml supplemented RPMI 160 medium 
with IL-2 so that cells were at a final concentration of 106 cells per ml. The flasks were then 
incubated at 37 °C, in a 5 % CO2 incubator for two weeks. Infected PBMCs were refreshed 
with 5 million activated PBMCs in fresh supplemented RPMI 160 medium with IL-2 every 
three days and virus supernatant was collected from day 7 and every three days thereafter. A 
volume of 1 ml of virus supernatant was aliquoted in cryovials and stored at -80 °C.  
4.3.6.2 Replication Kinetic assay 
PBMCs were isolated from HIV- negative donors and activated for 72 hours as previously 
described. PBMCs were plated at a concentration of 106 cells per ml in 96 well plates, and 
300 TCID50 of each virus was used to infect the cells in triplicate in a final volume of 200 
µl per well. Cells without virus were used as the negative control. Infection was enhanced 
by centrifugation at 1500 g for 2 hours. Infected cells were then incubated at 37 °C in a 5 % 
CO2 incubator and 50 µl of virus supernatant was collected on day 7, 10, and 14 post-
infection, replaced with fresh medium and stored at -80 °C for further analysis. Virus 
replication was monitored by measuring p24 using an in-house p24 ELISA technique (Alto-
Biosystems) as previously described (Section 2.3.4.3, Chapter 2). Replication kinetics was 
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plotted as p24 ng/ml vs days post- infection, and two analytical methods were used to 
compare RC between IMC chimeras: (i) area under the curve (AUC): area under the p24 
curve was estimated using GraphPad Prism version 5.0 (Chatziandreou et al., 2012) and (ii) 
slope of viral replication: slopes between RLU values at days 0 and 7, 0 and 10, 0 and 14 
were calculated and averaged for each virus and the mean and SEM was determined of two 
independent measurements (Weber et al., 2011). NL4-3 HIV provirus was used as a positive 
control and cells without infection was used as a negative control. 
4.3.6.3   PBMC donor selection 
There was high variability between donors with some not able to sustain viral replication. 
Thus, to identify donors that were consistently permissive to HIV infection, PBMCs were 
isolated from four different HIV-negative donors and an aliquot was activated and 
immediately tested while the remaining were cryopreserved at -80 °C for future use. 
Activated cells were infected with 300 TCID50 of three viruses: two lab control viruses 
(NL4-3 and Bal) (Gifted by Prof. C. Williamson, UCT) and one of the chimeric IMCs 
generated for this study (137c10). Infected cells were incubated at 37 °C in 5 % CO2 for 14 
days and supernatants were collected as previously described. Viral replication was 
determined by p24 ELISA for day10 samples only. 
 Statistical analysis 
IMC RC was compared using one-way ANOVA test with Bonferroni correction for multiple 
comparisons using GraphPad Prism version 5.0. p value of < 0.05 was considered as 
statistically significant. 




 Generation of Infectious Molecular Clones   
Chimeric IMCs were generated by cloning env into the HIV-1 NL4-3 proviral backbone to 
test the impact of Env on viral replication.  The yeast gap repair technique was used to rapidly 
insert different envs into the pNL4-3 backbone as cloning by restriction enzyme digestion 
and ligation is limited due to the extreme heterogeneity between HIV variants (Dudley et al., 
2009).  
Previously, we showed that a recombinant variant infecting CAP137 and CAP267 virus B 
dominated at 12 mpi with concomitant increased PSV entry efficiency (Table 2.1; Figure 
2.9, Chapter 2).  The changes in variant frequency and corresponding PSV entry efficiency 
of these two participants suggested that Env, and more specifically, gp41 could play an 
important role in viral fitness. Therefore, we determined whether the influence of Env on 
PSV entry could be extrapolated to IMC RC.  
Five IMCs were generated from CAP137, two representing virus A at 0 mpi, one representing 
virus B at 0 mpi, and two representing the AB viral population at 12 mpi (Section 2.3.3, 
Chapter 2). In addition, an IMC was also generated for the mutant clone 137c10sdm (Section 
2.3.5.2, Chapter 2). For CAP267, four Env IMCs were selected, two representing A and B 
viral populations at 0 mpi and two representing the A and B viruses at 12 mpi. Additionally, 
IMCs were also generated for the two chimeric mutant constructs (267c2/c6 and 267c6/c2) 
discussed in section 2.3.5.1, Chapter 2. 
 Identification and isolation of responsive donor PBMCs  
It was previously reported that in vitro HIV viral replication was influenced by variation 
between PBMCs from different donors making is difficult to determine whether differences 
between Envs were due to donor variation or intrinsic Env function (Spira and Ho, 1995).  
Furthermore, we found that some donor PBMCs did not support viral replication irrespective 
of whether CD8+ T cells were depleted or not (data not shown). Therefore, in order to select 
the most responsive donor PBMCs and obtain sufficient cells to test all Envs with the same 
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donor, we isolated PBMCs from four different HIV negative donors, generated aliquots for 
storage at -80 °C and tested the RC of two lab strain viruses (NL4-3 and Bal) and the 
replication competent chimeric IMC, 137c10.  
The RC of NL4-3, Bal and 137c10 differed within and between donor PBMCs with cells 
isolated from donor-2 the least permissive (Figure 4.2). The RC of NL4-3 was consistently 
more robust than 137c10, even though they only differed in Env. The replication of NL4-3 
and Bal was lower in donor-2 than that in the other three donors and 137c10 failed to replicate 
in these cells. Therefore, PBMCs isolated from donors 1, 3 and 4 were selected to compare 
IMC replication. However, in subsequent experiments we were unable to detect replication 
of our chimeric IMCS using donor-3 PBMCs and we will thus only report on two 
independent replication assays. 
 
 
Figure 4.2. Replication in PBMCs from different donors.  PBMCs from four donors were 
activated and infected with 300 TCID50 of two virus controls, NL4-3 and Bal and one 
experimental IMC, 137c10 in triplicate. Virus supernatant was collected and p24 concentration 
was measured at day10 using p24 ELISA. The mean p24 concentration is indicated with the error 
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 Replication of IMCs in PBMCs 
In vitro parallel, non-competitive replication assays have been used to compare the fitness of 
Envs from heterosexual and homosexual transmission, drug users, longitudinal samples and 
variants from long-term non-progressors (LTNP) to those of progressors as well as between 
subtype C, subtype A and subtype B viruses (Bunnik et al., 2010; Chatziandreou et al., 2012; 
Claiborne et al., 2015; Etemad et al., 2009; Pernas et al., 2012; Selhorst et al., 2017). Here 
we generated chimeric IMCs carrying Env of longitudinal samples from dual infected 
individuals which represented viruses A, B and/or AB as they fluctuated over the course of 
infection of CAP137 and CAP267.  
CAP137 
 Previous studies have used changes in p24 over time, the AUC (Chatziandreou et al., 2012), 
or the slope (Weber et al., 2011) to compare variation in replication fitness between variants. 
To determine whether these analytical approaches yielded the same results, we calculated 
changes in mean p24 concentration over time, the AUC of two independent experiments 
from two donors and the mean slope of the p24 curve.  
IMCs representing the AB viral population at 12 mpi had the highest RC: 137c9 and 137c10 
had 9-fold and 4-fold higher RC than virus A at 0 mpi, respectively (Figure 4.3A and B). 
This indicated that fitter viruses emerged over time (Figure 4.3). The RC of 137c9 was 
greater than the lab-adapted strain pNL4.3, suggesting high viral fitness. The same 
relationship between viruses was apparent when comparing the mean AUC with slight 
variation in the degree of statistical significance (data not shown).  





Figure 4.3. Replication of CAP137 IMCs.  PBMCs from two donors were infected with equal 
TCID50 of viruses generated from CAP137: two viruses representing A at 0 mpi, one representing 
B at ~2 mpi and two viruses representing AB viral population at 12 mpi. Viral replication was 
quantified by p24 ELISA at day 7, 10, and 14 post-infection. A) The mean p24 concentration from 
the two independent assays from 2 donors were plotted over time. Error bars represent SD. HIV-1 
NL4-3 virus was used as positive control and cells only was used as negative control. Viruses A, 
B and AB are indicated with red, blue, and purple, respectively, and clone names are indicated in 
the key. B) Mean slopes of p24 curves were calculated using the slopes between RLU values at 
days 0 and 7, 0 and 10, and 0 and 14 (Weber et al., 2011). All slope values for each virus was used 
to calculate the mean and SD of two PBMC donors. The mean slope of all viruses was compared 
to virus A (137c1) using One-way Anova test with Bonferroni’s multiple comparison test. P < 0.05 
(*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****). 
 
CAP267 
Four replicative IMCs were generated, two representing A and B viral populations at 0 mpi 
and two representing A and B viruses at 12 mpi. Compared to CAP137 IMCs, all the clones 
had lower replication capacity than NL4.3 suggesting that they were less fit variants. The 
slope of 267c6 replication kinetics was 6-fold higher than 267c2 (p < 0.01), suggesting that 
virus B variants gained replication fitness over time. However, the slope of 267c5 at 12 mpi 
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was 3-fold significantly lower than 267c1 at 0 mpi (p < 0.01) suggesting that virus A lost 




Figure 4.4. Replication of CAP267 chimeric IMCs.  IMCs generated from CAP267, representing 
A and B viruses at enrolment, and at 12 mpi were compared in parallel using a PBMC replication 
assay. A) The mean p24 concentration of two independent experiments using two donors are 
indicated. P24 ELISA was measured from viral supernatant collected at day 7, 10, and 14 post-
infection. Error bars representing SD. B) Mean slopes were calculated using the slopes between 
RLU values at days 0 and 7, 0 and 10, and 0 and 14 (Weber et al., 2011). The mean and SD of the 
three slope values were determined per donor and then the average was determined for the two 
donors. A and B viral populations are indicated in red and blue, respectively. Clone ID is indicated 
in the key. One-way ANOVA was used to compare the mean difference of slope between viruses, 
and the significant difference between viruses was calculated using Bonferroni’s multiple 
comparison test indicated with the asterisk: * = p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 
0.0001 (****). 
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 Association between viral replication in PBMCs and in vivo frequency of 
variants  
This study hypothesized that viral outgrowth in dual infected individuals was due to 
enhanced Env entry efficiency.  There was no consistent relationship between in vivo 
outgrowth of variants and the PSV entry efficiency of all clones at each time point. However, 
recombinants that outgrew other variants infecting CAP37, CAP84 and CAP137 had 
enhanced entry efficiency by 12 mpi (Figure 2.10, Chapter 2), suggesting that at 12 mpi, Env 
entry could be a determining factor of in vivo viral fitness. To confirm whether this 
relationship was upheld within the context of multiple rounds of replication, we evaluated 
the relationship between in vivo frequency of variants and chimeric IMC replication of 
CAP137 and CAP267.  
CAP137 
We were unable to conclude whether virus A clones, 137c1 and 137c2, had similar RC at 0 
mpi but given the experimental variation at 10 days post-infection, it is likely that 137c1 had 
higher RC than 137c2. The recombinant viral population at 12 mpi had the highest average 
RC and had outgrown all other variants at that time point (Figure 4.5A). Closer inspection 
of the AB population indicated that AB/B with 2-fold higher frequency had significantly 
lower RC than 137c9, the AB/A variant (Figure 4.3). This suggests that factors other than 
viral RC might have influenced the in vivo outgrowth of virus AB/B.  
CAP267 
The RC of CAP267 IMCs was associated with changes in in vivo frequency of corresponding 
viral populations. Virus A RC decreased ~3-fold over time which correlated with the ~2.4-
fold drop in in vivo frequency of this viral population at 12 mpi (comprised 24 % of all 
variants at 12 mpi) (Table 2.1). Virus B, which dominated with a frequency of 76 % at 12 
mpi, had significantly higher RC than virus B at 0 mpi (Figure 4.4), suggesting that viral 
population B evolved to enhanced replication fitness which then contributed to in vivo 
outgrowth (Figure 4.5B). 
Despite instances when CAP137 IMC RC did not correlate with changes in in vivo viral 
outgrowth, the two participants, CAP137 and CAP267, were infected with viral populations 
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with enhanced replication fitness and high in vivo frequency at 12 mpi. This suggests that 




Figure 4.5. Association between Replication Capacity and in vivo frequency of viral 
populations over time. 
Association between replication capacity (RC) of chimeric IMCs and in vivo frequency of viral 
populations over time showing an increase in IMC RC and population frequency at 12 mpi in A) 
CAP137 and B) CAP267. In vivo frequency (%) of variants was determined by calculating the 
relative proportion of sequences at each time point for each participant (Table 2.1, Chapter 2). 
Only frequency of CAP137 variants at 0, 2 and 12 mpi is shown. Virus A, B, and AB frequency is 
indicated by red, blue and purple lines, respectively. RC was expressed as the mean slope of curves 
of two independent donors and was compared to virus A over time. RC of virus A, B and AB is 
indicated by red, blue and purple bars, respectively. 
 Association between viral replication in PBMCs and PSV Entry Efficiency 
We have shown that overall changes in PSV entry efficiency and chimeric IMC RC over 12 
months of infection tracked the in vivo frequency of their source viral population, suggesting 
that Env was playing an important role in viral outgrowth in vivo. We next determined 
whether Env entry efficiency influenced the RC of matched chimeric IMCs for CAP137 and 
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fluctuate during the earlier time points and were not always linked to changes in population 
frequency. 
CAP137 
When we compared chimeric IMC RC, 137c9 RC was significantly higher than that of 
137c10 (Figure 4.3), whereas the opposite was true when comparing PSV entry efficiency 
of matched Env clones (Figure 2.9C, Chapter 2). In Chapter 2, we suggested that AB/B virus 
might carry potential CTL escape mutations that influenced differences in PSV entry 
efficiency but here we show that AB/B IMC RC is significantly lower than 137c9. However, 
when the average entry efficiency of clones representing virus A at 0 mpi and AB 
recombinants at 12 mpi were compared, there was a clear association between the enhanced 
PSV entry efficiency and chimeric IMC RC, at the population level, at 12 mpi, suggesting 
that Env is an important determinant of viral fitness for CAP137 (Figure 4.6A and C).  
CAP267 
Overall, RC differences between IMCs followed the same trend as PSV entry efficiency 
suggesting that Env entry efficiency was driving RC resulting in outgrowth of variants 
(Figure 4.4A and B): 1) virus A (267c1) replication kinetics was 7-fold higher than that of 
virus B (267c2) at 0 mpi (p < 0.01); 2) replication kinetics of virus B 267c6 was 2.4-fold 
higher than virus A (267c5) at 12 mpi (p < 0.5); 3) 267c2 had the lowest RC at 0 mpi and 
267c6 had the highest at 12 mpi (Figure 4.4). The RC of 267c6 was 6-fold higher than that 
of 267c2 (p < 0.01) which was almost identical to the difference in PSV entry. However, 
unlike PSV entry efficiency where virus A at 12 mpi was similar to virus A at 0 mpi, the 
slope of 267c5 at 12 mpi was ~3-fold significantly lower than 267c1 at 0 mpi (p < 0.01). The 
difference observed between 267c1 PSV entry and IMC RC is likely due to experimental 
variation.  
Despite the discrepancies between individual variants, there was a significant correlation (p 
= 0.03, r = 0.7) between the RC of chimeric IMCs in PBMCs and their corresponding PSV 
entry efficiency in TZM-bl cells (Figure 4.7A). Similar results were observed when 
correlation analysis was performed using the mean AUC to represent IMC RC (data not 
shown). However, when IMC RC of Env isolated from CAP137 and CAP267 was compared 
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to their corresponding PSV entry efficiency in Affinofile cells that mimic T-lymphocyte 
(CD4high/CCR5low), no significant association was observed (p = 0.3, r = 0.4) (Figure 4.7B). 
This finding was contrary to our previous data which showed a significant association 
between PSV entry efficiency in TZM-bl cells and entry of Affinofile cells 
(CD4high/CCR5low) (Figure 3.6, Chapter 3). The absence of correlation could be due to a 
number of factors such as the influence of cell type (Joseph et al., 2014) combined with 
differences between IMC replication and PSV entry assays (Etemad et al., 2009; Murakami 
and Freed, 2000b). Furthermore, comparison between IMC RC and Affinofile PSV entry 
was limited to variants of CAP137 and CAP267 previously suggested to being sensitive to 
changes in cell type and HIV-1 backbone (Table 3.3). Sample size also has a large impact on 
correlation statistics and thus the loss of a few points could skew the outcome of the analysis 
(Vaux, 2012). 




Figure 4.6. Association between overall outgrowth of viral populations and Env function.  Association between the in vivo frequency 
of dominant viral populations of CAP137 with A) PSV entry efficiency; B) Fusion capacity; and C) Replication capacity.  The increase in 
the in vivo frequency of CAP267 viral B populations at 12 mpi was associated with D) PSV entry efficiency; E) Fusion capacity; and F) 
Replication capacity. In cases where more than one clone represented a viral population at a particular time point then the average of entry 
efficiency, fusion or RC of the clones was calculated and used to represent the entry, fusion or RC of the viral population at that time point. 
Viral population A, B and AB are indicated in red, blue and purple, respectively.  In vivo frequency (%) of variants was determined by 
calculating the relative proportion of sequences at each time point for each participant (Table 2.1, Chapter 2) and the frequency of only 
























































































































































































































































Figure 4.7. Correlation between IMC Replication capacity and PSV entry efficiency.  
Spearman r correlation was carried out to determine the relationship between viral replication 
capacity (RC) in PBMCs and PSV entry efficiency in A) TZM-bl and B) Affinofile cells that mimic 
T-lymphocytes. RC is expressed as the mean slope of replication kinetics of two independent 
experiments and PSV entry efficiency was normalised to the cell only control. Spearman r test was 
determined as indicative of a negligible, weak, moderate, high and very high relationship based on 
previous reports (Hinkle et al., 2003), p value of < 0.05 was considered significant. GraphPad 
Prism 5.0 software (CA, USA) was used for statistical analysis. 
 
 
 Association between viral replication in PBMCs and Env fusion capacity   
In chapters 2 and 3, we suggested that gp41 might play an important role in determining PSV 
entry efficiency by influencing Env fusogenicity. As there was an apparent association 
between TZM-bl PSV entry and chimeric IMC RC, we determined whether IMC RC was 
also influenced by Env fusion capacity. 
CAP137 
Env fusogenicity followed a similar trend as IMC RC of matched variants across all time 
points. The difference between 137c1 and 137c2 IMC RC and PSV fusion capacity was 
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likely due to experimental error given the standard deviation of the independent experiments 
(Figure 4.3 and Figure 3.7). At 12 mpi 137c9 IMC had significantly higher RC than 137c10, 
similar to the difference in fusion capacity of the two clones except the relationship did not 
reach significance. When the average IMC RC and PSV fusogenicity of virus A and AB 
clones were compared instead of individual clones then RC and fusion capacity followed the 
same trend, suggesting that there is an association between Env fusogenicity and replication 
fitness of the viral populations infecting CAP137 (Figure 4.6B and C).  
CAP267 
The RC of 267c6 at 12 mpi was significantly greater than 267c2 and this corresponded to 
increased fusion capacity. However, whereas virus A IMC RC decreased over time, the 
fusion capacity of this viral population either increased ~2–fold or seemed to remain the 
same over 12 months of infection. (Figure 4.4; Figure 4.6E and F). This could suggest that 
fusion capacity contributed to the RC of virus B over time but not virus A. Although, virus 
A entry efficiency of TZM-bl and Affinofile cells, fusion capacity, and Env expression did 
not change over the course of infection, gp120 incorporation of 267c1 was higher than 267c5 
(Figure 3.13), mimicking the difference in RC between the two clones. Although there was 
no correlation between gp120 incorporation into PSVs and PSV entry efficiency, perhaps the 
poor incorporation of 267c5 gp120 had a detrimental effect on IMC RC when measured over 
multiple rounds of infection. Further analysis is required to confirm the potential 
relationship.  
Despite the variation between the replication fitness and fusion capacity of some clones, a 
significant correlation was determined between overall PSV fusion capacity and viral 
replication (p = 0.04, r = 0.7), suggesting that fusion capacity might play a role in ex vivo 
viral replication (Figure 4.8). A similar association was found between RC and fusion 
capacity when AUC was used as a measure of RC (data not shown).  





Figure 4.8. Correlation between RC and fusion capacity.  Correlation analysis was carried out  
to determine the relationship between viral replication capacity (RC) and PSV fusion capacity. RC 
was expressed as the mean of the slope derived from replication kinetics. T-20 IC50 in (ng/ml) 
was used as an indicator of fusion capacity. Spearman r test was used to indicate a negligible, 
weak, moderate, high and very high relationship based on previous reports (Hinkle et al., 2003), p 
value of < 0.05 was considered significant. GraphPad Prism 5.0 software (CA, USA) was used for 
statistical analysis. 
 
 Association between viral replication in PBMCs and disease progression   
HIV set-point viral load - the viral load (VL) at 12 mpi- is a predictor of disease progression 
(Mellors et al., 1996) and is driven largely by viral factors (Alizon et al., 2010; Hollingsworth 
et al., 2010; Mellors et al., 1996) suggesting that Env phenotype could influence how quickly 
HIV-infected individuals progress to AIDS. Our data supports this hypothesis as we showed 
that Env entry efficiency was significantly associated with CD4+ T cell loss (Figure 2.12, 
Chapter 2), a well-documented marker for disease progression (Phillips et al., 1991). As RC 
was previously shown to correlate with disease progression using both VL and CD4+ T cell 
count (Campbell et al., 2003; Quiñones-Mateu et al., 2000; Troyer et al., 2005), we 
determined whether the chimeric IMC RC of variants infecting dual-infected individuals 
revealed a similar association between RC and disease progression.  
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Increasing RC of chimeric IMC carrying CAP137 Env coincided with an increase in VL and 
sever decline in CD4 count over time with CD4+ T cells dropping to < 350 cells/µl in the 
first year of infection (Figure 4.9A). This suggested that the ability of variants to replicate to 
high titres due to Env entry efficiency within this individual might have contributed to her 
rapid disease progression. Similarly, the CD4 count of CAP267 also dropped to below 350 
cells/µl within 1 year of infection and this decline tracked the RC of the dominant viruses 
over the course of infection (Figure 4.9B). However, VL decreased over 12 months of 
infection, suggesting that enhanced RC was not translating into high viremia.  Due to small 
sample size, statistical analysis could not be performed. 




Figure 4.9. Association between replication capacity of chimeric infectious molecular 
clones and markers of disease progression.  
Replication capacity (RC) of variants infecting A) CAP137 and B) CAP267 and markers of disease 
progression over time were plotted. Viral load (copies/ml) on the left y-axis and CD4 counts on 
the right inside axis vs months post-infection (mpi). The slope of the replication kinetics curve was 
used as an indicator of RC and indicated as a percentage (%) relative to virus A at 0 mpi to show 
the changes over time and plotted on the left outside y-axis. RC of A, B and AB variants are 
indicated in red, blue and purple bars, respectively. Changes in VL and CD4 count data over time 
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 The impact of Env fitness determinants on IMC replication  
In chapter 2, we identified gp41 and PNGs might play a role in Env entry and thus determine 
viral fitness. In order to determine whether these sites impacted the ability of the virus to 
replicate, we generated IMCs of the mutant clones of CAP137 and CAP267. 
CAP137 
As previously mentioned, a PNG at position 332 was deleted from clone 137c10 (AB viral 
population at 12 mpi) and the mutant, 137c10sdm had significantly lower entry efficiency 
than WT (Figure 2.14). When the replication of 137c10sdm was compared to WT, both 
viruses replicated to similar levels till day 10, after which 137c10sdm seemed to gain fitness, 
reaching a peak of 22 ng/ml p24 at day 14 (Figure 4.11A).  However, there was no difference 
in either the slope or the AUC of 137c10sdm IMC RC compared to WT which differed from 
the 2-fold decrease in PSV entry efficiency of 137c10sdm. Furthermore, when the slope of 
137c10sdm replication kinetics was compared to virus A at 0 mpi (137c1), the mutant had a 
5-fold significantly higher RC (p = 0.01), whereas 137c10sdm had similar PSV entry 
efficiency to 137c1 (Figure 4.11B). This data suggested that the PNG at position 332, 
affected Env PSV entry efficiency without influencing the replication capacity of the virus.  
CAP267  
Virus B PSV entry efficiency was much higher at 12 mpi than at 0 mpi. We generated two 
chimeras where we swapped C5 and gp41 regions between the two infecting viruses 
(267c2/c6 and 267c6/c2) and found that the C5 and/or gp41 of the variant at 12 mpi was 
responsible for the increased entry efficiency. When the replication capacity of the chimeric 
viruses was compared to WT, the replication of both chimeras was significantly lower than 
267c6 and equal to the replication level of virus B at 0 mpi (Figure 4.12). This result did not 
correlate with PSV entry efficiency suggesting that C5 and/or gp41 of 267c6 was not 
influencing IMC replication. 
 





Figure 4.10.  Impact of CAP137 PNG at position 332 on infectious molecular clone 
replication capacity.  Viruses representing viral population A at enrolment (137c1), AB virus at 
12 mpi (137c10) and the AB mutant (137c10sdm) were compared in two independent replication 
assays using PBMCs. A) The mean p24 concentration of the two independent assays were plotted 
over days post-infection and error bars represent standard deviation. HIV-1 NL4-3 virus was used 
as a positive control and cells only was used as negative control. Viruses A, AB and AB-sdm are 
indicated in red, light purple, and dark purple, respectively, and clone names are indicated in the 
key. B) Mean slope of each curve from independent experiments were calculated using the slopes 
between days 0 and 7, 0 and 10, 0 and 14. The overall slope of each curve from the two independent 
biological repeats was averaged and represented as bars with error bars representing SD. The mean 
slope of 137c10 and 137c10sdm was compared to virus A (137c1) using One-way Anova test with 
Bonferroni’s multiple comparison test. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 
(****). 
 
















































Figure 4.11. Replication Capacity of CAP267 chimeras.  To test the importance of gp41 in PSV 
entry efficiency, restriction enzyme (RE) digestion of 267c2 and 267c6 was used to swap the C-
terminus between the two Envs using corresponding RE sites. RE digestion swapped gp41 and C5 
between the two clones but as C5 only differed by one amino acid residues between the two 
chimeras, gp41 is likely to be the important determinant of PSV entry efficiency. The two chimeras 
of CAP267 B viruses were compared with WT viruses in the replication assay to determine 
whether gp41 was important to viral RC. A) The mean p24 concentration change over days 
infection of two independent experiments using two donors are indicated. P24 ELISA was 
measured from viral supernatant collected at day 7, 10, and 14 post-infection. Error bars represent 
SD of two independent experiments. B) The overall slope of each p24 curve generated per 
independent experiment was calculated by finding the mean of the slopes between days 0 and 7, 0 
and 10, and 14. The overall slope of each curve was then averaged for each virus and standard 
deviation of two independent biological repeats is indicated. Viral population A, B are indicated 
in red and blue, respectively. The Chimeras 267c2/c6 and 267c6/c2 are indicated in blue striped 
bar and blue blocks, respectively.  One-way Anova was used to compare the mean difference of 
slope of the viruses, and the significant difference between viruses was calculated using 
Bonferroni’s multiple comparison test indicated with the asterisk: * = p < 0.05 (*), p < 0.01 (**), 
p < 0.001 (***), p < 0.0001 (****). 
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 Summary of results  
Table 4.1.  Ranking of replication capacity of IMCs in PBMCs 
Participant ID 
IMC Replication 
capacity in PBMCs 
Pseudovirion entry 






CAP137 c9>c10>c1≈c2≈c3 c10>c9≈c1>c2≈c3 c9, *c10, c1 
CAP267 c1≈c6>c5>c2 c6>c5≈c1>c2 *c1 
*137c10 and 267c1 was suggested to be sensitive to changes in cell-type and/or HIV-1 backbone 
differences (Table 3.3, Chapter 3). 
 
 
Table 4.2.  Summary of associations between infectious molecular clone replication 
capacity and in vivo outgrowth and other Env phenotypes 
Association of 
Increased replication 
capacity with variant 
outgrowth 
Significant association between increased replication capacity, 

















Yes *Yes *Yes *Yes No No *Yes No 
*Association was not apparent for all clones 
 










CAP137 PNG at N332 Deletion of N332 in 137c10 No 
CAP267 
5 amino acids in 
cytoplasmic tail of 
gp41 and one amino 
acid in C5 (gp120) 
chimeric Env clones 
(267c2/c6 and 267c6/c2) 
No 
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4.5 Discussion  
This study characterized the RC of chimeric IMCs that carry Env clones from variants 
infecting dual infected individuals over the first year of infection. Two participants 
classified as rapid progressors (CAP137 and CAP267) were selected for this study as 
both were infected with variants at 12 mpi with high entry efficiency with concomitant 
increased in vivo frequency but differed in the presence of recombinants. We succeeded 
in generating 9 IMCs that replicated within PBMCs generated from two donors in 
independent experiments.  The low number of functional clones could be due to the 
incompatibility between subtype C env and the subtype B NL4-3 backbone (Bagaya et 
al., 2015).  
RC of viruses using parallel replication assays over 2 weeks was measured using the area 
under the p24 curve and (Charpentier et al., 2006) the slope of the curve (Weber et al., 
2011). Despite differences in the degree of significance, both methods indicated the same 
relationship between IMC RC and Env phenotypes and we thus only reported on 
measurements using the slope of the replication kinetics curve.  
We compared frequency of variants and changes in IMC RC of viral populations to 
determine whether RC could be influencing in vivo variant outgrowth. RC of chimeric 
IMCs representing the recombinant population infecting CAP137 had out-competed 
viruses A and B at 12 mpi and had the highest RC of all variants, suggesting that 
recombination within Env had selected for variants with increased RC that enabled 
outgrowth. Virus B variants infecting CAP267 gained RC over time with corresponding 
increased frequency whereas virus A RC decreased with concomitant lowered frequency. 
Furthermore, at 0 mpi and 12 mpi the variant with the highest frequency also had the 
highest RC, suggesting that virus B had evolved within Env, conferring a competitive 
advantage. The ranking of CAP267 and CAP137 IMC RC from high to low was similar 
to the relative PSV entry efficiency of the clones (Table 4.1; Table 3.3) and there was an 
overall significant correlation with PSV entry efficiency (p = 0.03, r = 0.7), suggesting 
that Env fitness was a determinant of viral outgrowth. Therefore, at the population level, 
not only did PSV entry efficiency correspond to variant frequency but also RC, 
supporting the positive relationship between viral outgrowth and enhanced Env function 
(Figure 4.6).  
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However, when individual variants infecting CAP137 were compared, virus AB/A at 12 
mpi had higher RC than AB/B despite its lower in vivo frequency. In addition, the ranking 
of 137c1, 137c9, 137c10 and 267c1 IMC RC and PSV entry efficiency from high to low 
did not correlate (Table 4.1). There were also instances where PSV entry efficiency did 
not follow variant frequency, suggesting that variants might not always reflect population 
changes. The reasons why individual clones did not reflect population dynamics could be 
multifactorial such as the impact of immune escape, HIV diversity and the number of 
clones analysed. As the sample size of our study was small, with only nine functional 
IMCs, we might not have sampled sufficient variants to observe population level RC. 
However, similar to PSV entry efficiency, population-based RC correlated significant 
with PSV fusion capacity (p = 0.04, r = 0.7) suggesting that fusion capacity was 
influencing virus RC (Table 4.2).  Furthermore, similar to PSV entry, population RC was 
associated with CD4+ T-cell decline suggesting that high RC could hasten disease 
progression (Claiborne et al., 2015; Garg and Joshi, 2017).  Therefore, RC could play a 
role in the rapid disease progression of CAP137 and CAP267 (Campbell et al., 2003; 
Lassen et al., 2009; Quiñones-Mateu et al., 2000; Trkola et al., 2003; Troyer et al., 2005).  
We previously suggested that gp41 was a potential fitness determinant of variants 
infecting CAP137 and CAP267 (Table 4.3). As fusion capacity of these variants was 
apparently associated with IMC RC, it seemed probable that recombination within gp41 
had resulted in enhanced RC of viruses infecting CAP137 and CAP267.  However, 
contrary to the PSV entry efficiency and fusion capacity of 267c2/c6 that remained 
similar to 267c6, the RC of 267c2/c6 decreased significantly, indicating that the gp41 of 
267c6 was not responsible for the low RC of this IMC. Therefore, even though 267c6 
gp41 seemed to enhance PSV entry efficiency and fusogenicity, it did not impact IMC 
RC. Similarly, PNG 332 that seemed to play a significant role in the enhanced PSV entry 
efficiency of 137c10 had no effect on the RC of the AB/B recombinant. These unexpected 
results suggested that mutations can affect Env entry efficiency and fusogenicity without 
affecting the ability of the virus to replicate, despite the apparent association between 
PSV entry efficiency and IMC RC of the WT variants. However, the influence of 
PNG332 on Env function might be highly sensitive to changes at other a.a. residues as it 
had very different effects on YU2 and JR-FL (Lavine et al., 2012). 
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As the single-round PSV infection assay measures differences in entry, the first step in 
HIV replication, any differences detected should also be apparent in IMC infection assays 
which measures multiple replication cycles. It is thus likely that the inconsistent 
association between PSV entry efficiency and IMC RC between the mutants and WT 
viruses is due to differences in the assays. Provine et al., (2009) reported that IMC 
phenotype did not always resemble that of matched PSVs (Provine et al., 2009) 
potentially due to cell-specific differences between HEK293T cells PSVs and PBMCs 
(Herrera et al., 2005; Murakami and Freed, 2000b; Provine et al., 2009; Pugach et al., 
2007). It was previously suggested that factors that interact with Env vary between cell-
types so that mutations that influence Env entry efficiency in one cell type might have no 
effect in another (Murakami and Freed, 2000b). As replication in PBMCs represent a 
more physiologically relevant system to identify viral factors that could modulate HIV 
infection, it is possible that gp41 of 267c6 and N332 of 137c10 are not fitness 
determinants in vivo. However, as RC was determined using PBMCs from only two 
donors, additional experiments could prove otherwise.  
Conclusion 
In general, high IMC RC representing viral populations A, B and AB was associated with 
increased PSV entry efficiency, PSV fusogenicity and in vivo frequency, suggesting that 
Env played an important role in viral fitness and in vivo outgrowth. Although, the virus 
at the highest frequency at any given time would most likely be driving viremia and thus 
disease progression, IMC RC did not correlate with viral load. However, IMC RC was 
associated with CD4 T cell decline suggesting immune responses could be limiting viral 
load but not cytopathogencity.  Therefore, RC could be influencing disease progression. 
However, we were unable to confirm the importance of gp41 and PNG332 in PSV entry 
efficiency as RC of matched IMC chimeras and mutant were not similarly affected. This 
highlights the importance of differences between assay systems and the need to 
standardise methodologies when identifying potential fitness determinants for vaccine 








Summary and Conclusion 
 
5.1 Discussion 
HIV-1 vaccines have a small window of opportunity to elicit an immune response that 
could effectively prevent colonisation of mucosal lymphoid tissues and establishment of 
viral latency. One way to prevent HIV infection would be to stimulate broadly 
neutralising antibody (bnAb) responses that target Env, the viral component that mediates 
viral entry of CD4+ T cells. However, there are many challenges facing the design of an 
efficacious vaccine such as high viral diversity within and between individuals, the lack 
of a relevant animal model, evasion of immune responses by numerous viral mechanisms 
such as MHC down-regulation and the sequestering of CD4 and CCR5 receptor binding 
sites within inaccessible regions of Env. Vaccine design focussed on eliciting bnAb that 
prevent Env-mediated viral entry include numerous strategies including the use of 
purified recombinant gp120/gp140 monomers, Env trimers, hyperglycosylated Env and 
Env covalently bound to CD4 to induce exposure of receptor binding sites.  The extensive 
diversification of Env however impedes the generation of neutralising antibodies that 
prevent infection of a broad range of viruses (Girard et al., 2006). 
It has been suggested that conserved sites essential for the maintenance of Env structure 
and function, and more accessible than CD4 and CCR5 receptor binding sites, might 
make ideal targets for vaccine design. Recently, deep mutational scanning has indicated 
that epitopes of bnAbs are highly sensitive to mutation, suggesting that the identification 
of Env fitness determinants sensitive to change might be an alternative to apparent 
random selection of Env subunits as vaccine candidates (Haddox et al., 2016). One 
hindrance to the identification of fitness determinants is the flexibility of Env structure to 
accommodate multiple sequence changes without losing function.  Highly variable host 
immune responses coupled with extensive viral diversity will alter rates of evolution and 
generate highly heterogeneous variants with varied functional stability. However, one 
can assume that even a structure as plastic as Env has a preferred energy state most suited 
for its function. Directed evolution selected for variants that differed in sequence changes 
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but had homogeneous functional stability and when these mutations were combined in a 
single variant, it became the most stable of all (Leaman and Zwick, 2013). This finding 
suggests that rapid HIV evolution within disparate hosts could select for fitter variants 
that ultimately share common phenotypes despite the introduction of different sequence 
changes. Furthermore, another study showed that functional constraints limited in vitro 
recombination between subtypes A and D to C1 region within gp120 and gp41  (Bagaya 
et al., 2015).  
 In dual infected individuals, phylogenetically distinct viruses compete for survival in 
vivo under the same host selective pressures. The co-circulation of two different strains 
could provide the sequence space for rapid selection of Env recombinants with high entry 
efficiency that speed up viral replicative fitness and disease progression (Quiñones-
Mateu et al., 2000).  Therefore, dual infections could provide the ideal model system to 
identify fitness determinants within conserved regions of Env that emerge quickly after 
infection. Dual infections could also be used to determine the importance of Env function 
in viral replication capacity (RC) and viral population frequency as well as identify the 
phenotype of Env most sensitive to genotypic changes. Therefore, this thesis 
hypothesised that rapid viral evolution in dual infected individuals resulted in the early 
emergence of recombinants carrying Env fitness determinants that enhance viral 
replication capacity resulting in increased disease progression. The frequency of dual 
infections varies between reports and is highly dependent on methods used to identify 
and quantify variants (Pacold et al., 2010).  Our lab had previously identified only four 
dual infected individuals after screening 40 women- three were classified as rapid 
progressors and one a typical progressor- limiting the sample size and statistical power 
of the study.  This thesis therefore aimed to describe the change in Env function over time 
and to determine whether changes tracked those of viral outgrowth to identify regions of 
Env under positive selection. 
As the focus of the study was to characterise Env function, pseudovirus (PSV) was 
generated using Env cloned from longitudinal samples at 0, 3, 6 and 12 mpi. We 
hypothesized that the PSV single-round infection assay would be the best strategy to 
identify fitness determinants of Env. However, the limitation of this approach was that 
cell lines such as HEK293T cells were used to produce PSV and TZM-bl, U87 and 
Affinofile cells were used to monitor infection, instead of more physiologically relevant 
   
176 
 
cells. Furthermore, instead of using a subtype C backbone to determine PSV entry 
efficiency, two different subtype B vectors, pSG3 and pNL4-3.Luc.R–E–  backbones 
lacking env were used to monitor infection of the different cell lines by luciferase reporter 
assays. However, the effect of different cell lines and HIV backbone vectors seemed to 
have minimum impact on PSV entry efficiency as most Env clones had the same relative 
entry efficiency irrespective of cell type and HIV backbone. 
As changes in tropism have been linked to differences in Env function and disease 
progression (Koot, 1993; van Rij et al., 2003; Sucupira et al., 2012; Troyer et al., 2005) 
we firstly tested whether PSVs were able to enter cells with low CD4/high CCR5 density 
and cells with high CD4/high CXCR4 levels. All PSVs were unable to infect U87-
CD4+CXCR4+ cells and able to infect Affinofile cells induced to express high CD4 and 
low CCR5 levels, similar to T lymphocytes, indicating that all variants were R5- and T-
tropic. This finding supported previous studies that revealed no difference in viral tropism 
between transmitted and chronic viruses (Parrish et al., 2012; Ping et al., 2013). 
A total of 295 SGA-derived amplicons were generated over time for all four participants 
and the proportion of sequences belonging to a viral population at each time point was 
used as a measure of relative outgrowth of variants. High diversity and early 
recombination events challenged the identification of distinct viral populations and it is 
highly likely that recombinants were present at the earliest time point for all participants 
but as both parent viruses were not detected we could not confirm this suggestion. Despite 
this limitation, the combination of a number of strategies- Neighbour-joining trees, 
Highlighter plots, RIP and pairwise DNA distance- identified two viral populations that 
grouped separately at the earliest time points allowing us to track their frequency over 
time and the emergence of recombinants.  
Diversity was higher within the first 3-6 months and seemed to stabilize by 12 mpi 
suggesting that for all participants viral evolution was more rapid at earlier time-points. 
Abrahams et al (2013) suggested that immune responses drove rapid viral evolution 
during early infection until escape mutations became fixed within a population, lowering 
diversity (Abrahams et al., 2013). CAP84, classified as a typical progressor had lower 
sequence diversity than the other three participants, and it is interesting to speculate that 
slower evolution hindered the emergence of escape mutants, lowering viral load and 
slowing the disease progression of this individual. 
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We showed that evolution of the two viruses infecting 3/4 dual infected individuals 
resulted in the early emergence of recombinant viruses at 2 mpi for CAP137, 3 mpi for 
CAP84 and 6 mpi for CAP37. The emergent recombinants increased in in vivo frequency 
and outgrew other variants at 12 mpi. Previous studies showed an association between 
recombination and disease progression (Fang et al., 2004; Gordon et al., 2016; Nájera et 
al., 2002; Ramirez et al., 2008). However, in this cohort, the in vivo outgrowth at 12 mpi 
of emergent recombinants was associated with rapid disease progression for only two 
participants, suggesting that recombination is not always linked to disease progression 
(Table 5.1) (Liu et al., 1997). There was no apparent recombination between virus A and 
B for CAP267 although polymorphisms within the cytoplasmic tail (CT) of gp41 seemed 
to become fixed over time. The mapping of recombination events revealed that, although 
there was variation between participants, gp41 recombinants were apparently selected in 
3/4 participants (Figure 2.7, Chapter 2), similar to previous reports (Bagaya et al., 2015). 
Potentially, these genotypic changes were responsible for enhanced PSV entry efficiency 
as recombinants at 12 mpi were able to infect TZM-bl cells better than other variants at 
the same time point. Therefore, at 12 mpi, 3/4 individuals were infected with 
recombinants that had out-competed other variants, most likely due to their average 
enhanced Env entry efficiency.  
Although variants infecting CAP37 at 0 mpi had the highest level of diversity, emergent 
recombinants were detected later than those infecting the other participants. The high 
diversity made it difficult to identify regions that might have influenced PSV entry 
efficiency and viral outgrowth and thus the identification of fitness determinants focused 
on the other three participants (Table 5.2).  By 12 mpi, CAP84 AB virus had evolved to 
include regions of virus B gp41 sequence as well as unique changes within gp120 and 
the signal peptide whereas the recombinants AB/A and AB/B infecting CAP137 had 
differences mainly within HR2 and MPER regions within gp41.  Mutations were 
scattered across gp120 but most occurred in the CT of gp41 of the fit virus B infecting 
CAP267 at 12 mpi. As we wanted to determine whether survival pressure on the two 
variants infecting dual infected individuals selected for changes within a common region, 
we focussed on changes within gp41. Chimeras were generated for CAP276 and CAP84 
where gp41 was swapped between two Env clones that either had different (CAP267) or 
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similar (CAP84) PSV entry efficiency associated with point mutations (CAP267) or 
recombination (CAP84) within gp41. 
Escape from nAb and CTL immune responses have been shown to come with a fitness 
cost (Lynch et al., 2015; Moore et al., 2012; Wang et al., 2013). Chimeras of CAP84 and 
site-directed mutagenesis suggested that putative CTL escape mutations and the presence 
of a PNG at position 339 acted synergistically to decrease PSV entry efficiency and that 
recombination within gp41 restored fitness. The chimeras of CAP267 suggested that 5 
amino acids within the CT (and/or 1 a.a. in C5) were involved in the increased fitness of 
the dominant virus at 12 mpi. Reversion of CTL escape mutation to consensus sequence 
has been shown to rescue any loss of fitness associated with immune escape (Song et al., 
2014) Of the five a.a. in gp41 of 267c6, two reverted to consensus, suggesting that these 
two a.a. might play a role in CAP267 fitness. Further SDM might be able to confirm this 
relationship. CAP267 was HLA B*5802 positive but we could not detect any putative 
CTL mutations within the epitope associated with increased viral loads, QL11 (Kiepiela 
et al., 2007) nor HF9 identified by MotifScan (www.lanl.gov). CTL responses targeting 
Env have, in general, been associated with increased viremia, probably due to the 
plasticity of Env structure able to withstand amino acid changes (Kiepiela et al., 2004). 
However, without Elispot data, we cannot confirm the influence of CTL escape on 
disease progression and Env diversity of CAP84 and CAP267. Furthermore, PNG 
frequency did not increase consistently over time which suggested that bnAb pressure 
did not play a major role within the first year of infection as previously suggested 
(Abrahams et al., 2013). 
 The propensity of variants with high PSV entry efficiency and high frequency at 12 mpi 
to carry sequence changes within gp41 suggested that Env fusogenicity might play a role 
in influencing PSV entry efficiency as previously suggested (Brenchley et al., 2004; 
Gorry et al., 2014; Gorry and Ancuta, 2011; Lobritz et al., 2007; Marozsan et al., 2005; 
Rangel et al., 2003). There was an overall significant association between PSV entry 
efficiency and Env fusion capacity, with membrane fusion possibly the key Env function 
enhanced during the evolution of variants infecting CAP37 and CAP137. For CAP267 
there was no obvious association between PSV entry efficiency and fusion capacity 
although there was an association between PSV entry efficiency and fusion capacity of 
CAP267 chimeras. This suggests that fusion capacity might be the driving factor 
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enhancing Env function, although this relationship did not hold true for some clones 
(Brenchley et al., 2004; Gorry et al., 2014; Gorry and Ancuta, 2011; Lobritz et al., 2007; 
Marozsan et al., 2005; Rangel et al., 2003). 
On the other hand, differences in PSV entry efficiency of CAP84 wild-type (WT) clones 
and chimeras were unlikely due to Env fusogenicity. The apparent lack of association 
between PSV entry and Env fusogenicity for CAP84 chimeras suggested that other viral 
phenotypes might be influencing variant fitness in this participant. When Affinofile cells 
expressing 5- to 10-fold lower levels of CD4 and CCR5 than TZM-bl cells were infected 
with 84c1 and 84c4 PSVs, there was no significant change in entry of Affinofile cells 
over 12 mpi, similar to entry of TZM-bl cells but unlike PSV fusogenicity. CAP84 
diversity seemed to be driven by escape from immune responses (Appendix B) and these 
polymorphisms might have selected for viral populations highly divergent in Env 
phenotype. As characterizing immune escape was outside the scope of this study, CAP84 
phenotype was not further characterized.  
As CAP37, CAP137 and CAP267 gp41 fusion capacity was apparently contributing to 
PSV entry efficiency and gp41 had been shown to influence Env cell-surface expression 
(Lebigot et al., 2001), we wanted to determine whether expression and processing of Env 
might be influencing Env fusion capacity. Due to the high diversity of CAP37, this 
participant was not included in this analysis.  
Comparison between PSV entry efficiency and fusion capacity with cell associated Env 
levels and cleavage into gp120 and gp41, suggested that the more Env cleavage the higher 
PSV entry efficiency and fusogenicity although this relationship did not reach 
significance. We hypothesised that higher cell-surface expression of gp120 could 
increase the number of Env spikes incorporated into PSVs (Bachrach et al., 2005) and 
result in enhanced entry efficiency and fusogenicity (Chertova et al., 2002). However, 
there was no apparent relationship of Env expression and cleavage with incorporation of 
gp120 into PSVs. Possibly over-expression of Env might slow gp160 cleavage and 
folding during cell trafficking (Blay et al., 2007) that then differentially influences the 
incorporation of gp120 into PSVs. As incorporation of gp120 was also not associated 
with PSV entry efficiency, incorporation of functional trimers might not be limiting. 
Bachrach et al (2005) suggested that increased infectivity was only dependent on Env 
incorporation until a certain point after which it no longer had an effect (Bachrach et al., 
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2005). Alternatively, robust entry of TZM-bl cells due to high levels of CD4 and CCR5 
could mask subtle influences that Env expression, cleavage and incorporation might have 
on PSV entry. If this was the case, then TZM-bl cells might not be good model for HIV 
infection of T lymphocytes. However, there was a significant association of PSV entry 
of TZM-bl cells with entry of Affinofile cells induced to express high CD4/low CCR5 
levels and with the RC of matched chimeric IMCs, suggesting that PSV infection of 
TZM-bl cell model system was physiologically relevant.  
 When comparing TZM-bl entry with other Env phenotypes, such as fusion capacity, p 
values less than 0.05 was used to confirm whether one phenotype was associated with 
another. However, in some cases differences between entry efficiency, and fusogenicity 
of clones did not reach significance despite apparent trends. In addition, differences 
between independent experiments due to intra-experimental and inter-experimental 
variation made it difficult to confirm associations. To support the power of our p values 
(Nuzzo, 2014) given the small sample size, we applied multiple mechanistic experiments 
to confirm our findings in PSV entry of TZM-bl cells such as infection of different cells 
with varying receptor levels and alternative HIV backbones (Vaux, 2012). Lastly, we also 
compared the RC of chimeric IMCs to confirm the importance of Env differences. 
Furthermore, after identification of putative fitness determinants by sequence analysis we 
hypothesised that mutagenesis of Env clones could also be used to confirm relationships 
between TZM-bl entry and Env phenotypes.  
Similar to PSV infection of TZM-bl cells, variants infecting CAP137 and CAP267 had 
increased RC at 12 mpi and this coincided with high in vivo frequency of viral population. 
This suggested that PSV entry of TZM-bl cells represented changes in RC and facilitated 
the outgrowth of variants at 12 mpi. A similar relationship was observed between IMC 
RC and PSV fusion capacity, supporting our suggestion that Env fusogenicity could be 
responsible for differences in PSV entry efficiency. However, when we compared PSV 
entry and fusogenicity with IMC RC of Env mutants, a similar relationship was not 
observed (Table 5.2). The IMC replication capacity of CAP267 chimeras was lower and 
IMC RC of CAP137c10sdm lacking a PNG at N332 did not change compared to WT, in 
conflict with the decreased PSV entry efficiency of the mutants compared to the dominant 
variants at 12 mpi. Therefore, although IMC RC supported changes in PSV entry 
efficiency and fusogenicity of WT clones, it did not confirm the influence of gp41 and 
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N332 on in vitro viral replication in CAP267 and CAP137, respectively. Therefore, 
despite previous studies showing that gp41 played an important role in Env entry 
efficiency (Baatz et al., 2011; Lobritz et al., 2007; Marozsan et al., 2005; Reeves et al., 
2005) this did not translate into IMC replication fitness. There are differences between 
pseudovirion and IMC infectivity assays that might have contributed to the differences 
between the two study outcomes (Provine et al., 2009).  Furthermore, differences between 
in vitro IMC mono-infections and PSV entry efficiency could be due to the detection 
threshold of the replication assay. Although, competitive replication assays are more 
sensitive and might better represent in vivo viral fitness they are limited by in vitro 
recombination and was thus not considered in this study (Quiñones-Mateu and Arts, 
2001). Alternatively, perhaps determinants of replicative fitness should be identified first 
and then tested for a role in Env functions using PSV assays. We would also like to 
suggest that the effect of mutations on Env function and/or processing is highly clone 
specific due to amino acid interactions between different regions of Env: a salt-bridge 
required for CD4 binding in one clone might not be essential in another. Our lab has 
discovered that the introduction of PNGs can abrogate function of one clone and leave 
another unaffected (Manuscript in preparation). 
Two PNGs at positions 332 and 339 were identified that increased and attenuated Env 
fitness, respectively, possibly because gain or loss of N-glycans that facilitated escape 
from immune pressure came with a fitness cost (Cong et al., 2007; Liu et al., 2007; Song 
et al., 2012; Sunshine et al., 2015).  PNGs play a vital role in immune escape and 
neutralizing antibody recognition (Moore et al., 2012) and influence Env fitness (Lavine 
et al., 2012; Wang et al., 2013).  The effect of N332 on CAP137 Env fitness is noteworthy 
given that this N-glycan is responsible for eliciting bnAb and might make a good target 
in vaccine design. However, if it alters Env fitness then loss or gain of the PNG due to 
immune pressure could potentially generate fit variants able to out-compete others and 
drive viral loads and disease progression, mitigating the positive effect of the vaccine. 
This highlights the importance of screening potential vaccine targets for influencing viral 
fitness. 
Three of the four participants in this study were classified as rapid disease progressors 
and there was an association between PSV entry efficiency and CD4 decline (Table 5.1). 
This relationship was upheld when RC was compared to CD4 counts although sample 
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size precluded statistical analysis. This, suggested that both Env function and viral RC 
could influence disease progression, supporting previous studies (Gordon et al., 2016; 
Miura et al., 2010; Quiñones-Mateu et al., 2000; Rangel et al., 2003; Troyer et al., 2005).  
5.2 Conclusion 
 Changes within gp41 and concomitant variation in Env fusion capacity seemed to play 
an important role in PSV entry and IMC RC in general and that increased fusion capacity 
seemed a common feature of variants with high frequency. Therefore, although Env 
evolution seemed to follow different functional pathways, where some Env had enhanced 
cleavage and others had better incorporation into pseudovirus, it still culminated in high 
fusion capacity. Variant evolution was functionally constrained and occurred under 
different immune pressures within each participant so the strength of the relationship 
between viral diversity, Env function and disease progression varied between individuals.  
However, in spite of host-specific selective pressures, two phylogenetically distinct 
viruses in a single individual still tended to undergo early recombination within gp41 that 
favoured enhanced Env function leading to viral outgrowth and increased disease 
progression.  
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5.3  Summary of results 
Table 5.1.  Summary of Env phenotype associated with in vivo outgrowth overtime 
Participant 
ID 



















CAP37 Yes ND No No No ND ND ND Yes No 
CAP84 No ND No No No ND ND ND No No 
CAP137 Yes Yes No No *Yes Yes* Yes* No Yes No 
CAP267 Yes Yes No No *Yes No* No* No Yes No 
For each participant, an association was determined between variant frequency and Env phenotype (entry efficiency, replication capacity, co-receptor tropism, 
fusion capacity, gp160 cleavage and gp120 incorporation) and disease progression (CD4+ T cell counts and viral load). Yes, means there was an association 
whereas No indicates that there was no association for all clones. Yes* and No* means that the outgrowth of only some clones were associated with Env phenotype.  
 
  





















(84c1/c4 and 84c4/c1) 
Yes No ND ND ND 
 PNG at N339 
Introduction of N339 into the 
fit 84c1/c4 
Yes ND ND ND ND 
  
Deletion of N339 in unfit 
84c4 
No ND ND ND ND 
Cap137 PNG at N332 
Deletion of N332 in fit 
137c10 
Yes ND No No No 
CAP267 
5 a.a. in CT of gp41 
and 1 a.a. in C5 of 
gp120 
Gp120/gp41chimeras 
(267c2/c6 and 267c6/c2) 
Yes Yes No No No 
Clones from CAP84, CAP137 and CAP267 were mutated and each mutant was tested for changes in Envelope phenotype. Yes, means that when the Env was 
mutated then phenotype changes and No means that mutations did not impact Env phenotype.
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APPENDIX A.  
Primer Sequences and PCR Conditions 
 
Primers used for envelope PCR amplification 
 
 








Sequence 5’- 3’ HXB2 location 
Env N TTGCCAATCAAGGAAGTAGCCTTGTGT 9145←9171 
Env 1M TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 9068←9096 
Env 1A-RX CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA 5950→5982 
Env IF AGA AAG AGC AGA AGA CAG TGG CAA TGA 6202→6228 
Env IR TTT TGA CCA CTT GCC ACC CAT 8797←8817 
Rev 15 CTGCCATTTAACAGCAGTTGAGGTGA 6990←7012 
T7 TAATACGACTCACTATAGGG Not applicable 
Env-y F AATGTCAGCACAGTACAATGTACACATGG 6944→6973 
Env-y R GGAGCTGTTGATCCTTTAGGTATCTTTC 7973←8001 
Primers 
Name 
Sequence 5’- 3’ 
84c4/ 84c1sdm(F) AAAGGTAAAGGAATAGACTAACAATAAAAAACAGACTGG 
84c4/ 84c1sdm (R) TTCCTTTACCTTTTCTAGAGTTTTATTCCAGTCTGTTTT 
84c4-sdm (F) AGGGTAAAGGAAGGACTCAAAACTAAGAAAACAGACTGG 





















Buffer + MgCl2 1 X 94 5 - 
dNTP mix 0.2 mM 94 0.30 
45 times First primer (F) 0.4 mM 55* 0.30 
Second primer (R)  
 
0.4 mM 72 4 
Amplicon 1 µl 72 10 - 
Phusion Hot Start 
Polymerase 
2.5 U 
Total (made up with dH20) 50 µL 
* gradient PCR (55-62 °C) annealing temperature was used. 
 














Buffer 1 X  72 10 - 
MgCl2 2.5 mM   
dATPs 0.2 mM   
PCR product 18 µL   
Super Therm Taq polymerase 1.5 µL   
Total (made up with dH20) 50 µL   
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Buffer  1 X 94 5 - 
MgCl2 2mM 94 0.45 
35 times dNTP mix 0.2 mM 57 0.45 
Primer (F) 0.4 mM 72 4 
Primer (R) 0.4 mM 72 10 - 
Amplicon 1 µl  
- 
Supertherm Taq 2.5 U 
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APPENDIX B.  
Alignments and Phylogenetic Trees 
 
 
Figure B.1. CAP84 Env sequence alignment.  The Env sequences of two clones of CAP84  
were aligned using BioEdit program. CAP84c1 representing virus A at enrolment and CAP84c4 
representing AB virus at 12 mpi. Different Env regions are indicated. Restriction enzyme sites 
used for digesting the two clones for generating the chimeras are indicated as well. A potential 
N-glycan site at 339 of CAP84c4 was detected using N-glycosite (www.HIV.lanl.gov) and 







C4 V5 C5 gp120 gp41
SbfI
XmaI
10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus MRVRGIQRNWPQWWIWGMLGFWMIIMCRVMGNLWVTVYYGVPVWTDAKTTLFCASDAKAYEREVHNVWATHACVPTDPNPQEIVLGNVTENFNMWKNDMV
CAP84c4-AB virus ......L..Y.P.....I.....LMI.N.V......................................................................
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus DQMHEDIISLWDQSLKPCVKLTPLCVTLKCTNATYNNSNGEVKNCTFNTTTEIRDRKQNAFALFYRSDVVPIKENNKNGSEENSYILINCNTSTITQACP
CAP84c4-AB virus ........................................................E.K.........................................
210 220 230 240 250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus KVSFDPIPIHYCAPAGYAILKCNNKTFSGTGPCLNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNVKTIIVHLNESIQIVCTRPNNNTRKS
CAP84c4-AB virus ..........................................................................A.........................
310 320 330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus IRIGPGQTFFATNEIIGNIRQAHCNISKTDWEKTLEKVKEKLKEHYNKTIEFKQPVSGGDLEVTTHSFNCRGEFFYCNTTNLFNLNSTDGSNITNITIPC
CAP84c4-AB virus ...............................N....R...............E....................................~~.........
410 420 430 440 450 460 470 480 490 500
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus RIKQIINMWQKVGRAMYAPPIEGIITCNSSITGLLLTRDGGGNESETETFRPAGGDMKDNWRSELYKYKVVQIKPLGIAPTTAKRRVVEREKRAVGIGAV
CAP84c4-AB virus ...........................................K..K.....................................................
510 520 530 540 550 560 570 580 590 600
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus FLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTTVPWNSSWSNKS
CAP84c4-AB virus L...................................................................................................
610 620 630 640 650 660 670 680 690 700
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus HSDIWDNMTWMQWDREINNYTNTIYRLLEESQTQQEKNEKDLLALDSWNSLWNWFSITKWLWYIKIFIMIVGGLIGLRIIFGVLSIVKRVRQGYSPLSFQ
CAP84c4-AB virus ....................................................................................................
710 720 730 740 750 760 770 780 790 800
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP84c1-A  virus TLIPNPRGLDRLGRIEEEGGEQDKDRSIRLVNGFLALFWDDLRSLCLFCYHQLRDFILIVARAVGLLGHSSLRGLQKGWEALKYLGNLVLYGG~QELKRR
CAP84c4-AB virus .....Q..P..P.GT........SG...................................................R...........AQ.W.~L...KS
810 820 830 840
....|....|....|....|....|....|....|....|....|.
CAP84c1-A  virus AIRLLDSLAITVAEGTDRIIEVAQRICRAIRNIPRRIRQGFEAALL
CAP84c4-AB virus ..S..NTV..V.G........LI.......................





Figure B.2. CAP137 Env sequence alignment.  The Env sequences of three clones of CAP137  
were aligned using BioEdit program. Viruses A, and AB/B at 12 mpi are represented by 137c1 
and CAP137c10, respectively. Different Env regions are indicated. A potential N-glycan site 




10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi MRVRGILRNYQQWWTWSILGFWIIMSCKVMGNLWVTVYYGVPVWQEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQELVLENVTENFNMWKNDMV
CAP137_AB/B at 12 mpi ................G.....ML..YN..................................................D.....................
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi DQMHEDVISLWDQSLKPCVKLTPLCVTLNCTDVKNGTSNNNISNNNTFNNNTMDGEMKNCSFNTTTELRDKKQQVYALFYRLDVVSLKE-DKNNSEYRLI
CAP137_AB/B at 12 mpi ...................................D.F----------.........................................-..........
210 220 230 240 250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi NCNTSTITQACPKVTFDPIPIHYCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEDIIIRSENLTDNVKTIIVHFNESIGI
CAP137_AB/B at 12 mpi ......................................................................................A.........A...
310 320 330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi ECIRPNNNTRKSIRIGPGQAFYATGDIIGKIRQAYCSINKTKWLETLKRVSKKLAELLPNNTIKFEPHSGGDLEITTHSFNCRGEFFYCNTTQLFNSTYM
CAP137_AB/B at 12 mpi .............................D....H.NVSG--.NK..EQ.RE..K.HF..K....Q.P..............G........SD...N.--
410 420 430 440 450 460 470 480 490 500
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi PNGTHMSNDTGSNSSIIIPCRIKQVINMWQQVGRAMYAPPIAGNIRCKSNITGLLLVRDGG----NNTNNTETFRPGGGDMRDNWRSELYKYKVVQIKPL
CAP137_AB/B at 12 mpi -----------.ADN.TLQ.....F.....G..............................----..I................................
510 520 530 540 550 560 570 580 590 600
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi GIAPTKAKRRVVEREKRAVGLGAMIFGFLGAAGSTMGAASIALTVQARQLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLALERYLKDQQLLG
CAP137_AB/B at 12 mpi .....E.................V.................T.........................................A....I...........
610 620 630 640 650 660 670 680 690 700
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi IWGCSGKLICTTAVPWNSSWSNKSQKEIWDNMTWMQWDREISNYTDTIYTLLEVSQNQQEKNEKDLLALDKWQNLWTWFGISNWLWYIRIFIMIVGGLIG
CAP137_AB/B at 12 mpi .......................T.D...N...........N...NL..R...E..S............GS.DS..N..N.T......K...........
710 720 730 740 750 760 770 780 790 800
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP137_A at 0 mpi LRIIFAVLSIVNRVRQGYSPLSFQTLTPNPRGPDRLGRIEEEGGEQDRGRSVRLVNGFLALAWDDLRSLCLFSYHQLRDFILIVARAVELLGR-------
CAP137_AB/B at 12 mpi ..............................G.................D..I.......................R...LL............-------
810 820 830 840 850 860
....|....|....|....|....|....|....|....|....|....|....|....|....|....
CAP137_A at 0 mpi RGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDRIIELIQRLCRAIFNIPRRVRQGFEAALQ

















Figure B.3. CAP267 Env sequence alignment.  The Env sequences of two clones of CAP267  
were aligned using BioEdit program. CAP267c2 representing virus B at enrolment and 267c6 
representing B virus at 12 mpi. Different Env regions were indicated. The Restriction enzyme 
sites used for digesting the two clones for generating the chimeras are indicated as well.  
 
 
10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi MRVRGIQRNWPQWWIWVILGFWMIIMCKGVGNLWVTVYYGVPVWREAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMVLGNVTENFNMWKNDMV 100
CAP267-Virus B at 12 mpi .................................................................................................... 100
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi DQMHEDVISLWDQSLKPCVKLTPLCVTLNCTNVNV-TTKNGSGDVAMVGEIKNCSFNATTEIRDKKKKEYALFYKPDVVLLNETTSSYVLINCNTSTITQ 199
CAP267-Virus B at 12 mpi ...................................-...........E..................R............S..K................. 199
210 220 230 240 250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi ACPKVSFEPIPIHYCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIISSENLTNNVKTIIVHLSESVEIVCTRPNNNT 299
CAP267-Virus B at 12 mpi .................................................................G...................N.............. 299
310 320 330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi RKSIRIGPGQTFYATGSILGEIREAHCNISENKWNKALQRVTEKLEGHFPNKTITFEPHSGGDLEITTHSFNCRGEFFYCNTSKLFNGTYMN-----GTE 394
CAP267-Virus B at 12 mpi ....................N....................S....E....R..N.....................................-----R.. 394
410 420 430 440 450 460 470 480 490 500
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi SNSSTVITLPCRIKQFINMWQQVGRAMYAPPIAGNITCKSSITGLLLVRDGGSNTNKTRT-ETFRPGGGNMRDNWRSELYKYKVVEIKPLGIAPTEAKRR 493
CAP267-Virus B at 12 mpi ....A......K............................N...............T.K.E........D.............................. 494
510 520 530 540 550 560 570 580 590 600
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi VVEREKRAVGIGAVIFGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGIWGCSGKLIC 593
CAP267-Virus B at 12 mpi .................................................................................................... 594
610 620 630 640 650 660 670 680 690 700
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi TTAVPWNLSWSNRSQDDIWNNMTWMQWDREISNYTNTIYRLLEDSQNQQEKNEKDLLALSNWQNLWSWFSISNWLWYIRIFIMIVGGLIGLRIVFAVLSI 693
CAP267-Virus B at 12 mpi .................................................................................................... 694
710 720 730 740 750 760 770 780 790 800
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CAP267-Virus B at 0 mpi VNRVRQGYSPL---SFQTLTPNPRGP-DRLGRIEEEGGEQDRDRSVRLVDGFLALVWDDLRSLCLFSYHQLRDFILIVARTVELLGRSSLKGLQRGWEAL 789
CAP267-Virus B at 12 mpi ...........---............-......................N.....I............................................ 790
810 820 830 840 850 860
....|....|....|....|....|....|....|....|....|....|....|....|....
CAP267-Virus B at 0 mpi KYLGSLVQYWGLELKKSAISLFDTVAIAVAEGTDRGIELLQRIYRAICNIPSRIRQGFEAALL* 853















Figure B.4. Confirmation of infection with two phylogenetically distinct variants.   
Neighbour Joining trees of sub-genomic env sequences of the master sequences with randomly 
selected subtype C env reference sequences from South Africa. The two masters were separated 
by unlinked viruses. A) Infecting viruses from CAP37 and CAP84, labelled with red colour dots 




A) CAP37 and CAP84 B) CAP137 and CAP267




Figure B.5.  Neighbour joining tree of SGA-env sequences of CAP37 and CAP84.  The full- 
length SGA-derived env sequences of A) CAP37, B) CAP84, from 0, 3, 6 and 12 mpi were 
aligned using BioEdit. Neighbour-joining trees (Mega 5.0) were used to classified A (red) and 
B (blue) master sequences with the highest maximum DNA distance and AB variants (in purple) 
with equidistant maximum DNA distance from both masters. CAP37 sequences from 0 mpi, 3, 
6, and 12 mpi are indicated with red, green, yellow and purple circle, respectively. CAP84 
sequences from 0.25 mpi, 0.5 mpi, 1 mpi, 3 mpi, 6 mpi and 12 mpi are indicated with empty 
circle, red circle, filled square, green, yellow and purple circles, respectively. Boot strap values 


















Figure B.6. Neighbour joining tree of SGA-env sequences of CAP137 and CAP267.  The  
full-length SGA-derived env sequences of A) CAP137, B) CAP267, from 0, 3, 6 and 12 mpi 
were aligned using BioEdit. Neighbour-joining trees (Mega 5.0) were used to classified A (red) 
and B (blue) master sequences with the highest maximum DNA distance and AB variants (in 
purple) with equidistant maximum DNA distance from both masters. Sequences from 0 mpi, 3, 
6, and 12 mpi are indicated with red, green, yellow and purple circle, respectively, and sequences 
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Figure B.7. Epitopes targeted by HLA B* alleles previously linked to disease progression.    
Sequences were scanned for epitopes recognised by HLA B* alleles specific to the dual infected 
individuals (Abrahams et al., 2013) that were shown to be linked to disease progression (Kiepiela 
et al., 2007; Prentice and Tang, 2012) using Motif Scan (www.lanl.gov). The epitopes are 
representatives to illustrate the fixation of putative CTL escape mutations. 
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APPENDIX C.  




Luria- Betani (LB) Broth 
Mix the following: 
Tryptone  10 g 
NaCl 10 g 
Yeast extract 5 g 
ddH2O up to 1 L 
Autoclave and store at room temperature.  
If antibiotic media is required, add antibiotic Carbinocilline after autoclaving and prior to 
use immediately.  
 
Luria Betani (LB) Plates 
Mix the following: 
Tryptone  10 g 
NaCl 10 g 
Yeast extract 5 g 
Agar 15 g 
ddH2O up to 1 L 
Autoclave and cool to 55 °C in water bath. Add the required amount of Carbinocilline (100 
mg/ml) or ampicillin in (100 𝜇g/mL final concentration). Mix and pour into plates. Allow 
the plates to dry at room temperature before storing at 4 °C. 
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Yeast extract peptone dextrose (YEPD) media 
Mix the following: 
Yeast Extract 10 g 
Peptone 20 g 
Dextrose (D-glucose) 20 g 
ddH2O up to 1 L 
Autoclave and store at room temperature. 
 
Yeast Amino Acid Dropout plates + FOA 
Set the water bath to 55 °C 
1- Prepare the following (use a 500 bottle):  
 
Agar 20 g 
ddH2O up to 500 ml 
Autoclave. When agar is finished autoclaving, allow the agar to cool in the water bath for 
ten minutes. 
2- Mix the following (use another 500-mL bottle): 
 
Yeast Nitrogen Base (YNB) 6.7 g 
Dextrose (D-glucose) 20 g 
Complete Supplement Mixture minus Leucine 
(CSM-Leu) 
0.69 g 
FOA 1 g 
ddH2O up to 500 ml 
Stir until completely dissolved, Filter sterilise and Put in water bath to warm. Add the filter 
sterilised 500 ml mixture from above (the one that should be in the water bath as well in 
number 2) into the agar mixture and mix it slowly prior to pour into the plates. Allow the 
plates to cool at room temperature in the dark due to the possible inactivation of 5 - 
FOA by light. 
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(-Leu) Agar plates 
• Set the water bath to 55 °C 
1- Prepare the following (use a 500 bottle):  
 
Agar 20 g 
ddH2O up to 500 mL 
Autoclave. When agar is finished autoclaving, allow the agar to cool in the water bath for 
ten minutes. 
2- Mix the following: 
Yeast Nitrogen Base (YNB) 6.7 g 
Dextrose (D-glucose) 20 g 
Complete Supplement Mixture minus 
Leucine (CSM-Leu) 
0.69 g 
ddH2O up to 350 ml 
Stir until completely dissolved, filter sterilise and put in water bath to warm. Add the filter 
sterilised mixture from above (the one that should be in the water bath as well in number 2) 
into the agar mixture and mixed slowly prior to pour into the plates. 
 
(-Leu) media yeast drop out  
Mix the following: 
Yeast Nitrogen Base (YNB) 6.7 g 
Dextrose (D-glucose) 20 g 
Complete Supplement Mixture minus 
Leucine (CSM-Leu) 
0.69 g 
ddH2O up to 1 L 
Mix and autoclave 
 






Solutions for Agarose gel  
 
50 X TAE (Tris-acetate buffer) 
Tris  242 g 
Glacial acetic acid 57.1 ml 
EDTA (0.5 M) 100 ml 
ddH2O up to  1 L 
 
Ethidium Bromide (EtBr) Solution 
EtBr (Sigma) 0.1 g 
ddH2O up to 10 ml 
Shake well to dissolve. Do not autoclave. Store in a dark bottle at room temperature. This is 
a powerful carcinogene, gloves should be worn at all times when handling this solution. 
 
0.8 % agarose 
 
Weigh 0.8 g agarose and add to 100 ml Schoot bottle. Add 50 ml 1X TAE. Boil in microwave 
and leave it to cool. 
 
Solution for Pseudovirion Western Blotting 
 
RIPA lysis buffer 
Tris buffer, pH 7.5 10 mM 
Sodium chloride 150 mM 
Na2EDTA ph 8.0 2 mM 
Triton X-100 detergent 1 % 
1 tablet of complete protease inhibitor cocktail [Santa Cruz Biotechnology®] per 50 mL 
buffer solution). Aliquot into 1 ml and store at -20 °C. 
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10X SDS running buffer 
Trizma (250mM) 30 g 
Glycine (2M) 114 g 
SDS 20 % 50 ml 
ddH2O up to 1 L 
 
10X TBS 
Tris (200mM) 24.2 g 
NaCl 80 g 
Add 800 ml ddH2O. pH to 7.6 with HCl. Make up to 1 liter with ddH2O 
 
4X SDS loading buffer 
Tris (1M) pH 6.8 2.5 ml 
SDS (20 %) 1 ml 
β-mercaptoethanol 2 ml 
Glycerol  4 ml 
Bromophenol blue 0.5 ml 
Store at 4ºC. 
 
Blocking Buffer 
Mix the following: 
Fat free skim milk powder 4 g 
Tween-20 1 ml 
1 X TBS 100 ml 
Store at 4 ºC (Short term) 
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Ponceau S stock solution 
Ponceau S 2 g 
Trichloroacetic acid 30 g 
5-sulfosalicyclic acid 30 g 
ddH2O up to 100 ml 
For working stock, dilute 1:10. Reusable 
 
10% SDS separating gel (for 2 gels) 
Acrylamide mix (37:5:1) (30 %) 5 ml 
Tris pH 8.8 (1M) 5.6 ml 
SDS (20%) 75 µl 
ddH20 4.36 ml 
Ammonium persulphate (20 %) 40 µl 
TEMED 20 µl 
 
5% SDS stacking gel (for 2 gels) 
Acrylamide mix (37:5:1) (30 %) 0.85 ml 
Tris pH 6.8 (1M) 0.625 ml 
SDS (20%) 25 µl 
ddH20 3.5 ml 
Ammonium persulphate (20 %) 10 µl 
TEMED 2.5 µl 
 
Towbin transfer Buffer 
Tris  3.03 g 
Glycine 14.42 g 
Methanol 200 ml 
ddH20 up to 1 L 
Store at room temperature. 
 




Solutions for In-house p24 ELISA 
 
Coating solution 
5 % bovine serum albumin: Dissolve 5 g in in 1 X TBS 
 
Washing solution 
To 1 L of 1 X TBS add 1 ml of Tween-20 
 
PSV inactivation solution 
1.25 % Empigen detergent: 1.25 ml of Empigen (35 %) mixed with 33.75 ml of 1 X TBS 
 
Solutions for routine use 
 
0.5 M EDTA 
EDTA 93.05 g 
NaOH 10 g 
ddH20 up to 500 ml  
Dissolve the EDTA and NaOH in 400 ml of dH2O, adjust the pH to 8.0 and make up to a 
final volume of 500 ml. 
  
Phosphate Buffered Saline (PBS) 
NaCl  80 g 
KCl   2 g 
Na2PO4 14.4 g 
KH2PO4 2.4 g 
ddH20 up to 1 L 
Dissolve NaCl, KCl, Na2PO4 and KH2PO4 in 900 ml of ddH2O. Adjust the pH to 7.4 and 
make up to 1 L with ddH2O. 
 
 
